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ACAT Acyl : Cholesterol Acyl Transferase
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"f
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SDS Sodium dodecyl sulphate
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SV 40 Simian virus 40 ^
TLC Thin layer chromatography
TCA Trichloroacetic acid
Tris Tris(hydroxymethyl)methylamine
WBC White blood cell
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SUMMARY
The feasibility of using low density lipoprotein(LDL) as a selective 
drug-targeting vehicle is examined in this thesis. A number of 
animal tumours are seen to express considerable receptor-mediated 
uptake of the lipoprotein. The organs likely to suffer during 
chemotherapy -using this carrier, viz. liver and adrenals, are afforded 
some protection by the administration of bile salts and hydrocortisone 
respectively. Several methods are employed for incorporating 
adriamycin, chlorambucil and daunomycin into LDL and the drug-LDL 
complexes so formed show enhanced cytotoxicity in vitro and in vivo.
It is likely that LDL will be a useful targeting vehicle for anticancer 
agents if the level of drug incorporation can be increased.
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OVERVIEW
Despite recent advances in the design of cytotoxic agents, drug 
toxicity remains a major problem in the treatment of neoplastic 
disease. Consequently, there is much interest in methods by which the 
fraction of the drug dose reaching the tumour may be increased. One 
such method involves packaging the drugs into macromolecular vehicles, 
chosen for their ability to seek out tumour cells and deposit their 
contents only at those sites. In theory, this would markedly increase 
the efficacy of cytotoxic therapy while minimising any harmful side 
effects.
Over the years, numerous vehicles have been examined. Drugs have been
attached to, for example, DNA^, proteins hormones^ and
5 6
monoclonal antibodies and they have been encapsulated in liposomes
7
and liposome-antibody complexes . In vitro experiments with
liposomes were encouraging^. However, when drug-laden liposomes were
administered in vivo, the cells of the reticulo-endothelial system
8-11
rapidly removed the complexes from the circulation . The work 
reported in this thesis investigates the potential of a "natural 
liposome" - Low Density Lipoprotein (LDL) - as a vehicle for cytotoxic 
drugs.
In 1978 Ho et al observed 3-100 times the normal rate of degradation
of low density lipoprotein in human leukemic cells in vitro and in 1981 
13
Gal et al reported that a number of human gynaecological cancer cell
lines grown in culture exhibited a higher uptake of LDL than did the
equivalent non-neoplastic tissue. Other workers^^ have observed
similar trends in several types of human and animal cancer cells.
24
Recently Vitols et al concluded that mononuclear cells in patients
16
with acute leukemia were capable of metabolising about 35% of the total 
plasma LDL-cholesterol pool per day.
All cells require cholesterol and they may obtain this in two ways: by
endogenous synthesis or by assimilation of cholesterol-containing
particles, lipoproteins, from their environment (fig. 1). The most
important lipoprotein in this regard is LDL, the major cholesterol-
carrying particle in human plasma^^. LDL consists of an apolar core
of cholesteryl esters and triglycerides surrounded by a phospholipid
27
monolayer containing free cholesterol and apoprotein B . Cells may
take up this lipoprotein by two distinct pathways, one of which
25
involves specific high-affinity receptors on cell membranes
28
Following binding to these receptors, located in coated pits on the
cell surface, an autoregulated sequence of events occurs which
culminates in lysosomal degradation of the lipoprotein and
25
subsequent release of the cholesterol for use in the cell
The LDL particle possesses several characteristics which could be 
exploited if the particle is used as a drug vehicle:
1. Neoplastic cells readily internalise and degrade LDL 
by the high-affinity receptor pathway;
2. The LDL core has the capacity to store a substantial
amount of drug;
3. Drug sequestration in the core space provides 
protection from serum enzymes and water; and
4. The entry of drugs into cells via the LDL pathway
23
may circumvent drug resistance mechanisms
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PLAN OF WORK
Until recently the feasibility of using LDL as a vehicle for cytotoxic 
drug in vivo had not been investigated to any great extent. There 
were no reports of LDL assimilation by solid tumours in vivo, 
although several groups have documented high LDL uptake by tumour cells 
in vitro^^ A brief outline of the plan of work for this project
is given below:
(a) The quantitative significance of the LDL-receptor 
pathway was assessed in several animal models and 
attempts were made to protect the organs likely to 
suffer during chemotherapy using LDL as a vehicle.
(b) A number of cytotoxic drugs were chosen for loading 
into LDL. Several methods of incorporation were 
employed and the drugs were assayed by HPLC.
(c) The efficacy of the drug-LDL complexes was tested 
in vitro using human cancer cell lines and in 
mouse models in vivo.
SECTION 1 : INTRODUCTION
18
1.1 LIPOPROTEINS - STRUCTURE AND FUNCTION
Cholesterol is an obligatory constituent of all mammalian cells. It
is required for membrane synthesis and is also a precursor in the
29 30 31
metabolic pathways of bile acid , steroid hormone ’ and vitamin D.
Since it is insoluble in aqueous solution, cholesterol is carried in
32 33
complexes with other lipids and protein in plasma ’ . These
complexes are known as lipoproteins and are composed of apoproteins,
cholesterol, cholesteryl esters, phospholipids and triglycerides. All
lipoprotein particles share a common structure in which apolar
neutral lipids are enveloped in a phospholipid membrane containing
27 34
free cholesterol and apoprotein B ’ . Figure 2 shows a schematic
model of a lipoprotein. The lipoproteins are not a si-ngle species
but a heterogeneous mixture of particles of variable lipid and protein 
27 34
composition ’ . Several classes of lipoproteins may be identified
by virtue of differences in size, density (fig.3) and other physical 
properties.
The five major classes of lipoproteins from human plasma, as defined 
by density, are:-
1.1.1. CHYLOMICRONS - d<0.95 Kg/L
These particles are high in triglyceride and are secreted into the
lymphatic system by cells of the small intestine during the ingestion 
88 88
of dietary fat * .
1.1.2 VERY LOW DENSITY LIPOPROTEINS (VLDL) d 0.95 - 1.006 Kg/L 
The liver and small intestine secrete these lipoproteins into the
plasma. Like chylomicrons, their main function is to transport
. . , . , 33,35
triglyceride
%^  cholestero l
cholesteryl esters 
CK# phospho lip id  
3  t r ig lyce r id e  
Ea a p o p ro te in
Figure 2: Schematic diagram of lipoprotein structure,
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1.1.3. INTERMEDIATE DENSITY LIPOPROTEINS (IDL) d 1.006 - 1.019 Kg/L
IDL are produced in the plasma as intermediates in the metabolism of
VLDL^^. They may be removed from the circulation by the liver or
33 36
converted to LDL in the plasma '
1.1.4 LOW DENSITY LIPOPROTEINS (LDL) d 1.019 - 1.063 Kg/L
These are the major cholesterol-carrying lipoproteins of plasma. Two-
thirds of the circulating cholesterol is contained in LDL^^.
1.1.5 HIGH DENSITY LIPOPROTEINS (HDL) d 1.063 - 1.210 Kg/L
HDL are the smallest of the lipoprotein particles and their main lipid
33 37
component is cholesteryl ester ’ . They are involved in the
transport of endogenous cholesterol back to the liver from extrahepatic 
sites.
1.1.6 ELECTROPHORETIC PROPERTIES
Lipoproteins may also be classified according to their electrophoretic
35
mobility relative to the major plasma globulins . Thus chylomicrons 
remain at the origin, HDL migrate as the-^-globulin fraction and are 
termed —^^-lipoproteins, VLDL, as , pre-|3-lipoproteins, and LDL, 
P-Iipoproteins.
The major properties and compositions of lipoproteins are summarised 
in table 1.
1.1.7 APOLIPOPROTEINS
39
Thirteen apolipoproteins have been isolated from human plasma and
the functions and primary sequences of many have been determined. They
39
are commonly classified by the system of Alaupovic into structurally
and functionally related groups. Their importance in regulatir
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lipoprotein metabolism arises from their ability to interact with key 
enzymes and cell membrane receptors. The cardinal properties of 
apoproteins are shown in table 2.
1.2 LIPOPROTEIN METABOLISM
Two classes of lipids with distinct physical properties are carried
by the lipoprotein transport system: the apolar lipids (cholesteryl
esters and triglycerides); and the amphipathic lipids (cholesterol and
phospholipids). These are organised into pseudomicellar structures
in which the apolar lipids are sequestered from the bulk aqueous phase
in the hydrophobic interior of lipoprotein particles (fig.2) Prior to
their use in the cell the apolar lipids must be metabolised to yield
41
free cholesterol and fatty acids . The majority of triglycerides 
are removed by adipose tissue or muscle where their fatty acids are 
stored or oxidised to provide energy. Cholesteryl esters are 
transported to all cells of the body where they yield sterol for
inclusion in membrane structures and as precursors of steroid
30,31 , , 29
hormones and bile acids
Cholesterol present in the circulation may originate from dietary 
intake or from endogenous synthesis in the liver and extrahepatic 
cells^^'^^. The two "types" of cholesterol are initially 
transported in different pathways - the "exogenous" and "endogenous" 
routes.
1.2.1. EXOGENOUS LIPID TRANSPORT
Dietary lipids are absorbed by cells of the small intestine and
secreted into the lymphatic system as large triglyceride-rich 
33 35
chylomicrons ' . The nascent chylomicrons possess apo B and
TABLE 2: HUMAN PLASMA APOLIPOPROTEINS
APOLIPOPROTEIN DENSITY CLASS
AI
A U
AIV
B-lOO
B-48
CI , 
Cil
c m
D
S 2 - G 4
HDL
HDL
CHYLOMICRONS, 
REMNANTS
VLDL, HDL
VLDL, HDL
VLDL, HDL 
HDL_
MOLECULAR
WEIGHT
28,000
17,000
CHYLOMICRONS 45,000
VLDL, IDL, LDL 550,000
210,000
6,500
10,000
10,000
20,000
VLDL, LDL, HDL 35,000
HDL 30,000
VHDL 75,000
CHYLOMICRONS & 50,000
VLDL
PROPOSED FUNCTION
Cofactor for LCAT
Cofactor for Hepatic 
Lipase
Structural protein in 
VLDL, IDL & LDL. 
Receptor interaction in 
LDL pathway.
Structural protein of 
chylomicrons
Cofactor for Lipoprotein 
Lipase
? Cholesteryl ester 
exchange protein 
interaction
Receptor interaction in 
chylomicron remnant 
pathway
21
apo AI and All on their surface and obtain further apoproteins (apo C
and apo E) from HDL upon entering the bloodstream. In the course of
44
their metabolism 90% of the chylomicron apo C returns to HDL while
apo B, an essential structural component of chylomicrons, remains with
45
the particle throughout its lifetime in plasma . Chylomicrons are
46
too large to pass through the endothelial barrier and enter
interstitial fluid. Their triglyceride is hydrolysed in the
plasma compartment, yielding free fatty acids immediately adjacent to
the cells which use them. This is accomplished by the action of
lipoprotein lipase (E.C. 3.1.1.34) an enzyme which is attached to the
luminal surface of capillary beds in muscle and adipose tissue. The
47
lipase is activated by apo CII on the chylomicron surface and the
products of the reaction pass into adjacent adipocytes or muscle cells.
Having lost much of its core, the chylomicron now has an excess of
surface phospholipid which is shed and assimilated by HDL. The
triglyceride-depleted particle, known as chylomicron remnant, is
composed mainly of cholesteryl esters, with apo B and apo E as the
major apoproteins. This lipoprotein is removed rapidly from the
circulation by a receptor mechanism which recognises apo E on the
particle surface^^'^^. Following binding the remnants are subject
to endocytosis and transferred to lysosomes where they are degraded.
The average half-life of chylomicrons in the circulation is only a
few minutes^^'^^ and consequently, in normal individuals, they are
abundant only in post-prandial plasma. In this way dietary cholesterol
finds its way to the liver, the major organ involved in regulating
cholesterol homeostasis. Dietary cholesterol in excess of immediate
metabolic requirements is secreted in bile, both as free cholesterol
29 32 50 51
and in the oxidised form of bile acids > > » • Much of the
former material is reabsorbed in the gut, transferred to chylomicrons 
and eventually returned to the liver, thus completing an enterohepatic
22
circulation, (fig. 4). Each time the cycle is completed a portion of
the cholesterol is lost from the gut. Typically, humans acquire about
1 gram of cholesterol each day, 800 mg from endogenous synthesis and
51
the remainder from dietary sources . This is balanced by the faecal 
loss of neutral and acidic steroids.
1.2.2. ENDOGENOUS LIPID TRANSPORT
Fatty acids and carbohydrates are converted to triglyceride in the liver
and this lipid is incorporated into lipoproteins prior to its secretion
into the circulation. Similarly, cholesterol and cholesteryl esters
are packaged in lipoproteins for delivery to extrahepatic cells. As
noted above, some of the cholesterol is obtained from the diet and the
27 52
remainder is produced endogenously ’ from acetate under the
regulation of 3-Hydroxy-3-Methyl-Glutaryl Coenzyme A Reductase
(HMG CoA Reductase, E.C. 1.1.1.34) the rate-limiting enzyme in
53
cholesterol biosynthesis
VLDL are the major lipoproteins synthesised in the liver and when
released into the bloodstream they, like chylomicrons, bind to
lipoprotein lipase and, under its action, lose much of their tryglyceride
47
Apo CII is again required for activation of the enzyme and is mainly
44
acquired by transfer from plasma HDL . The apo B of VLDL remains an
integral component of the particle throughout the delipidation cascade
to IDL and LDL^^. The apo B of chylomicrons (termed apo B-48)^^
synthesised in the small intestine is known to be different from the
54
VLDL apo B (apo B-lOO) of hepatic origin. VLDL catabolism is much
slower than that of chylomicrons, (half-life 1-3 hours^^) due possibly
51
to their lower efficiency of binding to lipoprotein lipase . Again 
excess surface phospholipid and cholesterol is transferred to HDL.
The particles produced by the action of lipoprotein lipase are the 
triglyceride-deficient and much smaller intermediate density
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lipoproteins which, like VLDL have Apo B as the major
45
apoprotein, with trace amounts of apo C and apo £■ . At this stage,
56
there is some removal of the IDL from the plasma by the liver . The
remainder is metabolised to LDL, which are smaller particles, rich in
cholesteryl ester., and containing apo B as the only apoprotein. The
site of this second stage of conversion is uncertain but it is thought
to occur in the liver. The acquisition of too much cholesterol by
extrahepatic cells necessitates its export into the plasma. This
is thought to be achieved by transfer of the sterol from the cell 
57
surface to HDL and within the lipoprotein it is esterified by the
action of Lecithin : Cholesterol Acyl Transferase (LCAT). The
cholesteryl esters so formed are eventually transferred to VLDL, IDL
and LDL via the agency of lipid transfer proteins^^'^^. Several
genetic disorders result in elevation of one or more of the lipoprotein
fractions. Such defects contribute to about 20% of all myocardial
59
infarctions occurring in those under the age of 60
1.2.3. THE LDL RECEPTOR PATHWAY
In man, LDL carries more than two-thirds of the total plasma cholesterol^^ 
Plasma LDL has a half-life of the order of 2-3 days and delivers 
cholesterol to all cells of the body^^. Cells may obtain the 
cholesterol they require by endogenous synthesis of the sterol from 
acetate units or from LDL. When available, LDL is usually the 
preferred source. The lipoprotein is assimilated by high-affinity and 
low-affinity routes. On binding to specific high-affinity receptors 
in coated pits on the cell surface, LDL is rapidly taken into the cell 
by endocytosis^^ (fig.5). The endocytic vesicle so formed migrates to 
the interior of the cell and fuses with lysosomes, exposing LDL to 
hydrolytic enzymes which release cholesterol, fatty acids, 
monoglycerides and amino acids. Cholesterol taken up in this way
LDL Rocoptors->-j5^
1, THMG CoA 
FkxjuctaM
z  I aca t
,J CXtHwWroi
3. f  LDL B*c#pto<Ti/OW*4WfY#
LDL Binding
Figure 5 ; The LDL receptor pathway in cultured
25
human fibroblasts
(ÀCAT - Acyl : Cholesterol Acyl Transferase 
HMG CoA Reductase - 3-Hydroxy 3-Methyl- 
Glutaryl Coenzyme A Reductase)
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regulates several intracellular events which collectively mediate
cholesterol homeostasis within the cell, i.e. the activity of
HMG CoA Reductase, the rate-limiting enzyme in cholesterol
biosynthesis, is reduced^^’^ ^ and Acyl : Cholesterol Acyl Transferase
(ACAT) activity is increased^^ so that LDL cholesterol may be
esterified for storage as cytoplasmic lipid droplets. A further
consequence of receptor-dependent LDL uptake by the cell is the
suppression of receptor synthesis, which prevents over-accumulation
of cholesterol^^. Thus, by the use of these three mechanisms, the
intracellular and extracellular sterol concentrations may be
constantly balanced to maintain a stable cholesterol environment within
the cell. About half of LDL cholesterol assimilation is
accomplished via the receptor pathway in man. Low-affinity routes,
e.g. bulk absorptive endocytosis, account for removal of the remainder
of the LDL from plasma. One such route is thought to involve the
reticulo-endothelial system^^'^^ and when plasma LDL-cholesterol levels
are high, macrophages ingest LDL and can become "foam cells" which are
characteristic components of atherosclerotic plaques^^.
The exact proportion of cellular sterol which comes from receptor-
mediated LDL uptake in each type of cell is uncertain but it is thought
that de novo synthesis is sufficient for cells with a very slow rate of
25
cholesterol turnover . However, cells which are heavy users of
30 31 29 50
cholesterol, e.g. adrenals ’ and liver ’ , preferentially obtain
cholesterol from the LDL receptor pathway.
1.2.4. THE LDL RECEPTOR
LDL receptors from bovine adrenal cortex were purified by Schneider 
69
et al in 1982 and have been observed in a number of human and animal 
cells (table 3). The receptor molecule was found to be an acidic 
glycoprotein, with an apparent molecular weight of 164,000 on SDS
TABLE 3 : CULTURED CELLS WHICH OBTAIN CHOLESTEROL VIA THE
LDL RECEPTOR PATHWAY*
HUMAN Fibroblasts
Fibroblasts transformed by SV40 
Smooth muscle cells 
Endothelial cells 
Lymphoblasts 
Burkitt lymphoma cells 
Acute myelogenous leukemia cells 
HeLa cells
12
13
Epidermoid cervical carcinoma(EC-50)
13
Endometrial adenocarcinoma(AC-258)
20
Glioma cells
14
Hep-G2 Hepatoma cells
Non-small-cell lung carcinoma (L-DAN)#
MOUSE & RAT Adrenal cells(Y-1 clone) 
Teratocarcinoma cells 
L cells
L1210 leukemia cells
144
P388 leukemia cells
HAMSTER Chinese hamster ovary cells 
Fibroblasts
DOG & SWINE Fibroblasts 
Smooth muscle cells
COW Adrenocortical cells 
Endothelial cells
* From reference 28 unless otherwise stated
¥ Simian Virus 40
# This thesis, Section 2.4.8
25
polyacrylamide gel electrophoresis. The protein chain is composed
of 839 amino acids and may be divided into 5 domains, each with a
70
particular function . The NH^-terminal 322 amino acids constitute
the first domain. This section contains many cysteine residues whose
sulphydryl groups are bound in disulphide links, thus conferring
rigidity and stability on this part of the receptor. Overall the first
domain is negatively charged and probably provides the site for
interaction with the positive arginine and lysine residues known to
71
be crucial in the binding of apo B and apo E . Second and third domains
are 350 and 48 amino acids long respectively. The third domain is
immediately adjacent to the cell and probably serves to extend the
receptor so that binding sites are clear of the membrane. The fourth
domain spans the plasma membrane. This region of the receptor has 22
amino acids, all of which are apolar. The carboxy terminal end of the
receptor forms the fifth domain which projects into the cytoplasm. It
is thought that this sequence binds to clathrin or a clathrin-
associated protein, enabling the receptor to be incorporated into coated 
28
pits . The carbohydrate chains are attached, two through N-linkages
72
to asparagine and 18 via 0-linkages to serine and threonine . The
exact location of these chains on the protein backbone is unknown. The
LDL receptor is synthesised as a lower molecular weight precursor in
the rough endoplasmic reticulum and converted to the mature receptor
in the Golgi complex by addition and modification of the carbohydrate 
73
side chains . It is inserted into specialised areas of the plasma
membrane, which allows it to function as an effective transport
74 74
mediator. These areas are called "coated pits" . In 1976 Anderson , 
in collaboration with Goldstein and Brown, showed that, in cultured 
human fibroblasts, LDL receptors were found almost exclusively in these 
regions of the plasma membrane. The characteristic feature of these 
indented segments of the plasma membrane is a cytoplasmic surface lined
26
75
predominantly with the protein clathrin of molecular weight 180,000
Continually forming and pinching off, coated pits are transient in
nature and their lifespan is less than five minutes^^. Their rate of
formation and internalisation is not affected by the presence of LDL 
28
or LDL receptors and each pit contains receptors for many different 
macromolecules^^.
Unlike LDL, the receptor molecule is not degraded on fusion with
lysosomes within the cell. Instead, it returns to the cell surface
28
and into the coated pits . This was demonstrated by blocking the
synthesis of new receptors with cycloheximide and observing that there
was no reduction in the rate of binding or internalisation of LDL by
65
human fibroblasts over several hours . The coated pit, enclosing the
LDL-receptor complex, forms an endocytic vesicle which breaks away from
the plasma membrane. The endosome, containing the LDL, which has lost
28
its clathrin coat and its complement of receptors is carried through
74
the plasma to fuse with a primary lysosome where its contents are 
exposed to hydrolytic enzymes. Here apo B is enzymically degraded to 
its component amino acids and cholesteryl esters are hydrolysed to yield 
fatty acids and unesterified cholesterol^^.
1.2.5 SPECIFICITY OF LDL RECEPTORS IN VITRO
The receptor binds LDL by interaction with apo B on the particle's 
25
surface . This binding is dependent on a limited number of 
functionally significant arginine and lysine residues and it can be
abolished by modification of these particular residues on the
79 78 79
lipoprotein . Studies with human fibroblasts by Mahley et al '
showed that, in addition to apo B, the LDL receptor can bind apo E-
containing lipoproteins, viz. chylomicrons and IDL. This property was
discovered in experiments where dogs and swine were fed a high
cholesterol diet which caused the appearance of an HDL species, HDL^,
27
which is high in cholesteryl ester and contains apo E as the only 
78 125
apoprotein . I-apo E-HDL^, when placed in the culture medium of
human fibroblasts, was taken up by LDL receptcrs with 10-25 times the 
affinity of LDL^^. It was also observed that the receptors became 
saturated by HDL at 25% of the number of LDL particles required for 
saturation. Pitas et al^^ deduced that the enhanced affinity of HDL^ 
was due to the fact that four apo E molecules in each HDL particle 
bound to a receptor on the cell surface.
1.2.6 HEPATIC LIPOPROTEIN RECEPTORS
The liver is known to remove chylomicron remnants, VLDL, IDL, and LDL
from the plasma by receptor-mediated mechanisms^^. Although as noted
above, chylomicron remnants may be recognised by the LDL receptoq most
are removed from the plasma by interaction with a receptor which is
distinct from the former. Apo E binds to this receptor and initiates
endocytosis and degradation of the lipoprotein of which it is part.
82
Cholesterol so obtained by the cell suppresses HMG CoA Reductase as
125
in the LDL receptor pathway. In dogs . I- apo E-HDL^ is rapidly
cleared by the liver via the "chylomicron receptor pathway".
Clearance is retarded by preventing receptor binding by modifying the
lysine residues of apo E. Liver uptake of HDL^ is saturable and
48
subject to competition from chylomicron remnants . The observations 
that LDL does not compete for chylomicron remnant uptake, and LDL 
receptor-deficient animals and humans have normal chylomicron 
metabolism, indicate that the two receptors are distinct. This is 
further illustrated in familial dys-p-hyperlipoproteinemia, where a form 
of apo E is synthesised which is not recognised by receptors, and
remnants and IDL persist in the plasma, but LDL is metabolised as
,84
normal
A summary of the properties of the LDL receptor is given in table 4.
TABLE 4: PROPERTIES OF THE LDL RECEPTOR
#
LOCATION :
BINDING CAPACITY:
BINDING AFFINITY:
BINDING SPECIFICITY:
NUMBER OF BINDING
SITES PER CELL:
MOLECULAR WEIGHT :
RATE AT WHICH BOUND LDL IS 
INTERNALISED INTO THE CELL:
RATE OF TURNOVER OF 
RECEPTORS :
BINDING CHARACTERISTICS :
BINDING -pH OPTIMUM :
ENZYME TOLERANCE:
METABOLIC REGULATION :
Concentrated in regions of cell surface 
membrane called clathrin coated pits
Saturation at 50pg of LDL protein per mL
K - 2jig of LDL protein/mL at 4°C 
^ -10-15pg of LDL protein/mL at 37°C
Affinity for LDL more than 200-fold higher 
than for HDL. Affinity for canine HDL 
23—fold higher than for LDL . ^
7,500-15,000 at 4°C, 1,500-70,000 at 37°C 
164,000^^
t,, - 3 minutes at 37°C 
/z
tiy - approx. 20 hours
/z
Requires divalent cations
Abolished by chemical modification of
lysine and arginine residues of apoB & apoE
7.5
Sensitive to proteases.
Resistant to glycosidases.
Receptor synthesis repressed by LDL, 
cholesterol or oxygenated sterols.
37
# Data from reference 25 except where otherwise indicated
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1.2.7 THE LDL RECEPTOR PATHWAY IN VIVO
Results of in vitro experiments examining the regulation of LDL 
metabolism within the cell cannot be quantitively extrapolated 
to apply to the in vivo system. In order to calculate the uptakes 
of LDL by the receptor pathway in various cells in vivo it would be 
necessary to know the exact LDL concentration at the surfaces of 
extravascular cells and the extent of receptor expression in each 
cell type. Also, the LDL concentration in human interstitial fluid^^ 
is known to be high enough for suppression of cultured human fibroblast 
LDL receptors. Other methods have therefore been devised for the 
study of receptor mechanisms in vivo.
Since the lipids of LDL are constantly exchanging^^, their labelling
yields data of limited value in following the kinetics of the intact
LDL particle. Instead, the apoprotein moiety of the LDL is usually
trace-labelled since it remains with the particle throughout its
lifespan in the plasma, and the amount of apo B per particle is
constant^^'^^. Thus apo B metabolism reflects the metabolism of the
whole LDL particle. In typical experiments donors are injected with
their own LDL which has been labelled with ^^^I . Blood samples
are 'withdrawn at intervals and the clearance rate of LDL determined
from serial measurements of plasma radioactivity. lodotyrosine,'
generated in the degradation of LDL is rapidly filtered from the
circulation by the kidneys. When results are expressed as percentages
of initial radioactivity, a decay curve for LDL catabolism may be
constructed (fig.6 ). This allows calculation of the fractional catabolic
rate (FCR) of apo B^^. The decay curve for human ^^^I-LDL was found to 
89
be biexponential and this phenomenon may be explained with the use 
of a simple two-compartment model (fig.7), with intra- and
tï
Upi C W -iC i 
-4.2 24 ♦ 
40 I
_T% d XA
. rCR CL333 0.212
(j)oo4*,'c0
% iwodiftcoHoft of ilX «Nrynyl MwiJu-M - 60
UNTREATED UDl
12 13 W 139 K) 112 3 4 3 7 86
DAYS
Figure 6 : Plasma decays of Native- and 1,2-cyclohexane-
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dione(CHD)-modified- LDL»-in man 
(FCR : Fractional Catabolic Rate)
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extravascular pools. The first compartment contains approximately
two-thirds of the total LDL pool. This encompasses LDL in the
intravascular pool and in rapidly exchanging tissue spaces. The
remaining LDL is located in slowly exchanging extravascular spaces.
After 5-6 days the two pools have equilibrated and consequently the
89
decay curve becomes monoexponential . The FCR and apo-LDL
concentration together are used to calculate the absolute catabolic
rate (ACR), commonly expressed as mg Apo-LDL/day/Kg body weight. In
the steady state the ACR is equivalent to the rate of synthesis of apo 
89B . Although this method allows investigation of total LDL kinetics 
in vivo, it reveals no information about the extent of the contribution 
of the receptor pathway to LDL catabolism.
As mentioned previously, the lysine and arginine residues on the
binding site of apo B may be chemically modified so that the binding
of the apoprotein to its receptors is abolished^^*^^. Consequently,
LDL modified in this way cannot gain entry to cells by the receptor
pathway. It may enter only by non-receptor-dependent mechanisms and
therefore modified lipoprotein is cleared much more slowly from the 
92
plasma , (fig.6 ). The clearance of LDL by the receptor pathway may 
then be expressed as the difference between total LDL removed 
(native LDL) and the removal by receptor-independent methods 
(modified LDL). Using this approach, it has been shown that the
LDL pathway makes a significant contribution to cholesterol metabolism
93,94  ^ , . 91,92,95 „ ' ^
in man , and several animal species . Reports of the
proportion of LDL cleared by receptor vary according to the method
employed to modify the receptor-recognition site of apo B. Values
are in the range 30-60% of the total LDL catabolised.
Studies conducted using 1,2-cyclohexanedione (CHD) - modified LDL
91 96 97
appear to underestimate receptor activity ' ’ . The partial
reversal of CHD-modification has been shown to occur spontaneously at
30
pH 7.4 in but this seems not to affect significantly the
99
results obtained in vivo . Reductive méthylation of the lysine
residues of apo B yields a stable modified'LDL^^^. This complex is,
however, rapidly cleared from the plasma in man and dogs, with a
half-life of only a few minutes^^^ suggesting that it is recognised
as a foreign particle. In some species (rats, rabbits, monkeys),
however, méthylation is successful in retarding the removal of LDL
from plasma and gives a reasonable estimate of LDL clearance by
non-receptor routes^^'^^'^^^. More recently, LDL whose lysine
residues have been glycosylated has been used as a tracer. Estimates
of receptor-LDL uptake by this method indicate that more than 50% of
94
plasma LDL is metabolised via the receptor pathway
The above methods have also been used to assess the effects of genetic
defects, drugs, and hormones on LDL catabolism^^’^ ^. For example,
102 103
cholestyramine and thyroxine have thus been shown.to stimulate
the LDL receptor pathway in man and animals and thereby increase LDL
catabolism.
1.2.8 SITES OF LDL CATABOLISM IN VIVO
Different types of cells have different requirements for cholesterol,
therefore, the degree of expression of cellular LDL receptors is
variable. Several methods have been developed to assess tissue
30
receptor activity in vivo. Assays on isolated cell membranes
have shown that the receptors are present on most tissues (table 3),
although the majority have relatively low activity^^. Those tissues
which actively utilise cholesterol, such as liver, adrenal glands and
ovaries are all high in receptors^^. Adrenals have a rapid throughput
30 31
of cholesterol which they use as a precursor for steroid hormones ' 
Similarly, ovaries require cholesterol as a substrate for hormone 
synthesis, while the liver utilises LDL cholesterol in the synthesis
31
of bile acids and lipoproteins.
A second method of determining tissue receptor status is to use
non-degradable markers of LDL catabolism (fig.8 ). The radioiodinated
LDL commonly used in kinetic studies is degraded by the cell, releasing
iodotyrosine which is rapidly excreted by the kidneys. Thus the
tissue uptake values obtained using this tracer reflect only the
catabolism occurring immediately prior to assessment. Non-degradable
tracers have the advantage of remaining inside the cells they have
entered and give a cumulative assessment of LDL catabolism over the
time-course of the experiment. Pittman et al have used ^^C-sucrose^^^
and ^^^I-cellobiose-tyramine^^^ covalently bound to LDL as cumulative
probes of the metabolic fate of the lipoprotein. Also, Stein et al
have studied the metabolism of LDL whose core has been loaded with 
125
non-degradable I-cholesterol linoleyl ether. Regardless of the
tracer used, such experiments have indicated that the adrenal glands are
the most active tissues in LDL receptor-mediated uptake per gram
weight but, due to its size, the liver makes the largest contribution
to receptor catabolism of LDL, removing over 50% of plasma LDL by this 
99,104,106,107
process
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Figure 8 : Non-degradable markers of LDL catabolism.
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1.3 LDL AND CANCER
1.3.1. HYPOCHOLESTEROLEMIA IN CANCER
, Hypocholesterolemia has been observed in many cases of cancer^^^'^^^.
In 1930 Muller reported hypocholesterolemia as a frequent finding
110
in cases of leukemia . Since then several epidemiological studies
have been conducted^^^. Of these 15 provided evidence that men in
the lowest quintile of plasma cholesterol concentration were at
increased risk of cancer and 12 showed no such relationship. Hence
hypocholesterolemia, although common in cancer victims, cannot be used
as a predictive factor. Until recently, there was considerable
controversy as to whether the low plasma cholesterol observed in
cancer patients is a cause of the neoplasm or an effect of its
112
presence. Bases et al showed that plasma cholesterol levels 
returned to normal in leukemic patients receiving successful 
chemotherapy, so supporting the latter argument. Further studies 
conducted in 1980^^^ and 1982^^^, indicated that most subjects with 
low plasma cholesterol who died of cancer,, did so within 1-2 years of 
detection of the hypocholesterolemia and the concensus view now is 
that hypocholesterolemia in these patients was probably a consequence 
of cancer present, but undetected, at the time of blood sampling.
1.3.2. PLASMA LDL CHOLESTEROL 
115
Ginsberg et al examined the cholesterol content of lipoprotein ; 
fractions in groups of hypocholesterolemic-leukemic patients and 
normal subjects. The lowering of plasma cholesterol in the former 
was mainly due to a decrease in LDL cholesterol. The plasma 
concentration and metabolism of VLDL were found to be normal but the 
catabolic rate of LDL was significantly increased. They postulated 
that the increased mass of actively proliferating neoplastic cells had
33
elevated cholesterol requirements and so metabolised large quantities 
of LDL. This agrees with the findings of Gal et al^^- that cancer 
cells in culture exhibit high LDL receptor uptake and endogenous 
cholesterol synthesis when in a logarithmic growth phase. Gilbert 
et al^^^ later showed that plasma cholesterol levels in a patient 
with chronic myelocytic leukemic fluctuated inversely with disease 
activity. This is further evidence that hypocholesterolemia is an 
effect of cancer rather than a cause.
1.3.3. LDL RECEPTOR ACTIVITY IN NEOPLASTIC CELLS IN VITRO 
12
Ho et al in 1978 showed the rate of receptor-mediated degradation
of LDL was 3-100 times higher than normal in mononuclear cells from
patients with acute myelocytic leukemia,than in those from normal
subjects. In these cells there was also a higher rate of endogenous
synthesis of cholesterol. Despite the increased cholesterol
availability in these cells, the cholesterol:protein ratio was 50%
lower than normal. This implies a rapid turnover of cholesterol,
which may be attributable to a rapid efflux of the sterol from the
cells or, more probably, to a high rate of utilisation of cholesterol
for cell growth and replication. The LDL receptor pathway in four
human gynaecological cell lines was observed by Gal et al^^ to be
subject to all the regulatory mechanisms observed in the pathway in 
65
human fibroblasts . Furthermore, the rate of receptor-mediated
degradation of LDL was found to vary according to the cell density in
the cultures, with cells in log phase exhibiting the highest rate of
LDL degradation. These workers later reported fifty times the LDL
receptor activity in cultured neoplastic gynaecological tissue as
13
compared to the equivalent non-neoplastic tissue cultures . The 
cancer cells also had elevated HMG CoA Reductase activity and overall 
the neoplastic cells were metabolising much larger quantities of
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cholesterol than their non-neoplastic counterparts. When the same
cell lines were propagated in mice, the tumours had 15-30 times more
binding capacity for LDL than any of the vital organs. Tumour cells
may therefore exhibit a much higher uptake of LDL than "normal"
tissues and LDL, on the basis of.these observations may therefore
constitute a good vehicle for the delivery of cytotoxic drugs or
radioisotopes selectively to cancer cells. The classic LDL receptor
pathway has also been observed in human hepatoma cells^^'^^^ and
Leydig cells^^^ in vitro, and LDL has been shown to provide cholesterol
for steroid hormone synthesis in the latter.
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More recently, Vitols et al have correlated leukocyte LDL receptor 
activity and plasma cholesterol levels in leukemic patients. Mono­
nuclear cells were isolated from the blood of healthy donors and from 
patients with leukemia. Elevated receptor-mediated degradation of 
LDL was observed in cells from leukemic patients and there was an
inverse relationship between plasma cholesterol and receptor activity.
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On analysis of the chromosomes of leukemic cells , those taken from
patients with significantly higher LDL receptor activity were found to
have an extra chromosome 8 . On the basis of this finding Lindquist et 
120
al postulated that chromosome 8 may include genes of importance in
24
the expression of the LDL receptor pathway. Further studies 
revealed that leukemic cells in the bloodstream are capable of the 
catabolism of 35% of the plasma cholesterol pool per day. They 
conclude that the increased assimilation of LDL by leukemic cells may 
be the cause of hypocholesterolemia in acute leukemia.
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1.4 CURRENT APPROACHES AND PROBLEMS IN CANCER CHEMOTHERAPY
The factors which influence drug efficacy in the treatment of diseases
other than cancer apply equally in the management of cytotoxic therapy.
As with any type of drug, absorption, binding, distribution, metabolism
and excretion all affect the overall success or failure of treatment
but, in addition, other properties of cytotoxic agents are important.
For most anticancer agents the difference between an ineffective dose
and a lethally toxic dose is very small, that is, these drugs have a
121
very narrow therapeutic range (fig.9). Many of the drugs commonly 
used are relatively unstable and are effective at very low concentrat­
ions. Some agents work only on cells at a particular stage of the 
122
cell cycle . Major organ dysfunction is not uncommon with cancer and
may complicate chemotherapy since the absorption, excretion, etc. of
the drug may be consequently modified, leading to increased toxic
effects unless the dosage is changed accordingly. One way of improving
cancer chemotherapy is to look for highly specific agents, but to-date
there are no drugs which are completely specific for malignant cells.
This is due to the lack of a qualitative difference between "normal"
and "cancer" cells. For specificity, cytotoxic drugs rely on
123
quantitative differences in distribution , the presence of target
124
biochemical reactions within neoplastic cells , and differences in 
125
cell kinetics . In general, tumours possess a large proportion of 
actively dividing cells and it is these cells which are most sensitive
to cytotoxic therapy. Other rapidly dividing cells in the body,
126 12V 128
including bone marrow . ' and gastrointestinal tract epithelium
usually suffer the toxic effects of chemotherapy. A second method of
obtaining better results with the anti-cancer compounds has been to take
advantage of their dose response curve (fig.9).which has been shown in 
121
animal models to be very steep. ,The number of tumour cells which
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Figure 9: Dose response curve for cytotoxic drugs
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survive may vary by several orders of magnitude between toxic and non­
toxic doses. It is on this basis that high-dose chemotherapy is 
justifiable, despite the often inevitable myelosuppression and 
mucositis.
1.4.1 PHARMACOKINETICS
In order for any cytotoxic agent to be therapeutically effective, it must 
penetrate the tumour cell cytoplasmic membrane. Once inside, it must 
be present in sufficient concentrations and must be exposed to tumour 
for an adequate length of time. Physical and chemical properties of 
the drug determine tissue distribution and dictate its metabolism and 
excretion. These factors contribute to the concentration-time profile 
of the drug within body fluids, different tissues, cells and subcellular 
compartments.
The observed kinetics of many antineoplastic agents can be explained by 
a simple two compartment model (fig.7). This model assumes that the 
drug is distributed unevenly between a central compartment, of small 
volume, and a peripheral compartment of larger volume. Drug enters the 
central compartment and is rapidly distributed among the body fluids 
and tissues which it comprises. Although the two compartments are 
"theoretical spaces" and do not correspond directly to specific 
anatomical sites, the central compartment can be said to consist of 
serum and the extracellular fluid of well-vascularised tissues. Drugs 
in the serum and tissues within this compartment equilibrate rapidly.
The peripheral compartment, in contrast, equilibrates very slowly with 
serum. This compartment is thought to consist of the more poorly- 
perfused tissues e.g. muscle, skin, fat and some tumours.
Drug may enter or leave the system only by the central compartment.
The apparent volume of drug distribution for each compartment is 
dependent on the extent of blood flow to each tissue, the ability of
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the drug to penetrate the tissues and the drug's affinity for them.
The peripheral compartment serves as a reservoir for the central 
compartment. As drug is excreted from the central compartment, it 
is replaced by drug from the peripheral compartment.
1.4.2. DRUG ADMINISTRATION
There are several routes by which antineoplastic agents may be 
administered. The method by which a particular drug is given depends 
on its stability, solubility and sclerosant characteristics. Some 
drugs are unsuitable for oral administration because they are 
destroyed by enzymes or low pH in the gastrointestinal tract, or 
precipitate at acidic pH. Others cannot be given intravenously because 
they are insoluble in aqueous solvents.
Oral administration is convenient and suitable for many drugs, e.g. 
chlorambucil. However, gastrointestinal (GI) function is frequently 
abnormal in cancer patients as a result of pre-existing GI complaints, 
the presence of abdominal tumour or side effects of treatment. Even in 
the absence of GI complications there is great variability in absorption 
of drugs between patients.
Intramuscular, intraperitoneal, intrathecal and subcutaneous routes are
less commonly used. Anthracyclines, for instance, cannot be given by
these routes since the high local concentration of drug generated may
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cause bleeding and tissue necrosis around the injection site . Intra­
thecal injection is useful in cases where drug would not otherwise 
penetrate the blood-brain barrier in sufficient concentrations. 
Intravenous drug administration is the most common of parenteral methods. 
Drug is injected directly into the central compartment and a stable high 
drug concentration may be maintained over a defined time by continuous 
infusion. Drawbacks to this approach are the possibility of 
thrombosis or infection and drug extravasation may cause necrosis at the
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injection site. Intra-arterial injection may be given to induce a high
local drug concentration at the tumour. However, this requires
surgery and a sizeable tumour artery must be located. This procedure,
like IV administration, carries the risks of infection and thrombosis.
Also, the administration of drugs like cyclophosphamide by this method
is of no added benefit, since the drug requires enzymic activation in 
130,131
liver microsomes
1.4.3. DISTRIBUTION, METABOLISM AND EXCRETION
The distribution of cytotoxic drugs in different tissues of the body
depends on the chemical structure and physical properties of the drug
in question. Polar drugs have difficulty in crossing lipid membranes
and hence are largely excluded from the central nervous system. The
concentration of drug in a particular organ is dependent on the size
of the organ, the rate of blood flow through it, and the lipid
solubility and polarity of the drug. Certain sites are relatively
impermeable to polar drugs, e.g. central nervous system, testicles, large
tumours. There may be other pharmacological "sanctuary sites" in which
the penetration of particular drugs is limited. Response rates to
chemotherapy in metastic breast cancer are higher in some métastasés .
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than others . , This may be a result of biochemical and kinetic 
differences between sites, but it is likely that drug distribution is 
important. A "third space" has been described where drugs may
equilibrate very slowly with the central compartment. This third com­
partment probably includes pleural or peritoneal effusions. The rate 
of drug elimination from patients with these "extra" reservoirs may be 
so greatly prolonged as to produce increased toxic side effects.
Many cytotoxic drugs are extensively metabolised. Some require
enzymic activation, e.g. cyclophosphamide becomes a potent alkylating
130 131
agent only after metabolism by microsomal enzymes in the liver ’
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Nucleic acid antimetabolites are activated in several sites in the
133
body, including tumour cells . It is important that the sites of
123 124
activation function properly. Organ dysfunction ’ may result 
in a prolonged half-life of the ineffective form of drug, with a 
failure to attain sufficiently high levels of the metabolised active 
agent. Conversely, in the case of drugs destroyed on metabolism or 
inefficiently excreted, toxic levels of drug may persist in the body 
for dangerously long periods.
Some drugs are excreted as the active drug, therefore impairment of
the excretion of these drugs leads to increased toxicity and doses must
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be reduced accordingly. Anthracyclines are excreted in bile and 
consequently any blockage of the biliary tract, e.g. gallstones, 
reduces or prevents excretion and anthracycline concentrations may 
rise above the safe therapeutic limit. Similarly, drugs excreted via 
the kidney are more likely to reach toxic levels and may even produce 
nephrotoxicity if administered to patients with kidney dysfunction^^^.
1.4.4. CELL KINETICS
Growing tumours may be composed of both proliferating and non­
proliferating cells, and within the former subpopulation, the cells may
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be at various phases of the cell cycle (fig.10.) Thus in the 
optimisation of drug schedules account must be taken of the kinetics of 
tumour growth, since certain agents may be markedly more effective at 
particular stages of the cell cycle. As an alternative to classificat­
ion by their mode of action, anticancer drugs are commonly classified 
according to the stage of the cell cycle during which they are most 
toxic. Thus three classes of cytoxic agent are defined:-
1 ) cell cycle non-specific
2 ) cell cycle and phase-specific
3) cell cycle non-phase-specific
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Figure 10: Cell phase and cycle specificity of cytotoxic drugs
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The first of these classes includes Y-i^'^adiaticn and nitrogen ir.usta;
and these agents are toxic to both dividing and non-dividing cells. 
Methotrexate, vinblastine and cytosine-arabinoside belong to 
the second category. Drugs of this type are ineffective against 
cells which are not actively proliferating. The third type of 
drug e.g. cyclophosphamide, nitrosoureas, actinomycin D, is much 
more toxic to proliferating than non-proliferating cells. Since 
most tumours are composed of cells in various stages of the cycle, 
drugs from each of the above categories are commonly given in 
combination in order to maximise the proportion of tumour cells 
under attack during treatment. Consequently combination chemotherapy 
is usually more effective than single-agent therapy.
1.4.5. DRUG RESISTANCE
Drug resistance is often a complicating factor in the treatment of
cancer. The resistance may occur in normal tissues as well as
tumour and may be intrinsic (e.g. bleomycin and cytosine arabinoside
are not effective against bone marrow and bowel cancer respectively)
or acquired. Resistance may be conferred by a combination of
137
pharmacological, biochemical and kinetic factors . One beneficial 
aspect of acquired resistance is that normal cells may develop an
increased tolerance of chemotherapy with repeated drug treatments.
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Acquired resistance is often due to induction of drug metabolism
and changed kinetics, in both normal tissues and tumour. Another
mechanism of resistance in tumours is believed to be a result of
mutation, whether induced by drugs or irradiation therapy. In
general, normal tissues are less susceptible to mutation since they
contain a relatively smaller proportion of dividing cells than tumours.
The frequency of mutation increases with tumour size and is variable
between different tumour types.
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1.4.6 DRUG TARGETING
Thus there are a number of problems which beset the clinical oncologist 
in his efforts to rid the patient of cancer cells and retain normal ones. 
There are two obvious ways of improving the benefit/risk ratio of 
cytotoxic drug therapy
(1) Improved Drug Design - drugs or prodrugs should be designed so that 
they have a high affinity for the site at which their action is required, 
or are only converted to their active form at that site. This should 
markedly increase the efficacy of therapy while minimising any harmful 
side effects. However, this approach is limited by the strength of 
the target/agent relationship which is generally far from ideal.
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(2) The Use of Targeting Vehicles - As long ago as 1906, Ehrlich 
proposed that molecules with an affinity for certain tissues could be 
used as carriers for therapeutic agents. By encapsulating drug within 
a vehicle, the distribution, uptake and overall efficacy of the drug
may be beneficially altered so that tumour cells' are damaged substantially 
more than normal cells. The ideal vehicle would deliver drugs only to 
their site of action and, once there, they would be passively released 
or internalised upon recognition of their target.
In addition to drug selectivity, numerous other factors, e.g. distribu­
tion, kinetics may act to reduce the intrinsic activity of a highly 
selective drug. Thus it is preferable to target drugs within some 
sort of carrier system. Drug vehicles should be non-toxic, biodegrad­
able and of size and shape to allow the incorporation of many drug 
molecules, without evoking a response from the host's immune system.
They should have a high affinity for their target site, while ignoring 
irrelevant areas. There must be a mechanism by which the drugs enter 
the cells along with, or after release from, their carrier. Several 
types of drug carrier have been investigated. These fall into three 
main categories; drug-antibody complexes; drug-macromolecule complexes;
42
and drug microspheres
1.4.7. DRUG-ANTIBODY COMPLEXES
Drug-antibody complexes often have improved toxicity against malignant
cells^’^^^ ’^ "^^’^ ^^. Binding of the immunoglobulin to its antigen
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on the cell surface is thought to initiate endocytosis , followed 
by lysosomal degradation of the antibody-drug complex and release of 
the free drug inside the cell. Isolation and purification of target- 
specific antibodies, however, remains difficult and it is also 
possible that the antigenic specificity of the tumour may change during 
its progression. Furthermore, drugs may distort the antigen-binding 
site, and render the complex susceptible to removal by the reticulo­
endothelial system. The drug-antibody interaction may be subject 
to competition from endogenous circulating antibodies against target 
cells and the host may even develop an allergic reaction to the drug- 
antibody complex.
1.4.8. DRUG-MACROMOLECULE COMPLEXES
Phagocytes and some malignant cells are able to actively endocytose 
macromolecules. Among the many macromolecular carriers which have 
been studied are DNA, albumin, liposomes and LDL. Deprez-de Campeneere 
and co-workers^ have studied daunorubicin (DNR) and doxorubicin (DOX) 
linked covalently to DNA. In mice with leukemia, both complexes were 
more effective than the native drugs and the overall toxicity of 
DOX-DNA was significantly less than that of doxorubicin. Cornu et 
al^^^ have shown drug-DNA complexes to be effective on certain tumours 
in man. Proteins such as albumin have also been used as carriers, 
p-amantin coupled to albumin^^^ was selective in damaging kidney 
proximal tubules and liver sinusoidal cells in vivo. Daunorubicin
3
covalently bonded to albumin was found to be more effective than the
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free drug, both in vitro and in vivo. The major drawback of drug- 
protein carriers is that liver and kidneys will suffer during 
chemotherapy since they constitute the main sites of protein 
endocytosis.
A great deal of work has been done with drug-liposome complexes,
6
where the drugs are carried entrapped in lipid vesicles . Although
liposomes provide a protective environment for the drug, they are
leaky and small drug molecules may easily diffuse out into the plasma.
This has been overcome to some extent by incorporating drug-
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macromolecule complexes e.g. DNA, poly-L-Glu into the liposomes.
In early work, the size of the lipsomes used (|im) precluded their
entry to small capillaries and induced their rapid clearance from the
8-11
plasma by cells of the R.E. system . Recently, much smaller, more
stable particles have been synthesised, but the liver, spleen and lungs
8-11
remain the major targets for liposomes in vivo . Inclusion of 
monoclonal antibodies in the liposome surface has increased the 
specificity of the carrier and, consequently, the efficacy of the 
drug^^^. In the case of methotrexate in liposomes conjugated with
7
antibody to L929 murine fibroblasts , a 10-fold increase in drug 
efficacy in vitro was observed. Another promising macromolecular 
drug carrier is LDL. LDL is, in effect, a "natural liposome" and as 
such has many of the advantages of liposomes, with the added benefit 
that its removal from the circulation by the R.E. system is likely to 
present less of a problem. The potential of LDL as a drug vehicle is 
discussed fully later (1.4.10).
1.4.9. MICROSPHERES
These are relatively large (0.2-300 pm) microspherical colloids of
147
polymers such as albumin . They are employed in the controlled
localised release of drugs. Their target is dictated largely by their
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size. Very small microspheres are cleared from the circulation
by macrophages of the R.E. system and are ultimately delivered to
Kuppfer cells in the liver. Particles 7-12 pm become trapped in the
lungs. Liver and spleen filter out particles 2-12 pm. Particles
larger than 12 ym stick in the first capillary bed they encounter.
Thus large microspheres will become entrapped in tumour vasculature
if they are injected into the arterial supply of the tumour^^^. A
high local concentration of drug is therefore achieved with reduced
effects on non-target tissues. Microspheres 1-2 pm may be coated with
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magnetic substances and directed to the required sites by external
150
application of two-dimensional magnetic fields. Senyei et al 
demonstrated that magnetic carriers of doxorubicin can achieve high 
levels of drug in the tumour with no drug in any other organ.
1.4.10 STRUCTURAL AND FUNCTIONAL ADVANTAGES OF LDL AS A VEHICLE 
FOR CYTOTOXIC DRUGS
Low density lipoproteins are particles composed of an apolar core of
cholesteryl esters and triglycerides surrounded by a phospholipid
27 34
monolayer containing free cholesterol and apoprotein B ’ . The
proportions of each of the lipids is shown in table 1. The apolar
lipid core contains approximately 1500 cholesteryl ester molecules and
provides an excellent site for sequestration of lipophilic molecules.
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Since the studies of Rudman et al , it has been observed that
numerous lipophilic agents partition into the lipoprotein fractions
13
in vivo. Gal et al indicated that LDL might prove to be a suitable 
vehicle for targeting of cytotoxic agents. Membrane fractions from 
human tumour cells (EC50), after propagation in mice, were found to 
have 15-30 times the affinity for LDL expressed by vital organs of the 
mouse. Studies in our own laboratory^^^ and by other workers^^^'^^^ 
indicate too that mouse tumours in vivo have a. high affinity, for LDL,
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which they obtain by the high-affinity receptor pathway. Cell
experiments have shown that the LDL pathway in neoplastic cells^^'^^
has all the characteristics of the classic LDL receptor pathway
described by Goldstein and Brown in cultured human fibroblasts^^. On
binding to its receptors on the cell membrane, LDL is rapidly
endocytosed and degraded in the lysosomes liberating its charge to the
inside of the cell (fig.5). LDL has the potential to act like the
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"ideal" drug vehicle in many respects , providing adequate amounts of 
drug for therapeutic activity can be incorporated into the lipo­
protein.
1.4.11 IN VITRO STUDIES WITH DRUG-LDL COMPLEXES
Recently numerous groups have reported successful arrest of fibroblast 
or tumour cell growth in vitro using antineoplastic agents carried in 
LDL.
Using "reconstituted" LDL^^^, Mosley et al^^ delivered the photo-
sensitising agent, pyrene, via the LDL receptor pathway. Subsequent
exposure to U.V. light led to cell death, since pyrene activated in
this way produces oxygen radicals. Human A431 epidermal carcinoma
cells, SV40-transformed human fibroblasts and Chinese hamster ovary
cells were among those killed using this method. Fibroblasts from a
patient with familial hypercholesterolemia (FH) which had no LDL receptors,
were unable to take up LDL by the receptor pathway. Consequently,
pyrene accumulation in these cells was very low and they were not killed
19
after exposure to U.V. light. In later experiments , Chinese hamster 
ovary cells pre-incubated with pyrene were exposed to LDL containing 
photoprotective azo dyes, scavengers of singlet oxygen. After U.V. 
irradiation, cells exhibiting high LDL receptor activity were undamaged 
by the pyrene and it was established that the photoprotective dyes were 
delivered to the cells by a receptor-dependent process.
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In 1983, Rudling et al showed that cellular accumulation of LDL 
containing the anthracycline Aclacinomycin A v;as dependent on LDL 
receptor activity in cultured human glioma cells. LDL accumulation 
was found to be highest when the cells were proliferating rapidly. The 
receptor-dependent uptake of drug-LDL was subject to competition from 
native LDL but not HDL. Chloroquine, an inhibitor of LDL degradation 
caused increased LDL receptor uptake. The drug-LDL complex inhibited
growth in glioma cells but not in FH fibroblasts.
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Firestone et al synthesised a number of lipophilic derivatives of 
cytotoxic agents with a view to reconstituting them in LDL. Two of 
these derivatives, both steroid nitrogen mustard carbamates, reconstit­
uted well with LDL and were able to arrest the growth of Chinese 
hamster ovary cells and SV40-transformed human fibroblasts at low drug 
concentrations. Using one of these compounds, (^-^^^2-^3p^(oleoyoxy)- 
androst-5-en-17p~ylj propylj oxyj carbonylj-N,N-bis (2-chloroethyl)— 
amine), the growth of 98% of the cells was arrested at 10 j^/mL of the 
drug in LDL. However, only 50% of these cells were actually killed. 
Increasing the drug concentration gave no enhancement in cytotoxicity. 
There were two possible reasons for this: 1) saturation of the LDL 
pathway; and 2 ) inefficient hydrolysis of the drug-steroid bond in the 
lysosomes. A second derivative (N-^|^ [ 4-[3p~(oleoyloxy)androst-5-en- 
17p-y!^ pentylj oxyj carbonylj -N,N-bis-(2-chloroethyl)amine) was 
synthesised, in which the steric congestion around the drug-steroid 
link was reduced, so facilitating the rapid enzymic liberation of free 
drug within the cell. This derivative, when reconstituted with LDL 
was able to kill 100% of the cells at concentrations of 5 jig/mL and 
above.
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Lipophilic derivatives of adriamycin were used by Vitols et al ’ for 
reconstition in LDL. In cultured human fibroblasts, accumulation of 
(N-(N-retinoyl)-L-leucyl doxorubicin-14-linoleate) -LDL^^ was measured
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and found to be equivalent to the theoretical uptake implied by the 
observed rates of LDL assimilation and degradation. As in the afore­
mentioned studies, FH fibroblasts showed little or no uptake of the 
drug-LDL complex. Drug-LDL complexes whose receptor-binding ability 
had been abolished by méthylation were not assimilated by the cells.
The drug-LDL complex was found to inhibit growth of normal fibroblasts.
In human white blood cells from normal and acute myelocytic leukemia
22
patients, the uptake of AD-32-LDL was many times higher than the
amount which could have been assimilated by the receptor pathway alone.
Therefore, in this system, the authors concluded that non-specific
mechanisms were responsible for the accumulation of a large proportion
of the drug. This was analgous to the results of Remsem and 
157
Shireman who observed that the carcinogen benzo(a)pyrene, when 
carried within LDL, was able to enter cultured fibroblasts in signific­
ant amounts even in the absence of LDL receptors, apparently via a 
rapid distribution of the compound between lipoprotein and cell
membrane. *
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Daunomycin was incorporated into LDL by Iwanik et al using a simple 
incubation procedure. After fluorescence quenching with DNA and K I , 
they concluded that the daunomycin had partitioned into two domains of 
the LDL particle viz. the core and the surface. An interesting finding 
was that the complex was toxic to both daunomycin-sensitive and 
daunomycin-resistant P388 leukemic cell sublines. In both cases 
more drug entered the cells when daunomycin-LDL was administered than 
when free daunomycin was used. Subfractionation of subcellular 
organelles showed the drug to be located mostly (86%) in insoluble 
nuclear material when native daunomycin was used. After exposure to 
the drug-LDL complex, some of the drug was found in the plasma membrane 
and nuclear membrane fractions, but the majority (65%) was in the 
mitochondrial-microsomal-lysosomal membrane fraction and insoluble
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nuclear pellet. The daunomycin distribution in organelles correlated
125
well with the distribution of I-labelled native- and daunomycin-LDL.
In subsequent work^^^, the same group showed the LDL-drug complex to
be more cytotoxic than the native drug at shorter exposure times.
Uptake of daunomycin-LDL was subject to competition from LDL but not
HDL. On analysis of the DNA content of treated cells it was apparent
that cells exposed to daunomycin-LDL had accumulated in the G^-M phase
of the cell cycle, whereas those given daunomycin were evenly
distributed in each phase, thus illustrating the enhanced cytotoxic
effects of the daunomycin-LDL delivery system.
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Halbert et al linked methotrexate (MTX) covalently to the apo B moiety
of LDL. The complex was thirty times less active against murine
leukemia in vitro than native drug. It is likely that the drug
binding to apo B caused distortion of the protein molecule, so
preventing its recognition by the LDL receptor, although it has been 
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reported that other covalent methotrexate-macromolecule complexes 
are less active than MTX when tested under similar conditions.
Another possible explanation for this decreased cytotoxicity is that 
methotrexate is not being efficiently hydrolysed from LDL and 
insufficient concentrations of free MTX are being released inside the 
cell.
1.4.12 LDL AS A CYTOTOXIC DRUG VEHICLE IN VIVO
From the results of the many cell experiments with drug-LDL complexes, 
it is apparent that LDL has potential as a drug vehicle. It carries 
drug in appreciable quantities primarily to cells which express 
specific LDL receptors. On binding to the receptors, the drug, inside 
LDL, is internalised by endocytosis and transferred to the lysosomes. 
Here the complex is degraded releasing the drug, free to apply its 
cytotoxic action within the cell. LDL is an endogenous particle and as
49
a carrier, it is not susceptible to the possible resistance mechanisms 
and allergic responses that some other macromolecular drug vehicles 
evoke.
For LDL to act as a drug-vehicle in vivo it is, crucial that:
1) the structure of the particle is not
changed in such a way that it is 
rendered "foreign";
2) the conformation of apo B is 
maintained to allow efficient
binding to LDL receptors.
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Some of the above studies > > » » » used LDL which had been
freeze-dried and reconstituted with drug by Kreiger's method^^^. This
procedure was originally developed for replacing cholesteryl esters
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in the core of LDL with their labelled counterparts . The particles 
produced act like native LDL in vitro but, when injected in vivo, they 
are recognised as foreign and cleared rapidly from the circulation by 
cells of the R.E. system.
Masquelier et al^^^ found that when AD-32-LDL was injected into mice,
98% of the complex was removed from the plasma within 90 minutes. By
comparison only 40% of injected native LDL was removed. High relative
uptakes of AD-32-LDL were found in liver, kidneys and spleen, indicating
that removal of the complex was mediated largely by the R.E. system. In
an effort to reduce the rate of clearance of the complex, the method of
drug incorporation was modified. Lyophilisation of LDL with 25%
sucrose instead of starch, followed by reconstitution with AD-32 as
before, produced a particle which acted like native LDL in vivo. The
possibility of using a complex in which AD-32 was covalently linked to
82
lysine residues on apo B was examined. As reported by Mahley , 
modification of more than 15% of the lysine residues greatly inhibits 
apo B-receptor interaction. Consequently, degradation of the drug-LDL
50
particle decreased with increasing conjugation of drug to protein.
The authors concluded that drug could be incorporated into LDL, 
producing particles which acted like LDL in vivo.
The use of LDL as a drug vehicle is, of course, not without its draw­
backs. Drug-LDL has the potential to harm any of the cells in the 
body, since they all utilise LDL to some extent. Organs which, under 
normal circumstances, use large quantities of LDL, namely adrenal glands 
and liver, are likely to suffer along with tumour during chemotherapy, 
unless steps are taken to protect them. Drug toxicity will be 
limited by the rate of the receptor mechanism and it is therefore 
possible that the receptor pathway could become saturated before toxic 
drug levels are reached within the target cells. Drug uptake via 
LDL would also be subject to dietary influence, since cellular drug 
accumulation would obviously be lowered when receptor expression had 
been downregulated in response to dietary intake of cholesterol, and 
vice versa. Another potential drawback is the current lack of 
techniques for making synthetic LDL which acts like the endogenous 
particle in vivo. Preparation of native human LDL requires fresh, 
unfrozen p'lasma, which would ideally come from the patient who is to 
receive chemotherapy. However, this may not always be practical, 
and unless a substantial proportion of the 1500 cholesteryl esters in 
each LDL particle is replaced by drug, the quantity of LDL required to 
administer a therapeutic drug dose may be too large in terms of both 
the volume of plasma required and the induced rise in the level of 
plasma cholesterol following re-injection of the drug-laden LDL.
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1.5 CHLORAMBUCIL, ADRIAMYCIN AND DAUNOMYCIN
Three drugs, namely chlorambucil, daunomycin and adriamycin - (fig.11), 
were incorporated into LDL in the course of this project and the 
following section outlines the modes of action, toxicity and pharmaco­
kinetics of each of them.
1.5.1. CHLORAMBUCIL
Sulphur mustard poisoning in World War I was observed to cause: a 
combination of gastrointestinal tract ulceration, lymphoid tissue 
dissolution and bone marrow aplasia. The toxic effects of nitrogen 
analogues of sulphur mustard on lymphoid tissue were studied by Goodman, 
Gilman and Dougherty in 1942 and their observations on transplanted 
lymphosarcoma in mice^^^ prompted them to undertake clinical trials 
with the nitrogen mustards, the first of the antineoplastic 
chemotherapeutic agents. Since then many nitrogen mustard derivatives 
have been synthesised, although few have had any more cytotoxic 
activity than the original compound.
All nitrogen mustards are considered chemically unstable. However, 
modification of the side chain increases the stability of some analogues. 
For example, chlorambucil (fig.ll), the phenylbutyric acid derivative of 
mechlorethamine (fig.ll), is stable enough to be prepared in tablet 
form and administered orally, while cyclophosphamide (fig.ll), is 
stable and inactive prior to activation by the cytochrome P450 system 
in the liver^^^'^^^. In contrast, mechlorethamine is so hygroscopic 
that it is prepared as dry crystals and reconstituted with water only, 
immediately prior to injection.
1.5.2. CHEMICAL ACTION OF CHLORAMBUCIL
The nitrogen mustards act by virtue of their ability to form carbonium 
ions which subsequently participate in electrophilic attack on
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biological molecules^^^ (fig.12). They readily form covalent bonds 
with amino, sulphydryl, hydroxy, carboxy and imidazole groups. Many 
cell sites are susceptible to this method of alkylation, including 
DNA, RNA and enzymes. Therefore, cell function and viability may be 
greatly affected by nitrogen mustards. The alkylation of DNA, 
however, is thought to be the main mechanism of the cytotoxic action 
of these agents. By altering DNA, alkylating agents disrupt basic 
cellular process. They interfere with mitosis and cell division in 
rapidly proliferating tissues.
Nitrogen mustards exert their effects on cells at all stages of the
cell cycle but toxicity is usually expressed in the S-phase with
165
blockage at the (pre-mitotic) phase . However, synchronised
cells in culture are generally more sensitive in late G, or S-phases 
than Gg, mitosis or early G^. This is possibly because polynucleotides 
are more susceptible to alkylation in the unpaired state, during DNA 
replication (S—phase), than in the — -helical conformation. Cells 
accumulated in the G^ . phase continue to synthesise cellular materials, 
without dividing. Lethal toxicity may be the result of damage to many 
cellular sites, for example, glycolysis, respiration, protein synthesis 
and nucleic acid synthesis are all processes which may be affected. 
Non-proliferating cells may later differentiate, without further 
mitosis, to adult cells. Slowly proliferating cells are more likely 
to recover from alkylation since the effects of alkylated DNA may not 
be of great importance prior to mitosis. Slowly dividing cells there­
fore have a much longer time in which to attempt DNA repair and so 
overcome the effects of the alkylating agents.
Interaction of bifunctional agents like chlorambucil with DNA tends to
have toxic effects, whereas monofunctional agents cause only mutations 
164
or carcinogenesis . Bifunctional molecules have the ability to 
cross-link two DNA chains. This is potentially more harmful than
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Figure 12: The mechanism of action of alkylating agents
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mono-alkylation, where the modified DNA may be compatible with the 
continued life of the cell and may be successfully passed to the next 
generation. DNA repair may recover the monoalkylated DNA, whereas 
highly cross-linked DNA is much more difficult to free from the damag­
ing alkyl groups. High-dose chemotherapy circumvents the DNA repair 
system to some extent by causing formation of extensively cross-linked 
DNA, whereas DNA damage during low-dose therapy may be easily 
corrected.
Due to their properties of lipophilicity, acid dissociation, and
stability in aqueous solutions, alkylating agents are able to cross
cell membranes. This is crucial to their activity, as are the two
(2-chloroethyl) groups. Several different groups have been used as
the third substituent on the nitrogen in an attempt to increase drug
selectivity and decrease overall toxicity, with varying degrees of 
164
success . A degree of specificity may be obtained because of the 
inherent difference in proliferation rates between normal and neo­
plastic tissues. Since normal tissues proliferate more slowly, the 
effects of alkylating agents are not immediately apparent and these 
cells may repair their DNA successfully before division occurs.
1.5.3. CHLORAMBUCIL - THERAPEUTIC USES AND TOXICITY 
Chlorambucil is commonly used in the treatment of leukemia, Hodgkin's 
Disease and malignant lymphomas. Administration of the drug is 
usually oral, in doses of 0.1-0.2 mg/Kg daily. Absorption from the 
gastrointestinal tract is variable but is generally complete within 
2 hours. There is little information on the metabolism, distribution 
and elimination of chlorambucil. Toxic effects of chlorambucil are 
most apparent in bone marrow, gastro-intestinal tract, skin and
T n ■ 4-L, n • 166occasionally in the liver
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1.5.4. RESISTANCE TO ALKYLATING AGENTS
There is little information available on the possible mechanisms of
resistance to alkylating agents but it has been widely observed that
acquired resistance to one alkylating agent confers cross-resistance 
137
to all others . The acquisition of resistance has generally been
observed to be slow, and is thought to be a result of several mutations,
not just a single one as is the case with antimetabolites. In
resistant cells, there is a decrease in the permeability of the cell
membrane to the drug. Production of nucleophiles is increased to
137
compete with DNA for alkylation e.g. administration of cysteine 
reduces the antineoplastic efficacy of alkylating agehts and several 
resistant animal tumour cells have increased free thiol concentrations 
as compared to sensitive cells. It is likely too that 
resistance is potentiated by an increase in the activity of the DNA 
repair system.
1.5.5. PHARMACOKINETICS OF CHLORAMBUCIL
167
Alberts et al observed in man that chlorambucil was rapidly absorbed 
from the gastrointestinal tract and cleared from plasma with a terminal 
phase half-life of 92 minutes. On administration of chlorambucil at 
0.6 mg/Kg, the peak drug concentration was found to be 1.1 pm/mL 
plasma. The major metabolite of chlorambucil, phenylacetic acid mustard, 
was seen in plasma within fifteen minutes of drug administration. 
Comparison of gastrointestinal and IV routes of administration^^^ of 
chlorambucil showed peak; plasma concentrations to be higher after IV 
injection. Peak plasma concentrations were observed 40-70 minutes 
after gastrointestinal administration. Thereafter, decay curves for
the drug were identical in both cases. Two metabolites were detected, 
one of which was the p-oxidation product of chlorambucil 2^4-N,N,-bis- 
(2-chloroethyl)-aminophenylj -acetic acid (phenyl acetic acid mustard).
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a compound known to have alkylating action in animals.
1.5.6. ANTHRACYCLINES
These are relatively new antineoplastic agents. The anthracyclines
(fig.ll) are antibiotics and were first isolated in the early 1960's
from fermentation products of the fungus Streptomyces peucetius, var.
caesius. Daunomycin was simultaneously discovered by groups in
France^^^ and Italy^^^ and as a result it is known by several
different names (daunorubicin, rubidomycin and daunomycin). Adriamycin
171
was later isolated in Italy and differs from daunomycin in only one 
hydroxy substituent. Structures for both drugs are shown in figure 11. 
The anthracycline molecule consists of a tetracyclic ring structure 
joined to the sugar daunosamine by a glycosidic linkage (fig.ll). 
Although their structures are almost identical, the two drugs are 
effective in the therapy of quite different neoplasms. Daunomycin is 
used mainly in the treatment of leukemia and lymphomas, whereas 
adriamycin is effective against a much wider spectrum of tumours.
1.5.7. CYTOTOXIC ACTION OF ANTHRACYCLINES
The mechanism of action of anthracyclines is not fully understood.
171a
X-ray diffraction studies and DNA model building suggest that anthra­
cyclines bind tightly to DNA. It is widely accepted that these drugs
172
intercalate the strands of DNA . The-<i-helix of the DNA molecule is
thus disrupted and no longer forms an effective template for RNA 
173
synthesis . Adriamycin has a great affinity for myocardial DNA and
this is thought to be a cause of the cardiotoxic properties of this 
174
drug . Both drugs may also have cytoplasmic routes of action.
Adriamycin is thought to cause intracellular damage as a result of
130
free-radical formation and cell membrane behaviour may also be 
affected. As expected, maximal cytotoxic effects are expressed, after
56
exposure to these drugs, during the S-phase of the cell cycle,
129 175
although some cytotoxicity is observed at other stages ’
1.5.8. METABOLISM OF ANTHRACYCLINES
The reason for the observed differences in the spectra of cancers
against which these agents are active is largely unexplained, but
differences in their metabolism have been observed. Both complexes
176 177
are extensively metabolised ’ . The major metabolites
are adriamycin-ol and daunomycin-ol which are the results of enzymic
reduction of the C-13 ketone^^^ and both express antitumour activity.
In acute myelocytic leukemia, the activity of "daunomycin reductase"
has been directly correlated with patients' response to daunomycin
therapy. Two other metabolites of d a u n o m y c i n ^ a n d  five of adria- 
177
mycin , all aglycone fragments of the drugs, have been observed.
Major sites of anthracycline absorption are heart, lungs, kidneys,
^ 123,178,179 , ... .
liver and spleen . Anthracyclines do not appear to cross
the blood-brain barrier and, when administered by intrathecal
injection^^^, were found to be toxic to cells of the central nervous
system. The liver is the primary site of anthracycline metabolism and
178
excretion, with 60% of adriamycin and 20% of daunomycin removed here
179
and subsequently excreted in bile . These drugs are also excreted
179
in urine, 25% and 6% of adriamycin and daunomycin respectively are
178
removed from the body by this route
1.5.9. THERAPEUTIC USES AND TOXICITY OF ANTHRACYCLINES
Both adriamycin and daunomycin are effective in the treatment of acute 
leukemias and malignant lymphomas. Daunomycin is also effective in the 
treatment of solid tumours in children but, unlike adriamycin, it is of 
limited usefulness against solid tumours in adults. Cardiotoxicity^^^ 
is a major dose-limiting factor in the administration of anthracyclines.
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and consequently the cumulative dose of these drugs is generally
2
kept below 550 mg/m . Dose regimens for both drugs vary depending
on the tumour type and the extent of its progression. Daunomycin
2
is usually given at a dose of 30-60 mg/m daily for 3 days or once 
weekly^^^. The recommended dose for adriamycin is 60-75 mg/m^, 
administered as a single IV infusion and repeated after 21 days^^^. 
Toxic effects of anthracyclines include stomatitis, alopecia, 
gastrointestinal disturbances and cardiomyopathy. Myelosuppression 
is frequently the main dose-limiting factor.
1.5.10 RESISTANCE TO ANTHRACYCLINES
In common with numerous other antineoplastic agents, acquired 
resistance to anthracyclines is frequently observed and the reasons 
for it are poorly understood. As in the case of alkylating agents, 
resistance to one anthracycline confers complete resistance to the 
other anthracyclines^^^'^^^. Cross-resistance has also been 
reported between anthracyclines and other natural products viz. 
dactinomycin and the vinca alkaloids^^^'^^^. It is likely that 
this type of cross-resistance is the result of modifications in 
cellular permeability. Cellular drug accumulation has been found 
to be lower in several resistant sublines when compared to the sensitive 
sublines^^^'^^^. It has not been established whether this is a 
consequence of increased drug efflux or decreased influx, although a 
number of authors have shown the former to be more important in several 
tumour models in vitro, and in vivo^^^.
1.5.11 PHARMACOKINETICS OF ANTHRACYCLINES
Anthracyclines are administered intravenously and so are immediately 
distributed in the central compartment. The plasma decay curve for 
daunomycin is biphasic with half-lives of 45 minutes for the initial
58
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rapid distribution phase, and 55 hours for the terminal phase
Adriamycin removal is triphasic, reflecting the participation of a
larger number of metabolites in adriamycin pharmacokinetics. Half-
lives of the drug in the three clearance phases are 12 minutes,
179
3.3 hours and 29.6 hours, as measured by Bachur et al
SECTION 2 . : MATERIALS, METHODS AND RESULTS
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2,1 MATERIALS
Suppliers of the materials used in the following experimental sections 
are detailed below. All other reagents and solvents were of Analar 
grade.
Adriamycin and daunomycin were supplied as gifts from Farmitalia Carlo 
Erba, Milan, Italy, and May & Baker Ltd., Dagenham, U.K., respectively. 
Chlorambucil was donated by The Wellcome Foundation, Crewe, U.K., 
or purchased from Sigma Chemical Co. Ltd., Poole, Dorset.
Radioisotopes ( ^^^I, ^^^I, [7-^h]-cholesterol, and [4 ,5-^h]-leucine) 
were obtained from the Radiochemical Centre, Amersham, Bucks.
MATERIAL SUPPLIER
Bio-Rex 70 Cation Exchanger 
Brij-35
Cellobiose
Cholesterol
Cholesterol Oleate 
Cholesterol Tosylate 
Cholic Acid 
Cyanuric Chloride 
1,2-Cyclohexanedione 
Dimethyl Hydrazine 
Dimyristoyl Phosphatidyl Choline 
Dipalmitoyl " "
Bio-Rad Laboratories, Watford, Herts
Sigma Chemical Co.,
Poole,. U.K.
Sigma
British Drug Houses (BDH)
Poole, U.K.
Sigma
BDH
Sigma
Fluorochem Ltd., Glossop, Herts 
Sigma
Na^EDTA BDH
MATERIAL SUPPLIER bU
Dulbecco's Modified Eagle's Medium
Folin-Ciocalteu Reagent
Glycine
Ham's FIO Medium
Human Serum Albumin
Hydrogen Peroxide Solution(40% w/v)
Hydrocortisone sodium succinate 
for injection
Iodine Monochloride
Lecithin
Microtitre Cell Culture Plates
Millipore Filters 
N-Nitrosobis(2-oxopropyl)amine
PDIO Columns 
QAE-A50 Anion Exchanger 
Scintillation Liquid (Dimilume 30) 
Silica
Silica Gel60p254 TLC Plates 
Sodium Dodecyl Sulphate 
" lodoacetate 
" Potassium Tartrate 
" Taurocholate 
Spectrapor Dialysis Tubing
Tissue Culture Flasks
Tris(hydroxymethyl)methylamine
Triton X-100
Trypsin .
Gibco Biocult Ltd., Paisley, U.K. 
BDH
II
Gibco
Sigma
BDH
Organon Laboratories,
Newhouse, Scotland
Sigma
Corning Medical 
Halstead, U.K.
Millipore Corpn., Bedford, Mass
Ash Stevens Inc.,
Detroit, USA.
Pharmacia(GB)Ltd, London
Packard Instruments
Sigma
BDH
BDH
Sigma
BDH
Sigma
Spectrum Medical Industries 
Los Angeles, USA.
Flow Labs., Irvine, Scotland
Sigma
Sigma
Gibco
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EQUIPMENT
Beckman L5-65 Centrifuge and rotors Beckman Instruments Ltd.,
Glenrothes, Scotland
Isco UA_ U.V. Absorbance Monitor 
b
Amicon B15 Concentrating Cells 
and Membranes
Packard Scintillation Counters
Iridectomy Scalpel & Trocar
MSE Scientific Instruments 
Crawley, W. Sussex
Amicon Corpn.
Lexington, Mass., U.S.A.
Packard Instruments 
Illinois, U.S.A.
MacCarthy'-s Surgical Instruments 
Dagenham, U.K.
ANIMALS & DIETS
NMRI and CFLP mice were obtained from inbred colonies at the Departments 
of Medical Oncology, Glasgow University, and Pathology, G.R.I., 
respectively. NIC B6D2F1 mice were purchased from . Bantin and 
Kingman Ltd., Hull, U.K.
Rats, Sprague-Dawley and Wistar were purchased from Strathclyde 
University and Lions Lab., Ringwood, Hants., 
respectively.
New Zealand White rabbits were purchased from Leslie Moore Ltd., 
Bradford, U.K. and fed diet SGI (Oxoid Ltd., Basingstoke, U.K.).
Standard small animal diet was obtained from Special Diet Services, U.K, 
Cholesterol and bile salt-enriched diets were prepared as described in 
Section 2.1.13.
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2.1.1. PREPARATION OF LDL
LDL was separated from human plasma by rate-zonal ultracentrifugation
by the method of Patsch et al^^^. A diagram of the apparatus used in
this procedure is shown in figure 13. Using a Beckman L5-65 ultracentrifuge
and Ti—14 zonal rotor, the LDL from 40-60 ml of human plasma was separated
from other plasma constituents by flotation through a linear sodium
bromide gradient, density range 1.0-1.3 Kg/L, at 45,000 rpm and 10°C
for 110 minutes. Eluant from the rotor was collected in fractions of
14 mL and the optical density at 280 nm monitored using an Isco UA5
Ultraviolet Absorbance Monitor. A typical elution profile is shown in
figure 14. The peak fractions containing LDL were pooled and concentrated
by pressure filtration in an Amicon ultraconcentration cell using an 
o
XMIOO A filter, under nitrogen pressure at 25 p.s.i. Excess sodium 
bromide was removed by washing with working buffer (0.15M NaCl, 0.01% EDTA, 
pH 8.1) and reconcentrating, several times, or by exhaustive dialysis 
against working buffer.
2.1.2. PREPARATION OF HDL AND d>l.21 Kg/L PLASMA FRACTION
HDL was prepared from human plasma by sequential ultracentrifugation at 
1.063 Kg/L and 1.21 Kg/L^^^. Human plasma was made up to density 1.063 Kg/L 
by the addition of 0.0834 g/mL of solid potassium bromide, overlayed 
with solution of the same density and centrifuged at 45,000 rpm and 10°C 
for 18 hours in a Beckman Ti60 rotor and L5-65 ultracentrifuge. Buoyant 
lipoproteins of density less than 1.063 Kg/L were aspirated. The solution 
containing HDL and plasma proteins at the bottom of the centrifuge tubes 
was made up to density 1.21 Kg/L by the addition of 0.236 g/mL of solid 
potassium bromide, overlayered with 1.21 Kg/L density solution and 
centrifuged overnight as above. ‘
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HDL (d 1.063 - 1.21 Kg/L) was aspirated from the tops of the tubes and 
desalted, either by dialysis against working buffer or gel matrix 
filtration through Pharmacia PDIO columns with working buffer (0.15M 
NaCl, 0.01% EDTA, pH 8.1) as eluant.
The remaining fraction at the bottom of the tube was dialysed against 
distilled water for 24 hours at 4°C, prior to further dialysis against 
working buffer (0.15M NaCl, 0.01% EDTA, pH 8.1) with several changes of 
solution.
2.1.3. RADIOIODINATION OF LDL
93
The protein moiety of LDL was labelled using a modification of the 
iodine monochloride method of McFarlane^^^. This involves the substitution 
of iodine at the meta-position on the phenyl ring of tyrosine residues 
of the apoprotein. Since this reaction is only 40% efficient with LDL, 
a 2.5-fold excess of ICI is required in order to label each mole of 
apoprotein, taken as 64000 daltons, with one mole of iodine. Apoprotein 
concentration was determined by the method of Lowry et al^^^, Section 2.1.9. 
or estimated by measuring absorbance at 280 nm on a Beckman Du-7 
Spectrophotometer and relating 1 optical density unit to a concentration 
of 1 mg/mL. (It should be noted here that, since this method was first 
described, the molecular weight of apoprotein B has been reported to be 
500,000 Daltons. Thus the estimation of apo B concentration here was 
purely empirical and overestimates the amount of protein present by a 
factor of 7.8. Consequently each mole of apoprotein is labelled with 
7.8 moles of iodine). To each mL of LDL solution (protein 2-5 mg/ml) 
prepared as described in Section 2.1.1. was added 250 pi of IM glycine 
buffer, pH 10.
64
125 131
After addition of the required amount of I or I, usually 1-2 mCi 
in 10-20 p L , the appropriate volume of 25 nM ICI was added, giving a 
final ICI concentration of 125-315 nM,, The reaction is complete in a 
few seconds and glycine and unreacted iodide were removed by gel filtration 
through a Pharmacia PDIO column, using working buffer (0.15M NaCl, 0.01% 
EDTA, pH 8.1) as eluant.
2.1.4. SYNTHESIS AND lODlNATlON OF CHOLESTERYL LINOLEOYL ETHER
Cholesteryl Linoleoyl ether (CE), figure 8, was synthesised as described
189
by Halperin and Gatt The cholesteryl ether was labelled by mixing
15 mg of the ether, in 250 pL of chloroform, with 250pL methanol,
2 mCi of ^'^^1 or ^^^1 and 250 pL of 25nM 101. This mixture was washed 
several times with distilled water to remove unreacted iodide. The 
labelled ether was further purified by thin-layer chromatography on silica 
gel 60p2g^ plates. These were developed in heptane: ethyl acetate (9:1) 
and the cholesteryl ether band (which migrated near the solvent front 
leaving iodide at the origin) was scraped off into a plastic bag. The 
radioiodinated cholesteryl ether (1-CE) was extracted into chloroform 
(3 X 5 mL) and transferred to a ,pre-wefghed glass tube before evaporation 
of the solvent under nitrogen at 40°C. The yield of 1-CE was usually 
ca. 10 mg.
2.1.5. INCORPORATION OF LABELLED CHOLESTERYL LINOLEOYL ETHER INTO LDL
This procedure (figure 15) has been adapted from Stoffel's method^^^ for
loading HDL with labelled cholesteryl esters and fatty acids. In brief,
the 1-CE was co-sonicated with cholic acid and lipids to generate micelles
which, when mixed With HDL undergo exchange of lipids. The ester-containing
HDL was purified and mixed with LDL.and the d >1.21 Kg/L fraction from
191
human plasma which was a source of cholesteryl ester transfer protein
1-CE/LiPlD M îX T U k E 4- u H u L Al t 1:1. w/v/
S O N IC A T IO N  IN 
0.02M TRIS, NaCl ,  EDTA. pH8.2
30 mins, 1/2 max oulpul,  0°C
MIGELLAR LIPID MIXTURE
NATIVE HDL 
1 : I . w /w 10 -24  hrs STIRRING, 25°C
1-CE H D L / LI PI D/C H OI. AÏE MI XT U R E
CHOLATE SEPHADEX G-25  
0.02M TRIS, NaC l ,  EDTA, pH8.2
1-CE HDL /LIPID MIXTURE
Y
MEMBRANE EILTRATION,0.22pm
CENTRIFUGATION AT c l L 0 6 3  K g /L ,4 5 K rp m ,1 0 "C ,  lOl irs
EXCESS
LIPID
5mg LDL PROTEIN 
15 m L d >1.21 Kg/L 
PLASMA FRACTION
SEPHADEX G-25 
0.15 M No Cl, 0 01% EDTA, pHO.2
i-CE-MDL
Y
24hrs  37"C
i -C E -L D L /  l -C E -H D L /  PLASMA FRACTION MIXTURE
MEMBRANE FILTRATION, 0.22pm
CENTRIFUGATION AT d 1.0 63 Kg/L. 4 5 K r p m . U A C .  IBhrs
1-CE HDL +  
PLASMA FRACTION
SEPHADEX G-25  
0 .1 5 M N o G I ,  001% EDTA, pH8.2 
MEMBRANE FILTRATION, 0.22pm
Y
-CE LDL
Figure 15: Protocol for the preparation of radioiodinated
cholesteryl ether-LDL (I-CE-LDL) by the 
modified Stoffel method, Section 2.3.2.
65
The labelled LDL was purified by centrifugation, and desalted by gel- 
matrix chromatography.
A) PREPARATION OF CHOLATE MICELLES^®^
Phospholipid, cholesterol and I-CE, in chloroform, were mixed in molar 
ratios of 80 : 24 : 53 and dried into the surface of a conical glass
tube under a stream of nitrogen. This required 10.9 mg lecithin (13.6jumol),
1.6 mg cholesterol' (4.1 pmol ) and 10 mg I-cholesteryl ether (9.0 pmol).
Cholic acid was dissolved in tris buffer (0.02 M tris(hydroxymethyl) 
methylamine, 0.02 M NaCl, 0.02 M EDTA, pH 8.2) to a final concentration 
of 4.6 mg/mL... Equivalent weights of cholic acid and lipids (i.e. 5 mL 
cholate solution to above quantities of lipids) were mixed and sonicated 
at 0°C for 30 minutes.
B) LOADING OF HDL WITH CHOLESTERYL ETHER
Cholate micelles and HDL were mixed 1 : 1 (weight/weight) and stirred 
overnight at room temperature. After 18-24 hours cholate micelles 
were removed by filtration of the mixture through 0.22 millipore 
filters. The HDL solution was made up to density 1.063 Kg/L by the 
addition of 0.0834 g/tiL of KBr, overlayered with dl.063 Kg/L density 
solution and centrifuged at 45,000 rpm for 18 hours in a Beckman Ti60 
rotor and L5-65 centrifuge. Fragments of HDL and lipid micelles and 
density solution were aspirated from the top of the centrifuge tube, 
leaving HDL labelled with 1-CE at the bottom. The l-CE-HDL was desalted 
by filtration through a Pharmacia PDIO column, eluting with working 
buffer (0.15M NaCl, 0.01% EDTA, pH 8.1).
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C) TRANSFER OF CHOLESTERYL ETHER FROM HDL TO LDL
By utilising the cholesteryl ester transfer protein found in human 
57 58 191
plasma ’ ’ the I-CE was transferred from HDL to LDL. Fifteen mL
of d >  1.21 Kg/L bottom fraction was incubated with I-CE-HDL and 5 mg 
LDL (protein) for 24 hours at 37°C.
D) PURIFICATION OF LABELLED LDL
The above mixture, after incubation,, was made up to density 1.063 Kg/L 
and overlayered with dl.063 solution prior to centrifugation at 45000 rpm 
and 10°C in a Beckman Ti60 rotor. Labelled LDL was removed by aspiration 
from the tops of the centrifuge tubes and desalted on a Pharmacia PDIO 
column using working buffer or phosphate - buffered saline, (PBS; 0.15M 
phosphate; 0.15 M NaCl pH 7.4) as eluant.
2.1.6. TRANSFER OF CHOLESTERYL ETHER FROM LDL TO OTHER LIPOPROTEINS
Man and many animals possess a cholesterol ester transfer protein^^'^^'^^^ 
which facilitates the exchange of cholesteryl esters between the 
lipoprotein classes. If I-CE-LDL is to be used as a tracer of LDL 
catabolism, it is essential that the animal whose metabolism is being 
studied does not have high cholesteryl ester transfer activity. It was 
therefore necessary to establish which of the animal models used had suitably 
low transfer activity.
125
I-cholesteryl ether HDL was prepared as described above (2.1.5.)
One.mL of mouse, hamster, rat, rabbit and human plasma were each incubated 
125
with 10 ^ L of I-CE-HDL (approx. 20,000 cpm) at 37“C for 24 hours.
67
The LDL from each sample was separated by centrifugation at 1.063 Kg/L
in a Beckman Ti40.3 rotor at 39K rpm and 4°C overnight. On completion of
125
the spin, 1 mL fractions were removed from each tube and their I—
activity measured using a Packard Twin-Channel Autogamma Liqui'd 
Scintillation Counter. The percentage of the total activity found 
in each fraction is shown in figure 16. It was concluded that hamster 
and rabbit plasma have high transfer activity, like human plasma, 
whereas mouse and rat have much lower activity. The use of I-CE-LDL 
as a probe of LDL catabolism is therefore likely to be confounded by 
transfer of the cholesteryl ether between lipoproteins in the former 
two species.
2.1.7. CELLOBIOSE-TYRAMINE-LDL:SYNTHESIS AND LABELLING
Cellobiose is a disaccharide (4-0-|^D-Glucopyranosyl-D-Glucopyranose)
which has a reducing aldehydic group available on the second ring.
Tyramine is a primary amine which will react rapidly with aldehydes to
form a Schiff's base. This linkage can then be reduced to make a stable
bond to LDL-lysine residues via cyanuric chloride (figure 8 ). Cellobiose-
tyramine (CT) was synthesised in a manner similar to that described by 
105
Pittman et al . 1  mmol each of cellobiose and tyramine and 5 mmol of 
sodium cyanoborohydride were suspended in 10 mL of distilled water and 
dissolved by heating to 50-60°C in a stoppered glass tube. The mixture 
was allowed to react at 37°C for 24 hours. Unreacted tyramine was 
removed by chromatography using a 1.6 x 100 cm column of Sephadex G15 in 
0.1 M ammonium acetate. The reaction mixture was applied to the column 
and eluted with ammonium acetate buffer at a flow rate of 20 mL/hr. 
Fractions were collected and assayed for tyramine, by measuring absorbance 
at 280 nm in a Beckman DU-7 spectrophotometer, and sugar by the enthrone 
reaction. Two peaks were obtained, the first contained 75% of the
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applied and all of the sugar, the second contained the remainder
of the ODggQ, that is, non-oonjugated tyramine. Exoess celloboise 
was removed by ion exohange ohromatography using Bio-Rex 70 Cation 
(Na"*" form) Exohanger, 200-400 mesh. The resin was washed in 50 
volumes of 0.12N HCl, three times, followed by three washes with 50 
volumes of water. The oolumn was paoked and eluted with water 
until the eluate was of pH 5-6. Peak I from the sephadex oolumn was 
applied in three aliquots, eaoh interspersed with 5 mL water. The 
unretained peak was eluted with water and was found to oontain 
sugar. The water elution was oontinued until there was no 
deteotable absorbanoe at 280 nm. The retained, positively oharged 
oonjugate was eluted using 3.5% ammonia solution. Ammonia and water 
were removed by overnight lyophilisation leaving pure oellobiose- 
tyramine.
To 250 nmol of CT in 50 pL of distilled water was added 10 pL of
125 131
O.SM KHgPO^, pH 4,5, 10 pL of Na I or Na I solution (Im Ci) and 
10 pL of ICI (250 nmol). The mixture was allowed to stand for 
15 minutes before the addition of 500 pL of distilled water.
Unreaoted iodide was removed on a 0.9 x 6 om oolumn of QAE-A50 
(Anion Exchanger),in distilled water. The I-CT was eluted in 
3-4 mL of water and lyophilised overnight.
Linkage of CT to LDL : A dried aliquot of the freshly made I-CT 
was dissolved in 5 x 10 pL of distilled water and 10 pL of the 
solution mixed with 20 pL of cyanuric chloride (2.5 mg/mL in acetone),
15 pL of 0.008 M NaOH and 10 pL of distilled water. This was 
allowed to stand for 15 seconds before the rapid addition of 5 mg LDL 
protein in 1 mL of working buffer. After 2-3 hours at room temperature, 
the I-CT-labelled LDL was purified on a Pharmacia PDIO oolumn, eluting 
with working buffeiu
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2.1.8. CHEMICAL MODIFICATION OF LDL
In order to prevent binding of LDL to its receptors, the arginine
.residues of apo B were modified .by 1,2- cyclohexanedione (CHD), as
90
described by Mahley et al , (figure 17). 0.15M CHD was made up in
0.2 M sodium borate buffer pH 8.1. Two volumes of CHD solution were
•mixed with each volume of the LDL solution (protein concentration 2-5 mg/mL),
and incubated at 35°C for two hours. Sodium borate and unreacted CHD
were subsequently removed by gel filtration through Pharmacia PDIO columns,
eluted with working buffer. This process modifies at least 55% of the
90
arginine residues in the apoprotein B , so preventing CHD-LDL from 
binding to LDL receptors.
Reversal of modification in vitro is possiblp by incubating the CHD-LDL
90 98
with a strong nucleophile such as hydroxylamine ’ . For this
reason tris buffers-should not be used in the preparation of CHD-LDL.
Reaction of the arginine molecules with CHD removes the positive charge 
■ characteristic of arginine residues. As a.result, the. modified .LDL 
has.substantially.more .anodic mobility than native LDL on agarose gel 
electrophoresis.
2.1.9. PROTEIN DETERMINATION
The apoprotein content of LDL was assayed by the method of Lowry et al^^^
using human serum albumin as standard- Reagents were prepared as follows
Solution A - 2% NaHCO^ in O.IN NaOH;
Solution B - 2% NaK Tartrate in deionised water;
Solution C - 1% CuSO^ in deionised water.
Biuret reagent - to 100 mL of solution A was added 1 mL of solution B 
and 1 mL of solution C.
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Folin-Ciocalteu reagent - the stock reagent was diluted 1 : 1 with 
distilled water.
Standards
Human serum albumin 1 mg/mL was diluted with deionised water to give 
25-100 pg protein / 400 pL. Bovine serum albumin, 0.3 mg/mL, was 
diluted 1 : 4 and used as a quality control.
Method
To each 400 pL sample, control and standard was added 2 mL of Biuret 
reagent. Following vortexing and a 10-minute stand, 200 pL of Folin- 
Ciocalteu reagent was added to each tube during further vortexing.
Colour was allowed to develop for 30 minutes and the optical density 
at 750 nm was measured using a Beckman DU7 spectrophotometer. A standard 
curve of OD^^^ v s . protein concentration was constructed and unknowns 
were read from the curve.
2.1.10. STERILISATION OF SAMPLES FOR INJECTION
All solutions used for injection into animals were sterilised by 
filtration through sterile millipore filters, pore size 0.22 pi*
2.1.11. COLLECTION OF BLOOD SAMPLES
Blood removed from a peripheral vein was placed in 10 mL glass tubes 
containing 0.1% EDTA, unless serum was required, in which case 
10 mL glass tubes containing no anticoagulant were used.
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2.1.12. INDUCTION OF TUMOURS
A) NMRI/MAC13 - This was carried out at the Department of Oncology 
at Glasgow University with the cooperation of Dr J Welsh. Solid 
MAC-13 tumour was passaged in two-month old NMRI mice from an inbred 
colony at the above department by subcutaneously injecting each animal
3
with approx 1mm of finely minced tumour. After 10 days the tumour 
had grown to approximately 1.5 g in weight (1.49- 1.13g, n=14). At 
this stage the animals were used in the study, or tumour was passaged 
through another group of mice.
B) CFLP/PAROTID ADENOMA - Parotid adenomata were induced in these mice
by inoculating them subcutaneously in the neck with A2LP polyoma virus
192
within 24 hours of birth, as described by Lamey et al . Following a 
latent period of 10-12 weeks the tumours became visible and therafter 
the animals were ready for use in ca.3 weeks. At this stage the tumours 
weighed approximately 0.5 g (0.43- 0.35 g, n = 8).
C) SPRAGUE - DAWLEY RATS/ COLONIC TUMOURS - Rats weighing 300g were 
injected for 16 weeks with dimethyl hydrazine in 0.05% EDTA solution,
193at a dose of 15 mg/%. Controls were injected with EDTA solution only 
Two to three weeks after the last injection, tumours were approximately 
Ig in size (0.92 -0.87, n = 25).
D ) WISTAR RATS/WALKER2.56 Tumour — Walker256 tumour was maintained in 
serial subcutaneous passage, in a colony of inbred Wistar rats, by 
Dr K Fearon at the Department of Oncology, G.U. Tumour was cut into 
fragments of 100 mg and placed under the skin in the flanks of rats 
weighing 200-250g. After 10 days, the tumours had grown to approximately
72
8g (8.01-3.75, n=8). The rats were used at this stage. This type 
of tumour was used for implantation in the subrenal capsular assay, 
described later. Section 2.3.14'.
E) HAMSTERS/PANCREATIC TUMOURS - Pancreatic tumours were induced in
Syrian hamsters by repeated weekly injections of N-nitrosobis (2-oxopropyl)
amine in normal saline at a dose of 5 mg/Kg over 23 weeks as described 
194
by Pour et al
2.1.13. ANIMALS AND DIETS
Unless otherwise stated, rats, mice and hamsters were maintained on 
standard small animal diet and allowed free access to drinking water 
(containing 1% potassium iodide for 1 day before and during LDL turnover 
studies, to inhibit thyroidal uptake of radioiodide).
Sodium Taurocholate - Enriched Diet
Standard small animal diet was spray-coated with a saturated solution 
of sodium taurocholate in ethanol. The ethanol was allowed to evaporate 
and the preparation had a final sodium taurocholate composition of 
1% (W/W).
High Cholesterol Diet
Cholesterol was heated in coconut oil (Ig in 10) and used to coat standard 
diet pellets. The final cholesterol content of the diet was 1% (W/W).
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2.1.14. MEASUREMENT OF LDL RECEPTOR ACTIVITY IN VIVO
LDL was prepared by rate-zonal ultracentrifugation of human plasma, as
previously described (2.1.1.). Aliquots of the concentrated and desalted
125 131
LDL were labelled, one with I and the other with I (2.1.3.).
131
One aliquot, usually the I-labelled, was then chemically modified
with cyclohexanedione. (2.1.8.) Tumour and control animals were each
injected with 0.1 mL of solution containing 5 pCi of each LDL tracer via
a tail vein in the mice, and by jugular vein in the rats. After 18 hours,
the animals were sacrificed and exsanguinated. The organs were removed,
125 131
rinsed in saline, blotted, weighed and I-LDL and I-CHD-LDL radio­
activity measured using a Packard Twin-channel Autogamma Liquid 
Scintillation Counter. Results were expressed as counts per minute/ 
gram of tissue per mL of plasma for each isotope.
This approach relies on the observation that CHD-modified LDL is cleared
more slowly than native LDL from the plasma (figure 6) since it is
unable to interact with LDL receptors and cannot therefore be catabolised
90
via the LDL receptor pathway . CHD-modified LDL is consequently cleared 
only by receptor-independent mechanisms. Whereas native LDL is subject 
to catabolism via receptor-dependent and receptor-independent routes.
Thus LDL receptor activity may be expressed as the difference between 
native- and CHD-LDL clearances (figure 18), if it is assumed that the 
distribution of modified LDL is identical to that of native LDL in the 
plasma and extravascular spaces.
Tissue radioactivity due to uptake of native LDL is a composite of 
receptor-bound, internalised and degraded LDL, and a non-specific 
component of LDL trapped in interstitial fluid. Since no
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difference.is assumed between the distribution of native
and chemically modified lipoproteins in interstitial fluid, calculated
CHD-LDL uptake contains this same non-specific component. The calculated
receptor-mediated LDL uptake into each tissue may then be attributed to
receptor- bound, internalised and degraded LDL/ The low-molecular weight
LDL degradation products after extraction of tissue homogenates with
trichloroacetic acid were found to correspond to less than 10% of the
total radioactivity in all tissues except kidney. Ninety percent of the
observed LDL uptake was then a result of the presence of high molecular
weight, presumably intact,lipoprotein. In the kidney 35% of the total
radioactivity consisted of degradation products, reflecting the role of
this organ in the excretion of iodotyrosine. Radioactivity assimilated
via the receptor pathway generally accounted for 25-40% of the total
tissue activity. The major breakdown products of LDL labelled in this
way are rapidly excreted from the cell. Thus LDL receptor activity
measured using I-LDL as a tracer reflects only the LDL metabolism securing
immediately prior to assessment in any particular tissue. In order to
measure cumulative LDL metabolism, it is necessary to employ a tracer
which is not excreted so rapidly from the cells which it enters. To this
end, several cumulative probes of LDL catabolism have been investigated.
Stein et al^^^ have used radioiodinated cholesteryl ether and, more
105
recently, Pittman et al have studied radioiodinated cellobiose- 
tyramine.
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2.2 RESULTS I
2.2.1. MEASUREMENT OF RELATIVE LDL RECEPTOR ACTIVITY IN ANIMAL TUMOUR 
MODELS USING NATIVE AND 1,2-CYCLOHEXANEDIONE-MODIFIED LDL.
Eighteen hours after injection of native and CHD-modified LDL into control 
and tumour-bearing animals, the radioactivity in their tissues and plasma 
was measured and used to calculate relative receptor-mediated LDL uptakes 
(2.1.14). The values obtained for each tumour type are shown in tables 
5,7-9 and figures 19,21-23.
A) MAC-13 TUMOUR IN NMRI MICE
All tissues examined showed some degree of receptor-mediated LDL uptake 
(figure 19). The liver is clearly the most active in receptor expression 
per gram of tissue (table 5), and per organ (figure 19). Apparently 
high receptor activity is found in the kidney (table 5) although this 
is partly a result of this organ's role in the excretion of the degradation 
products of iodinated LDL, namely iodotyrosine and free iodide - note 
the high TCA-soluble activity in figure 19. In animals with tumours, 
receptor-mediated hepatic assimilation of the lipoprotein fell 
(pCO.OS, Wilcoxon Rank Test) while uptake into other tissues remained 
the same as in the control situation. The tumour was moderately active 
in taking up LDL by the receptor pathway, and when account was taken 
of its mass (figure 19) it was found to be second only to liver in 
activity. The presence of MAC-13 tumour in these mice did not perceptibly 
change their total plasma cholesterol value (table 6), nor did it change 
the whole body clearance of native or CHD-modified LDL (figure 20).
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Figure 19 : Assimilation of LDL via the receptor pathway,
in NMRI mouse tissues and MAC-13 tumours,. 
measured as described in Section 2.1.14. The 
low molecular weight degradation products of 
the lipoprotein were extracted from tissue 
homogenates using trichloroaceticacid(TCA).
TISSUE
.RELATIVE RECEPTOR-MEDIATED LDL UPTAKE
{CPM/GRAM TISSUE/mL PLASMA)
CONTROL, GROUP (n=ll) TUMOUR GROUP (n=15)
Liver 30±11 21±9 **
Spleen 14+11 15+7
Kidney 23+12 26+5
Heart 13+5 19+6
*
Lung 14±9 ND
Muscle 6+3 11+3
Tumour - 16+8
Table 5 : Receptor-mediated LDL uptake into the tissues
lb?
of NMRI/MAC 13 mice .
* ND : Not determined.
** Wilcoxon Rank Test, p<0.05
GROUP
PLASMA CHOLESTEROL 
(mmol/L)
Control*
(N=ll)
2.91-1.07
Control,
cholesterol
(n=12)
fed
4.62-0.64
Tumour*
(n=15)
2.72-0.81
Tumour,
cholesterol
(n=15)
fed
4.44-0.79
* Tissue uptakes of LDL for these groups are shown in 
Table 13.
Table 6 ; Effects of cholesterol feeding on plasma cholesterol
concentrations in control and MAC-13 tumour
152
inoculated NMRI mice
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B) POLYOMA VIRUS-INDUCED ADENOMATA IN CFLP MICE
The pattern of receptor-mediated LDL assimilation observed in NMRI mice 
was repeated in this model. Uptakes of LDL per gram of tissue are shown 
in table 7 . Again the liver, the most active organ in the control 
group, was suppressed by the presence of tumour (p«<0.05, Wilcoxon Rank 
Test). In these animals the opportunity was taken to measure adrenal LDL 
uptake. As expected, it was very high per gram of tissue (table 7), but 
because of its size, made a negligible contribution to overall LDL 
catabolism (figureZl). The tumour was also very active on a per gram 
basis and was matched only by hepatic uptake when its mass was taken 
into account (figure 21).
C) DIMETHYLHYDRAZINE-INDUCED COLONIC TUMOURS IN RATS
As in the mouse models, liver was the most active normal organ in 
receptor-mediated uptake of LDL, whether uptake was expressed per 
gram (tableS) or per organ (figure 22). The presence of this type of 
tumour in the rats did not suppress hepatic LDL uptake (figure 22), 
however, there was a significant (p<T0.05, Wilcoxon Rank Test) reduction 
in receptor-mediated assimilation of LDL by the ovaries of animals with 
tumours. Once again, both adrenals and ovaries had high LDL receptor 
activity per gram (table 8) although their contribution to overall 
LDL catabolism is minimal (figure 22). Tumour made a large contribution 
to receptor-mediated LDL catabolism with higher uptake of LDL by this 
pathway than any other organ.
TISSUE
RELATIVE RECEPTOR-MEDIATED LDL UPTAKE
(CPM/GRAM TISSUE/mL PLASMA)
CONTROL GROUP (n=9) TUMOUR GROUP (n=9)
Liver 60+14 27+9
Spleen 22+18 22+7
Kidney 36+12 28+10
Heart 31+5 23+7
Lung 36+16 24+7
Muscle 8+2 7+15
Adrenal 51+36 36+24
Tumour 31+9
Table 7 : Receptor mediated LDL uptake into
the tissues of CFLP/viral adenoma
. 152
mice
^ Wilcoxon Rank Test, p<0.05
R eceptor m ed ia ted  o rg an upta k e  o f L D L  
in  C F L P y/a d e n o m a  m ice
60
40
~o T3
Figure 21: Uptake of LDL via the LDL receptor pathway,
in CFLP mouse tissues and polyoma virus- 
induced tumours, measured as described in 
Section 2.1.14.
RELATIVE RECEPTOR-MEDIATED LDL UPTAKE
(CPM/GRAM TISSUE/mL PLASMA)
TISSUE CONTROL GROUP (n=3) TUMOUR GROUP (n=3)
Liver 88±3 104±15*
Adrenal 71 ±10 63±16
Spleen 58±13 57±10
Ovary 70±3 29±7 *
Lung 72±13 50 ±8 #
Kidney 70±6 83±24
Gut 64±2 64±12
Heart 28±5 26±6
Muscle 8±0.2 8±3
■ Fat 5±1 14±4
Tumour 160±35
Table 8 : Receptor-mediated uptake of LDL by the tissues
of normal rats and those with dimethylhydrazine- 
induced colonic tumours.
* Wilcoxon rank test vs controls, p^O.05,
# Not significant
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D) WALKER-256 TUMOUR IN WISTAR RATS
This tumour was very active in receptor-mediated LDL assimilation.
When compared to rat vital organs, tumour came second only to liver 
(figure 23) and gram for gram (table 9) tumour was more active than any 
other type of tissue assayed. Adrenals and spleen had high uptake per 
gram of tissue, but as organs they catabolised only a small proportion 
of the LDL injected (figure 23).
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Figure 23: Relative receptor-mediated uptake of LDL by rat organs
and Walker256 tumour implants.
RELATIVE RECEPTOR-MEDIATED LDL UPTAKE
TISSUE (CPM/GRAM.TISSUE/mL PLASMA)
Tumour 36^12
Liver 29-5
Spleen 29-5
Adrenal 17-10
Lung isis
Kidney lois
Ovary 8-2
Gut 7-10 ,
Skin 5-4
Muscle 1-2
Fat lil
Table 9 : Relative Receptor-Mediated uptake of
LDL into tissues of 8 rats with Walker 
256 Tumour implants.
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2.2.2. MEASUREMENT OF LDL CATABOLISM USING CUMULATIVE NON-DEGRADABLE 
MARKERS
In an attempt to improve the assessment of LDL uptake into tumour tissues 
^^^I-cellobiose-tyramine-LDL^^^ and ^^^I-cholesteryl linoleyl ether-LDL^^^ 
(figure 14), were used as probes. It has been reported^^^'^^^ that, once 
assimilated by cells, the leakage rate of these tracers is less than 35% 
per day compared with the instantaneous release of iodotyrosine from 
cell-ingested radioiodinated LDL.
125 125
Animals were injected with native I-CT-LDL (2.1.7.) or I-CE-LDL
(2.1.5.) and after 18 hours tumour and tissues were removed, rinsed, blotted
and assayed for radioactivity. The uptake of labelled LDL into each
tissue was expressed as a percentage of the injected dose per organ and
per gram of tissue. In NMRI mice with MAC-13 tumours receptor activity
was measured after injection of ^^^I-native- and ^^^I-CHD-modified-
cholesteryl ether LDL.
A) MAC-13 TUMOURS
In the control group adrenal uptake of CE-LDL (per gram) by the receptor 
pathway was highest of all tissues (figure 24). Uptake by adrenals in 
tumour-inoculated animals was significantly lower (p<C0.05 Wilcoxon Rank 
Test), table 10, a phenomenon which was not observed using I-LDL as a 
probe (figure 20). Most tissues in tumour animals showed slightly lower 
LDL assimilation by both receptor-dependent and receptor-independent routes 
Using this marker of LDL catabolism, relative tumour LDL receptor activity 
was quite low, although it was second only to liver when considered as a 
whole.
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RELATIVE RECEPTOR-MEDIATED LDL UPTAKE
(CPM/ORGAN/DOSE) x 100
TISSUE CONTROL GROUP (n=5) TUMOUR (n=3)
Liver 14.1+1.1 10.7+0.2 *
Spleen 0.35+0.51 0.44+0.03
Kidneys 0.12+0.01 0.08±0.009*
Adrenals 0.05+0.005 0.0210.007*
Heart 0.03+0.007 0.02+0.002
Lung 0.09+0.008 0.1310.01
Thymus 0.03+0.002 0.04+0.001
Gonads 07018+ 0.004 0.018+ 0.002
Tumour - 2.13+ 0.18
Table 10 : Relative receptor-mediated uptake of
Cholesteryl ether-LDL by NMRI mouse 
organs and MAC-13 tumour.
* Wilcoxon rank test vs controls, p<0.05.
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B) COLONIC TUMOURS
125
In the rats, spleen had the highest uptake of I-CT-LDL/g (table 11).
It is likely that this high activity largely represents the accumulation 
of denatured tracer material, which is less than 5% of the injected dose 
(figure 25) but is directed specifically at this organ and accumulates 
there. Next highest in LDL assimilation was liver, where there was 
comparatively higher hepatic LDL uptake in the tumour group than the 
control group (p<CO.05,Wilcoxon Rank Test) - exactly the opposite of the 
situation in both mouse models studied (tables 5 and 7). Tumour uptake 
was surpassed only by liver and spleen (table 11).
C ) PANCREATIC TUMOURS
As a whole, liver had considerably higher overall LDL uptake than any 
other tissues in these animals (table 12). When uptakes were expressed 
per gram of tissue, spleen had the highest value (figure 26), as observed 
in the rat model above. In tumour animals splenic uptake was suppressed 
(p<C0.05-îWilcoxon Rank Test) as compared to control rats. In both cases 
the overall contribution of the spleen to LDL catabolism was relatively 
small. Adrenals in the tumour group had high LDL assimilation, whereas 
the activity in control animals was considerably smaller (p<CO.05,Wilcoxon 
Rank Test). In this model a number of tissues were quite active in 
assimilation of LDL (figure 26) and tumour appears to be only moderately 
active.
TISSUE
TOTAL LDL UPTAKE 
(CPM/ORGAN/DOSE) X 100
CONTROL GROUP (n=18) TUMOUR GROUP (n=22)
Tumour - 0.7010.23
Spleen 3,1511.07 2.6011.18
Liver 1.00±0.19 1.24±0.20*
Adrenal 0.60±0.28 0.6210.17
Ovary 0.3310.24 0.5110.28
Kidney 0,43+0.07 0.4310.07
*
Thymus 0.2310.09 0.4010.09
Gut 0.38 0.22
Lung 0.4010.13 0.3110.07
Heart 0.1910.09 0.1810.04
Skin - 0.0810.02
Fat 0.0910.07 0.0610.06
Muscle - 0.0510.04
125
Table 11 : Uptake of I-cellobiose-tyramine-LDL by
rat organs and dimethyl hydrazine—induced- 
colonic tumours.
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TOTAL LDL UPTAKE 
(CPM/ORGAN/DOSE) X 100
CONTROL GROUP (n=5) TUMOUR GROUP (n=4)
Tumour - 0.8810.77
Liver 3.68+2.13 6.2 ±1.6
Spleen 0.11+0.05 0.2610.04*
Kidneys 0.70+0.30 1.0310.25
*
Adrenals 0.06+0.03 0.7710.03
Heart 0.28+0.15 0.3310.14
Lungs 0.69+0.26 0.7210.07
Thymus 0.10+0.10 0.1010.07
Gonads 0.11+0.02 0.1110.01
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Table 12 ; Uptake of I-cellobiose-tyramine-LDL 
by Hamster organs and BOP-induced 
pancreatic tumours.
* Wilcoxon Rank Test vs. controls, 
p<0.05
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2,2.3. FEEDING EXPERIMENTS
In all of the preceding animal models, liver has been the major organ 
of receptor-mediated LDL catabolism, both as a whole organ and per 
gram of tissue. It is likely therefore that chemotherapy using LDL 
as a vehicle would be greatly damaging to this essential organ. In
order to reduce the potential toxicity we have looked at a number of
ways of minimising hepatic uptake of LDL during therapy (figure 27).
Also identified as organs at risk during "LDL chemotherapy" are the
adrenal glands. Although they are very small and their overall contribution 
to LDL catabolism is relatively low, they rapidly utilise LDL in the 
synthesis of essential steroid hormones. As a result, adrenals have very 
high LDL receptor activity per gram, and are likely to be damaged during 
chemotherapy using LDL as a vehicle. Hydrocortisone has been used to 
reduce adrenal LDL uptake.
A) CHOLESTEROL FEEDING
NMRI mice with and without tumours were fed a diet containing 1% cholesterol 
(g/g) (2.1.13.) for 7 days prior to the experiment. Plasma cholesterol 
concentrations were measured at the time of sacrifice in groups of 
animals fed the normal diet or the higher cholesterol diet and these 
are shown in (table 6). Despite the increase in plasma cholesterol levels, 
a similar pattern of LDL catabolism was observed in both groups of 
animals. No significant suppression of receptor-mediated assimilation 
was apparent in any of the mouse organs or tumour (table 13).
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RELATIVE RECEPTOR-MEDIATED LDL UPTAKE
(CPM/GRAM TISSUE/mL PLASMA)
TISSUE CONTROL GROUP (n=12) TUMOUR GROUP (n=15)
Liver 26±7 20^12
Spleen 22±8 17-7
Kidney 53^32 30^20
Heart 21^6 27^11
Muscle 12±6 10-7
Tumour — 20^10
Table 13 : Effects of cholesterol feeding on
receptor-mediated LDL assimilation by
the tissues of control and MAC—13 tumour
152 ’
inoculated NMRI mice
Both groups received a diet containing 
1% cholesterol (W/W) for 7 days prior 
to the experiment. Plasma Cholesterol 
values for these animals are given in 
table 6.
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B) BILE SALT SUPPLEMENTATION
It is known that bile acid feeding suppresses hepatic sterol synthesis
195 196 197
and LDL receptor activity in the dog ’ and in the rat. When
sodium taurocholate was administered to NMRI mice (table 14) at a dose
of 1% of the dietary intake (g/g) a fall incurred in receptor-mediated
LDL uptake by the liver (p<cO.05,Wilcoxon Rank Test). As expected this
agent did not affect LDL uptake into other organs, including the adrenal
gland.
C ) HYDROCORTISONE THERAPY
In an attempt to inhibit adrenal uptake of LDL, hydrocortisone was 
administered daily by intraperitoneal injection at a dose of 5mg per 
day to NMRI mice for 7 days. This effectively reduced (p<CO.05,Wilcoxon 
Rank Test), the receptor-mediated adrenal uptake of LDL (table 14) by ca.
50% in the control mice and by a similar amount in the tumour-inoculated 
group. In rats with colonic tumours, hydrocortisone reduced adrenal uptake 
by 40% in control animals and 30% in tumour bearing animals (table 15).
D) COMBINATION OF BILE SALTS AND HYDROCORTISONE
When sodium taurocholate feeding was combined with hydrocortisone injections 
in NMRI mice, adrenal receptor activity fell dramatically (by 80% in 
controls and 60% in tumour-bearing mice) table 14. In the rats, the 
fall in adrenal LDL receptor activity (table 15) remained the same 
whether hydrocortisone was administered alone or in conjunction with bile 
salts.
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Assimilation of LDL by the tumour did not change significantly during 
either hydrocortisone or bile acid therapy, or as a result of their 
simultaneous administration.
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2.3. METHODS II
The following section describes the methods employed for incorporation 
of cytotoxic drugs into LDL, and assessing the cytotoxicity of the 
drug-LDL complexes so formed.
2.3.1. SYNTHESIS OF CHLORAMBUCIL CHOLESTERYL ESTER (QBE)
Molar equivalents of chlorambucil, cholesterol and dicyclohexyl- 
carbodiimide and (when required) 1 mCi ^7-^hJ-cholesterol were 
dissolved in dry diethyl ether in a pre-dried round-bottomed flask.
The flask was flushed with nitrogen, sealed and its contents stirred 
at room temperature for 24 hours. The progress of the reaction was 
monitored by thin-layer chromatography (TLC) using chloroform ; ethyl 
acetate 8 : 1 as eluant, on silica gel TLC plates. Chlorambucil
remained near the origin (R^ = 0.35) while the ester migrated near the 
solvent front (R^= 0.92) and cholesterol between the two (R^= 0.65).
On completion of the reaction, precipitate was removed by filtration and 
the solvent evaporated from the remaining solution. The residue was 
dissolved in chloroform, prior to removal of unreacted starting 
materials on silica and basic alumina columns. Elution was achieved 
using chloroform and carbon tetrachloride alternatively in 5 mL 
aliquots. The purified cholesteryl ester was dried, weighed and 
infrared and ^H-NMR spectra obtained (figure 28). The infrared spectrum 
showed a characteristic peak for the ester carbonyl stretch at 1740 cm 
and confirmed that the product was free of unreacted cholesterol 
(no H-0 absorption). The reaction yield was typically 60-80%.
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2.3.2. INCORPORATION OF CEE INTO LDL BY EXCHANGE FROM CHGLATE/LIFID 
MICELLES
Initially we used an adaptation of Stoffel's method^^*^ for loading HDL 
with labelled cholesteryl esters. This procedure has been described in 
detail in Section 2.1.5. In order to improve the overall efficiency of 
drug incorporation, several other modifications were made to the method 
(figure 29).
A) "RECONSTITUTED" HDL
HDL (dl.063 - 1.21Kg/L) was prepared from human plasma as described 
in Section 2.1.2. An aliquot containing 23mg of HDL protein was extracted 
twice with two volumes of chloroform : methanol (3:1), washed with ether 
and lyophilised overnight. Phospholipid, cholesterol, and 7- Hj - 
cholesterol chlorambucil ester were added to give the molar ratios of 
each found in HDL (80:24:53, lipid:protein,1:1,W/W) and the mixture 
sonicated in 5 ml. 0.02M tris, 0.02M NaCl, 0.02M EDTA buffer, pH 8.2 
for 15 minutes at 0°C. For comparison, an aliquot of HDL containing 
the same amount of HDL protein was loaded with[^nj-CBE by exchange from 
cholate micelles as outlined in Section 2.1.5., replacing I-cholesteryl 
ether with[^H]-CBE. Both^^nj-CBE preparations were purified by filtration 
through 0.22 pm millipore filters and centrifugation at 1.063 Kg/L. 
Fractions of 5 mL were removed from each centrifuge tube and assayed for 
CBE by 1^"' nj-specific activity.
DRUG /LIPID MIXTURE -f CHOLATE 1:1 , w /w
/
/
/
SONICATION IN 
0.02M W lS ^ N c C l,  EDTA, pH 8.2. 
3 0 mins^f/2 max out pur, 0°C
NATIVE HDL 
1 -1 . w / w  ■
X/  OMIT HDL ^
E X C H A N G E y ^ ' ^ n O L A T E  ^
Z  \  /^REPLACE WITHÂ
MIGELLAR LIPID MIXTURE "— I • /
Y
N . J H O S P H . A T X ' /
18-24 hrs STIRRING.25’"C \
\
DRUG-H D L-/L1 PI D/CHOL ATE MIXTURE
I
V
\
^gJHADEX G -25 I
0.02M ItrTsN N gCI. EDTA, pH 3.2 j
' " - A
DRUG HDL /LIPID MIXTURE \ /
/
\
MEMBRANE FILTRATION, 0.22 pm
\  CENTRIFUGATION AT d 1.0 63 Ka/L, 4 5 K rpm.. lO '^C, 18 hrs
\
\^  EXCESS
\
N
LIPID
SEPHADEXG-25 
0.15M Na Cl, 0 01% EDTA, pH 8.2
DRUG-HD
5 mg LDL PROTEIN;
. 15mL cf>1.21 Kg/L;
PLASMA F R A C T IO N ;^  ^
24hr5 37°C
Y
D R U G - L D L / D R U G - H D L /PLASMA FRACTION M IX T U R E
(OR MICELLES)
MEMBRANE FILTRATION. 0.22pm
V  Q
CENTRIFUGATION AT d 1.0 Ô3 Kg/L, 45 K rpm, 10-C, .18 hrs
HDL,
PLASMA FRACTION 
EXCESS LIPID.
SEPHADEX G -25 
0.15 M No Of, 001% EDTA, pH 8.2 
m e m b r a n e ’ FILTRATION, 0.22pm
DRUG-LDL
Figure 29 : The modified Stoffel method, section 2.3.2, used to load
LDL with chlorambucil cholesteryl ester (CBÉ).
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B) EXCHANGE OF CBE FROM CHOLATE MICELLES DIRECTLY TO LDL
5 mL of drug-laden cholate micelles, Section 2.1.5, was stirred overnight 
at room temperature with 5 mg human LDL (protein) and 15 ml d >  1.21 Kg/L 
plasma fraction (prepared as described in Sections 2.1.1. and 2.1.2. 
respectively). Chlorambucil ester-laden LDL was purified as described 
for I-cholesteryl ether LDL (2.1.4.)
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2.3.3. DEGRADATION OF CBE DURING INCUBATION WITH LDL
Mixtures contained 2mg of CBE in ImL of: micelles, Section 21.1.5. and 4mL
of either PBS, heat-inactivated^^ d >1.21 Kg/L plasma fraction (prepared
as in section 2.1.2., heated for 1 hour at 60°C and filtered through
a 0.45 jam filter), or sodium iodoacetate-treated d >1.21 Kg/L plasma
fraction (pre-incubated overnight with 5 m.M NalOAc and dialysed against
, 199
PBS to remove free NalOAc) . Each mixture was stirred gently at 
room temperature for 24 hours and samples were removed at 0,1,2,4 and 
24 hours and assayed for CBE by HPLC (2.3.6.)
2.3.4. TRANSFER OF CBE FROM SYNTHETIC MICROEMULSIONS TO LDL
As an alternative to the Stoffel^^^ method (2.3.2.) drug/phospholipid/
Cholesteryl oleate microemulsions were made by the method of Craig et al^^^
(figure 30) using the molar proportions of each component suggested by 
201
Parks et al . 2.4 mg each of dimyristoyl pholphatidyl choline (DMPC)
and CBE were added to 2.37 mg of cholesteryl oleate, in chloroform, the
solvent evaporated and the mixture dried under vacuum for at least
1 hour. The dried lipids were dissolved in 200 pL isopropanol (pre­
dried over molecular sieves). Sixty-six pL of the lipid mixture 
were injected quickly into 1 mL of rapidly vortexing PBS, with the
entire system kept at 46°C throughout the procedure. Several millilitres
of microemulsions were prepared in this way and mixed with equal volumes 
of LDL (protein 2-6 mg/mL), prior to incubation for 5 hours at 37°C. 
Thereafter, solid KBr, 0.012 mg/mL, was added to the solution making its 
density 1.006 Kg/L. The preparation was overlayered with dl.006 solution 
in Beckman 40.3 centrifuge tubes and the drug-laden LDL separated from 
the microemulsions by overnight centrifugation a 45 K rpm and 25°C in 
Beckman 40.3 rotor. •
PREPARATION OF CBE-LDL
drug “ l ip id  mixl-yre in isopropanol
r a p i d l y  in jec f ô ô j j L  into 
1 mL vortexing PBS
Y
D R U G -L IP ID  MICROEMULSIONS
add 1 mL LDL 
incubate  fo r 4hours 3 7  G
y
f i l te r  thro ' 0 .2 2p m  m ill ipore 
adjusj- density to 1.006 kg/L w ith KBr 
overlayer with 1.006 density soln.
Centrifuge
40k  rpm , 25  C , 18 hrs 
aspirate microemulsions & density soln.
o
- 4 6  C
de-sa lt C B t-L D L  on PDIO column
sterilise & assay fo r CBE & protein
Figure 30 : Protocol for the preparation of chlorambucil
ester(CBE)-LDL using drug-lipid microemulsions 
as described in Section 2.3.4.
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Microemulsions and density solution were aspirated and the infranatant 
CBE-LDL desalted by gel filtration on a PDIO column, eluting with PBS.
The CBE-LDL was sterilised by filtration through a 0.22 pm millipore 
filter. This treatment also removed aggregated LDL and microemulsions 
which were of density greater than 1.006 g/mL_. The .protein and drug 
concentrations of the CBE-LDL complex were measured by Lowry protein 
assay (2.1.9.) and HPLC (2.3.6.) respectively. Identical incubations 
were performed in the absence of LDL and centrifuged as described 
above for the LDL-containing preparation. The infranatant was then 
filtered through a 0.22 pm millipore filter and assayed for CBE to ensure 
that no microemulsions remained after purification.
2.3.5. INCORPORATION OF ANTHRACYCLINES INTO LDL
23
A) Daunomycin was incorporated following the method of Iwanik et al 
(figure 31). Drug (20-50 mg) was dissolved in methanol and dried onto 
the surface of a glass tube under N^, 5 mL of LDL (protein 2-10 mg/mL) 
in buffer (5mM sodium phophate, 0.15M NaCl, 0.3 mm EDTA, p H 7.3) was 
added and the mixture flushed with nitrogen and stirred gently at 
room temperature for 2-3 hours in darkness. The daunomycin-LDL 
complex was separated from the unbound drug by gel filtration through 
PDIO columns, using PBS as eluant. LDL-containing fractions were 
pooled, filtered through a 0.22 pm millipore filter and assayed for 
drug (2.3.6.) and protein (2.3.7.).
In procedures 2.3.5. B—G, LDL prepared by zonal (2.1.1.) was used without 
concentrating o r 'de—salting in an attempt to reduce aggregation of the 
LDL during incubation with adriamycin.
PREPARATION OF DAUNOMYCIN -  LDL
Daunomycin + 1 mL LDL in PBS
^2-5 mg p ro te in /m L
stir g e n t ly  
4 hours
room temperature 
darkness
REMOVE FREE D A U N O . 
PDIO column ^Sephodex-G 25 
Elute D -LD Lw ith  PBS
STERILISE D-LDL 
0.22 [jm f i l t e r
Assay Daunomycin 
by HPLC
Assay protein 
by Lowry
PBS’ 5mM sodiunn phosphate, 0.15 M NaCl, O.SmM EDTA, pH 7. 3
Figure 31: Protocol for the preparation of daunomycin-LDL
as described in Section 2.3. .
b ) Cholate Method: As described for CBE (2.3.2.), adriamycin, phospho­
lipid, cholesterol, cholate micelles were prepared using 5 mg adriamycin,
10.9 mg lecithin and 1.6 mg cholesterol per 5 mL of cholic acid buffer.
To each mL- of micelles was added 1 mL of LDL (0.5 mg p r o t e i n / mL)
and the solution stirred overnight at room temperature.
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C) DMSO Method: 2 mg adriamycin was dissolved in 2 mL of DMSO buffer 
(0.15 M NaCl, 0.3 mM EDTA, pH 7.2 containinglO% DMSO,v/v) and warmed to 
37°C for 10 minutes before adding 2 mL LDL solution (protein 0.1-0.5 mg/ 
mL). The mixture was incubated overnight at 37°C, in darkness.
D) PBS Method: Adriamycin (2 mg) was dissolved in 2 mL buffer (5 mM
sodium phosphate, 0.15 M NaCl, 0.3 mM EDTA pH 7.3) and 2 mL LDL solution
added (protein 0.1-0.5 mg/mL). The solution was stirred in darkness
at room temperature for 2-3 hours.
E) Dialysis : LDL (0.1 mg/mL) in dialysis tubing, molecular weight 
cut-off 2,000-8,000 was surrounded by various concentrations of adriamycin 
(2-150 ug/mL) in DMSO buffer. The concentrations of free and bound 
adriamycin in the dialysis bags were measured at intervals by HPLC (2.3.6.). 
Free adriamycin was removed by chromatography on PDIO columns, with PBS
as eluant.
F ) Incubation in Glycine Buffer: Adriamycin-LDL was prepared by overnight 
incubation of 5 mg of drug with 2 mL LDL (0.5 mg protein/mL), and 5 mL 
NaCl/DMSO buffer, pH 7.2 or 5 mL IM Glycine/DMSO buffer, pH 10. The complexes 
were concentrated by centrifugation at 38 K for 4 hours and at 10°C in 
Beckman SW41 rotor, after making the density of the solutions up to 1.4 g/mL 
by the addition of solid KBr. The drug-LDL complexes were desalted on
PDIO columns using PBS as eluant.
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G) Surfactants: Following the method of Tucker et al surfactants 
were used to enlarge the LDL particles. Ten per cent solutions (w/v) 
of Brij-35, Triton x-100 and SDS were prepared in PBS and filtered through 
0.22pm filters prior to use. The surfactants were each added gradually 
to a different aliquot of LDL (protein 2 mg/mL in PBS), giving final 
surfactant to phosholipid molar ratios of 1:1. The mixtures were left 
to react for 30 minutes before adding two volumes of adriamycin solution 
(Img/mL in PBS). After 24 hours incubation at room temperature, surfactant 
and free drug were removed by PDIO filtration.
In all of the above procedures, anthracyclines were assayed by HPLC 
(2.3.6.) and protein determined as described (2.3.7.)
2.3.6. HPLC ASSAYS
202 203
Chlorambucil , chlorambucil cholesteryl ester, adriamycin and
daunomycin were measured by reversed-phase high pressure liquid chromato­
graphy (HPLC). A 20 X 0.5 cm stainless steel column, slurry packed in 
the laboratory with 5 Hypersil-ODS, was used in all assays. Typical 
chromatograms and standard curves for each system are shown in figures 
32 and 33.
H P L C  O F  A N T H R A C Y C L I N E S
A D R I A M Y C I N
D A U N O M Y C I N
1
24  -16 8  0
R E T E N T I O N  T I M E  mL
Figure 32: HPLC profiles of adriamycin and daunomycin
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Figure 33 : HPLC profiles of chlorambucil and
chlorambucil-e<-cholesteryl ester 
obtained using the system outlined 
in Section 2.3.6.(C).
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A) ADRIAMYCIN ASSAY203
APPARATUS :
INJECTION VALVE 
PUMP
DETECTOR
RECORDER 
MOBILE PHASE
FLOW RATE
: Ryeodyne 7125 with 20 pL loop.
: Varian 8500
; Pye-Unicam LC-FL Fluorescence monitor, fitted
with interference filters for excitation at 450 nm 
and emission at 550nm.
Servoscribe single pen chart recorder.
: Acetonitrile: 10 mM Phosphoric acid (65:35)
containing 6 mM Brij-35.
: 2 mL/minute.
EXTRACTION PROCEDURE: To 1 mL of solution was added 200 ng of daunomycin
(as internal standard), in methylene chloride and the solution mixed with 
1 mL 10 mM phosphate-buffered saline, pH7.8, followed by extraction 
with 2 X 5 mL methylene chloride. After centrifugation for 5 minutes 
at 2000 rpm, the organic layer was removed and evaporated to dryness at 
40°C under a stream of nitrogen. The residue was dissolved in 100 pL of 
mobile phase and 20 pL injected onto the column.
STANDARDS: A standard solution of 10 pg adriamycin /mL was used to spike
LDL solution, giving final drug concentrations of 10 ng-lpg/mL. Extraction 
of standards was carried out as described for samples and a standard curve 
plotted of adriamycin: daunomycin peak height vs adriamycin concentration 
(figure 34).
LU
3
U
O
<a
Z
<
h-
CO
u
>-
<
û
< 1
LU
g  z
o oo oo
o CO CO <N
1HOI3H MV3d O N n v a  : v i d a v
w
s-
œ
M
d
cS
(H
O
g
d)
E
d)
g
Cfi
•H
-P
C
•H
o
a
rC
o
d
M
00
d
P
M
•H
k
91
B) DAUNOMYCIN ASSAY
Daunomycin was measured either on the system used for adriamycin or on 
the following system:
APPARATUS :
INJECTION VALVE 
PUMP
DETECTOR
RECORDER/INTEGRATOR 
MOBILE PHASE
FLOW RATE
: Rheodyne 7125 fitted with 100 pL loop
: Gilson 300
: Gilson Holochrome U.V. Monitor, absorption
measured at 330 nm.
: Schimadzu
: Acetonitrile : 10 mM phosphoric acid (68:32)
containing 6 mM Brij-35.
2 mL/minute
EXTRACTION PROCEDURE AND STANDARDS: Daunomycin was extracted from
samples and standards as described for adriamycin (2.3.6 A) omitting 
the addition of 200ng of daunomycin. A standard curve was constructed
by plotting daunomycin peak area against concentration (fig.35).
C) CHLORAMBUCIL AND CHLORAMBUCIL CHOLESTERYL ESTER ASSAY
202
APPARATUS: as described for the daunomycin assay, with the following
amendments :
DETECTION : 254 nm
MOBILE PHASE : Methanol :water (65:35) containing
lOmM phosphoric acid 
FLOW RATE : ImL/minute
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EXTRACTION PROCEDURE : Each mL of plasma or LDL solution was extracted 
with 2 volumes of chloroform and centrifuged, twice. The organic phase 
was aspirated and dried down under a stream of nitrogen at 40°C. The 
extract was dissolved in methanol and injected onto the column.
STANDARDS: Chlorambucil cholesteryl ester, purified by TLC, or
chlorambucil was dissolved in chloroform and spiked into LDL solutions 
and extracted by the same procedure as the samples. Peak areas were 
plotted against drug concentration (figure 36).
2.3.7. LDL PROTEIN DETERMINATION IN SOLUTIONS CONTAINING ANTHRACYCLINES
The apoprotein content of the various lipoproteins prepared was assayed 
by the method of Lowry et al^^^, as described in section 2.1.9. In 
the case of LDL containing anthracyclines, protein concentration was 
observed to be much higher than expected (figure 37). The Lowry assay 
conditions are basic and this changes the colour of the anthracyclines 
from orange to purple. A scan of adriamycin absorption in the ultraviolet 
and visible regions (figure 38) showed however that the high pH was not 
causing the "extra" absorbance at 750 nm. It is likely that the Lowry 
reagents form a complex with these drugs in much the same way as they do 
with peptides, so giving rise to an enhancement of the blue colour of the 
solution and consequently elevated estimates of protein concentration. 
Apoprotein B was therefore precipitated from solution using 1 volume 
of 1,1,3,3-tetramethyl urea, delipidated by extraction with 2 volumes 
of chloroform : methanol (2:1) and dried with ether before solvation in 
0.5M NaOH and Lowry protein assay.
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INTERFERENCE OF ADRIAMYCIN IN TFiE LOWRY PROTEIN ASSAY
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Figure 37: Apparent protein concentration in LDL solutions of
constant LDL content and increasing adriamycin 
concentration.
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Figure 38 : Absorption spectra of adriamycin in neutral and
basic conditions. Note that there is no 
enhancement of the drug's absorption at 750nm 
on changing pH.
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2.3.8 PLASMA CLEARANCE OF RADIOACTIVE LDL
I- or I- labelled LDL or drug were administered to New Zealand 
White rabbits by injection into a canulated marginal ear vein. Blood 
samples were taken after 5 minutes and at intervals over the following 
24 hours. Isotope dilution in the 5-minute sample gave an indication 
of plasma volume. Plasma clearance of the radioactive species was 
directly related to the disappearance of radioactivity with time. 
Re-isolation of the labelled LDL was unnecessary since non-protein 
bound iodine has been repo.rted to correspond to less than 1% of the 
total radioactivity and apoprotein B does not transfer to the other 
plasma lipoproteins^^^. Iodide was administered, O.lg/L in drinking 
water, for two days prior to and throughout these studies. 
Radioactivity remaining in the plasma at each time point was expressed 
as a percentage of the level of radioactivity in the 5-minute sample.
2.3.9. CELL CULTURE MEDIA
HeLa cells were maintained in Ham's FIG medium containing 20mM HEPES 
and supplemented with 10% foetal bovine serum, 2mM glutamine, 5% CO^ 
and 50 units/mL of penicillin and streptomycin. For culture of human 
glioma(G-CCM) and human lung carcinoma(L-DAN), medium containing 
50% Ham's FIO and 50% Dulbecco's Modified Eagle's media supplemented . 
with serum etc., as above, was used.’ Tumour samples were collected in 
balanced salt solution with antibiotics as above prior to dissection.
2.3.10 DETACHMENT OF CELLS FROM CULTURE FLASKS
Cells were detached from culture flasks using 0.25 % trypsin in 
balanced salt solution(BSS). After removing medium, cells were washed
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with BSS and soaked in trypsin for one minute. The trypsin solution 
was aspirated and the flasks sealed and incubated at 37°C until the 
cells had detached from the surface of the flask. This usually 
required 10-15 minutes, after which the cells were re-suspended in 
medium prior to counting cell density using a Coulter Counter or 
haemocytometer.
2.3.11 PREPARATION OF LIPOPROTEIN-DEFICIENT SERUM
Fresh human blood was obtained from healthy volunteers and allowed 
to clot in lOmL glass tubes, and the serum was aspirated following 
centrifugation at 2500 rpm for 15 minutes. The density of the serum 
was adjusted to 1.25 Kg/L by the addition of 0.371g KBr/mL. This 
solution was overlayered with dl.25 density solution and centrifuged at 
45000 rpm for 24 hours in a Beckman Ti60 rotor at 10°C. Lipoproteins 
and density solution were aspirated and the lipoprotein-deficient 
serum dialysed, first briefly against distilled water, and then against 
PBS, pH 7.4.
2.3.12 MICROTITRE DRUG SENSITIVITY ASSAY
Freshney and co-workers have established microtitre assays for testing
207 208
cytotoxic drugs against human glioma and HeLa cell lines. This 
procedure has a number of advantages over the commomly used cloning 
experiments^^^ for assessing cytotoxicity ; large numbers of replicates 
can easily be handled, giving better reproducibility; and the long 
drug-exposure times enable all of the cells in culture to pass through 
the cell cycle at least once, thus excluding the cycle-dependence of 
some drugs as a variant in the assay. Protein synthesis was identified 
as a fundamental metabolic process without which the cells could not
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survive. Since leucine is an essential amino acid it is unlikely that 
protein synthesis could carry on for long within the cell without the 
incorporation of leucine obtained from the surrounding medium. Thus, 
the failure of cells to incorporate -leucine into protein several 
days after drug exposure will almost certainly correlate with cell 
death.
Protocols for HeLa and Glioma microtitre assays are shown in figure 39.
3 3
Cells were seeded at a density of 5 X 10 cells/mL, i.e. 10 cells/well,
in the central 60 wells of 96-well microtitre plates. The edge wells
were filled with cell-free medium. Throughout the experiment the
cells were incubated at 37°C in a humidified 5% CO atmosphere. After
being allowed to adhere to the surface for 3 days the cells were
re-fed with fresh medium. Medium and drugs were administered on day 5
in the case of HeLa cells, and days 4, 5 and 6 for glioma cells.
Drugs were added to the plate wells in 10-50 pL of PBS in serial
dilutions of 1:10 or 1:5, with duplicate incubations at each
concentration. Twelve wells of cells in each plate were left free of
drugs to serve as controls. Following drug exposure the medium was
replaced and the cells allowed to recover for 4 days(HeLa) or 5 days
(glioma) before [4 ,5-^Hj-leucine (1 pCi/mL) was added in fresh medium.
During this recovery period medium was replaced at least every 48 hours.
The cells were exposed to p  h]-leucine for 24 hours prior to washing
with PBS, extraction with 10% (w/v) trichloroacetic acid (2 X 15 minutes)
rinsing with distilled water, fixing with methanol and drying. The
contents of each well were dissolved in 200uL of 0.3M NaOH containing
SDS (1% w/v). An aliquot from each well was placed in a ImL Sarstedt
tube, neutralised and liquid scintillant added. Each tube was well
mixed and counted for -activity in a Packard ^-Counter. The
counts obtained for each well were corrected for background and expressed
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as disintegrations per minute (ûPM). The mean DPM for controls was 
taken to be 100% survival and the [^h]-leucine uptakes for other wells 
expressed as a percentage of this value. A plot of log(% cell survival) 
against log{drug concentration(M )) was constructed for each of the 
drugs and drug-LDL complexes studied. From these curves, the doses 
which corresponded to 50% inhibition (ID^^) and 90% inhibition(ID^^) 
of cell growth, compared to controls, were calculated for each drug.
An extra plate of cells was seeded on day 0 for use in monitoring the 
cell growth rate. At intervals during the experiment several wells 
were trypsinised as described in Section 2.3.10 and the number of cells 
per mL measured using a haemocytometer. This was to verify that the 
majority of cells was in the logarithmic growth phase throughout the 
assay. This is essential if the maximum relative changes in 
p Hj-leucine uptake between control and drug-treated cells are to be 
assessed. Biased results would be obtained if -leucine 
incorporation was measured while controls had reached stationary phase 
and drug-treated cells were in log. phase. Growth curves for G-CCM 
and HeLa cells plotted from data obtained in this way are shown in 
figure 40.
2.3.13 L-DAN CLONOGENIC STEM CELL ASSAY AND SPHERIOD MODEL SYSTEM
This work was carried out with the collaboration of Dr. D.J. Kerr of
the Department of Medical Oncology, Glasgow University. L-Dan cells
were maintained in exponential growth in monolayer culture prior to
disaggregation using trypsin (Section 2.3.10). Thereafter cells were
209
seeded for clonogenic assay or used for initiation of tumour 
210
spheroids (fig. 42).
M IC R O TITR E ASSAY G R O W T H  CURVES
E
LO
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U
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G - C C M
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TIME (days)
Figure 40: Growth curves for HeLa and glioma (G-CCM) cells in the
microtitre assays (Section 2.3.12). Cell number was 
measured using a haemocytometer and each point is the 
mean of duplicate counts for a pool of the cells from 
twelve wells of the culture plate.
C L O N O G E N I C  ASSAT
ce!! mono!ayers in exponential growth
Drug Exposure 
1 hr
y
harvest with 0.25/^ Trypsin in BSS 
wash in ice-cold medium 
seed a t  2 0 0  cells/mL in 5cm petri dishes
incubate
3:2° c
12 days
Ÿ
wash &  f ix  
V
count colonies > 4 0  cells
Figure 41 : Protocol for the clonogenic stem cell assay used
in the testing of free and. LDL-encapsulated 
daunomycin against L-DAN lung tumour cells, as 
described in Section 2.3.13.
SPHEROID GROWTH DELAY & CLONOGENIC ASSAYS
2 - 3 0 0  spheroids 350pm diam. in glass universal
Drug Exposure 
1 hr
wash with ice-cold medium 
re-suspend in medium
disaggrega te  with 0.1 25 /6  Trypsin
y
C L O N O G E N IC  ASSAY
GROWTH DELAY ASSAY
transfe r to agar 
1 spheroid/wel I
Imeasure cross-sectional area
tv/ice weekly
un ti l  spheroid volume has 
increased 10“  fold
Figure 42 : Outline of the experiments performed with native
and LDL-encapsulated daunomycin on lung tumour 
(L-DAN) cell spheroids as described in 
Section 2.3.13.
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Monolayers were exposed to varying concentrations of daunomycin and 
daunomycin-LDL for one hour. Following treatment, the monolayers 
were harvested with trypsin, as described in Section 2.3.10, 
centrifuged, and washed with ice-cold medium, after which the cells 
were diluted in medium and seeded at 200 cells/mL in 5cm Petri dishes. 
The dishes were incubated for 12 days at 37°C in a 2% CO atmosphere 
before fixing and staining of colonies with methylene blue. Colonies 
of more than 40 cells were counted. The cloning efficiency of the 
untreated cells was defined as 100% survival and the cloning efficiency 
of treated cells expressed as a percentage of control survival.
210
Spheroids were prepared , with a mean diameter of 350 pm, at 200-300 
spheroids/glass universal tube and subjected to similar drug concentra­
tions and exposure times as in monolayer, at 37°C with intermittent 
agitation. The spheroids were then allowed to sediment and washed 
with ice-cold medium, re-suspended in medium and subdivided for 
further analysis.
One aliquot of spheroids was incubated with 0.125% trypsin in PBS for
14 minutes at 37°C, after which the trypsin solution was replaced with
medium. Disaggregation of the spheroids was acheived by repeated
pipetting of the suspension. The clonogenic assay was performed as
described above. A second aliquot of spheroids was used for a growth
delay experiment. Intact spheriods were transferred to agar-coated
wells on a plastic tissue culture multidish, 1 spheroid per well,
using a pasteur pipette. The cross-sectional areas of 24 spheroids
from each treatment group were measured twice weekly using a
"micromeasurements" image analysis system coupled via a television
211
camera to an inverted optical microscope . These measurements were 
converted to volumes, assuming spherical geometry. Treatment-induced
98
growth delay was defined as the time taken for median spheroid volumes 
to increase by a factor of 10 above initial size.
2.3.14 THE SUBRENAL CAPSULAR (SRC) ASSAY
212
A six-day assay has been described by Bogden et al for assessing the 
sensitivity of primary human tumour explants to chemotherapeutic agents 
in normal immunocompetent mice. Following this protocol (fig. 43), 
with the cooperation of Dr. D. Cunningham, Medical Oncology, G.R.I., 
the anti-tumour effects of some drug-LDL complexes have been tested.
Tumour samples were removed from patients or animals and immediately 
placed in sterile balanced salt solution containing penicillin and 
streptomycin, 50 units/mL. The tumour was cut into fragments measuring 
approximately Imm^. The mice (NIC B6D2FI) were weighed and 
anaesthetised and a lateral incision was made over the left kidney, 
which was then exteriorised. Tumour was inserted under the renal 
membrane using a trocar, after a small incision had been made in the 
membrane with a Ziegler iridectomy knife. This procedure was carried 
out under magnification with a Zeiss stereoscopic microscope. Two 
perpendicular diameters of the tumour fragment were measured in situ 
using a micrometer scale, fitted to the microscope and calibrated so 
that 10 micrometer units were equivalent to 1mm. Kidney was gently 
replaced and the incision closed using 9mm autoclips.
Six animals were implanted with tumour in each treatment group. One 
group of six mice was left untreated to act as controls, and the rest 
received drugs by tail vein injection on the following day, i.e. day 1, 
and on days 3 and 5. On day 6 the animals were sacrificed and the 
tumour dimensions remeasured, befqre the kidneys were placed in
tr>
C
<
LO
LO
<
u
LO
_0
3
LO
Cl
D
u
O
c
0 )
(D
u
C
3
3
O
E
3
<D
"o)
E
D
03
3  ^II
C
"5 B
cu
CO O-
E
E CN
0
C  3
i s
P
o
<
o
> -
<
Q
0
>
D
D
D 
>  
— I
Û
O
CD
3
"D
0
2
CO
Û o
3
0 
E'
3
•4-“
0
L_
3
LO
a
0
E
1
0
0 )
L)
0
U
in
o
0
E
_ 3
O
>
V—
3o
E
. 3
Ü)
3
o
<
Û
0
E
_ 3
O
>
to
o
LO
LO
0
D  ;□ S-
I/) V  uj
Ü
PC
in
rH
5
CO
Ü
c
(D
S-t
5
m
m
CO
3
O
Ê
<u
g
uo
(H
o
Ü
o
-p
o
L
CL
00
CD
L
•H
99
formol saline, pending histological analysis. The change in tumour 
volume, %(length X width^ ), was expressed as a percentage of the 
original volume.
2.3.15 MEASUREMENT OF PLASMA WHITE BLOOD CELL DENSITY
Blood was removed from the mice used in the SRC assay, on day 6, via 
the vena cava, and placed in glass tubes containing K^EDTA. White 
blood cell density was measured at the Department of Haematology, G.R.I. 
on an automated Coulter Counter system.
2.3.16 HISTOLOGICAL ANALYSIS OF TUMOUR SECTIONS
Three micron thick sections from mouse kidney and implanted tumour were 
stained with haematoxylin and eosin and examined by Dr. A. Jack of the 
Pathology Department, G.R.I.
2.3.17 LDL RECEPTOR ACTIVITY ASSAY IN VITRO
High-affinity LDL degradation was measured as the difference in cellular 
125
degradation of I-LDL in the absence and presence of an excess of
213
unlabelled LDL (fig. 44). Twenty-four-well culture plates were seeded
on day 0 with cells in medium containing foetal bovine serum. Section
2.3.9, and incubated in a 5% 00^ atmosphere at 37°C. Two wells of each
plate were filled with medium only. On day 3, the medium was replaced
with medium containing 10% lipoprotein-deficient serum, prepared as
described in Section 2.3.11, instead of foetal bovine serum. Fresh
lipoprotein-deficient medium was added to the cultures on day 6 and 
125
I-LDL was added at concentrations of 0-100 pg LDL protein/mL with 
duplicates of each concentration. . Identical incubations were set up
LDL DEGRADATION ASSAY
Seed cells in 24-we i l  plates 
4
IQ ce ils / well
72 hrs, 5% CO^, 37°C
Change to l ipop ro te in - cleHcienI 'medium
72hrs ,  5 % C 0 2 .  37" 'c
Renew medium
Add * '^^ I- label led LDL (a n d  excess cold LDL where required)
2 4  h r s ,  5 %  C O ^ ,  3 7 ' ' C  
Remove medium
CELLS
y
PBS wash
I  .
Precipi lale protein with IO% TCA
I
Wash w i th  c is til led water
Eix w i th  methanol 
Dry
Dissolve in 1.0 M PlaOld
Lowry protein assay
125,.Count I  ac t iv i ty
MEDIUM
y
Precipi tate protein with !0 %  TCA
Centr i fuge Discard 
Preci pi tale
Y
Ex Ira cl free iodi
Kl, H^O^,
chloroform
Centr i fuge
Di 5 c a rd 
organic phase
DEGRADED-LDL /pg cell protein
INTER.N.ALISED LDL /pg cell protein
Figure 44: Scheme for assessing LDL degradation and internalisation
in monolayer cell cultures.
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and excess LDL added to a concentration of 0.5 mg LDL protein/mL in the
culture medium. After a further 24 hours incubation, the medium was
removed from the cells and its degraded LDL content measured. Cell-
125
free incubations contained I-LDL at 100 jjg LDL protein/mL and were
subsequently analysed for spontaneous degradation of the tracer. This
amounted to less than 3% of the total tracer used and was subtracted
from the values obtained in other incubations. High molecular weight,
presumably intact, LDL was precipitated by adding 1,1,1-trichloroacetic
acid to the medium to a final concentration of 10% (w/v). The
supernate was separated from the pellet by centrifugation and free
iodide extracted from it by the addition of excess potassium iodide
(10 pL, 40% solution) and 10 juL of 30% w/v hydrogen peroxide, followed
immediately by 2mL chloroform. After thorough mixing and centrifuga-_
tion, the aqueous phase, containing degraded LDL, was separated and 
125
assayed for I-activity in a Packard Autogamma Twin-Channel Scintilla­
tion Counter.
The cells remained attached to the surface of the culture wells and,
after washing with PBS, extraction with 10% trichloroacetic acid (2 x 15
minutes), rinsing with distilled water, and fixing with methanol, the
cell residue was dissolved in 1.0 M NaOH. Aliquots of the dissolved
cellular material were assayed for protein by the Lowry method. Section 
125
2.1.9, and for I-activity using a Packard Scintillation Counter as 
above. This procedure isolated intact intracellular lipoprotein and 
the amount of LDL internalised was expressed per microgram of cell 
protein for each incubation.
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2.4 RESULTS II
2.4.1. CHLORAMBUCIL CHOLESTERYL ESTER-LDL
Chlorambucil cholesteryl ester (CEE) was loaded into LDL by the modified 
190
Stoffel method described in Section 2.3.5. Approximately 50% of 
the drug-ester (as measured by specific h] activity) was transferred at 
each stage (table 16), producing LDL which had approximately 10% of its 
cholesteryl ester core replaced with CEE.
In an effort to increase the net amount of drug incorporated into HDL 
and subsequently into LDL, reconstituted HDL containing increased 
amounts of CEE,was generated as described in Section 2.3.2 (A). The 
percentages of total drug-ester found in each fraction after 
centrifugation at 1.063 g/mL are shown in fig.45. The HDL formed by 
the reconstitution procedure was of a wide density range and would prove 
difficult to separate from LDL after the next step in the procedure.
For this reason, reconstituted HDL was not used in any subsequent 
preparations.
The CBE-LDL complex was tested on human glioma cells in the microtitre
assay outlined in Section 2.3.12. Results (fig.46) indicated that the
drug-LDL complex was inactive. It is likely that the drug itself had
become inactive during the incorporation procedure, since the G-CCM
20
cells had already been reported to express high LDL receptor activity 
under similar conditions. Possibly tris (tris(hydroxymethyl)- 
methylamine), a nucleophile in the cholate sonication buffer. Section 
2.3.2., was attacking the carbon attached to the terminal chlorine of 
the drug and rendering it inactive. Replacing tris with phosphate in 
the sonication buffer appeared to reduce the inactivation of the drug
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Figure 4 6 : Comparative cytotoxicities of LDL, chlorambucil,
and chlorambucil ester-LDL (prepared by the 
method used to prepare radioiodinated cholesteryl 
ether-LDL, fig. 15) on human glioma cells in the 
microtitre assay. Each point is the mean of 
duplicate incubations.
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since the drug-LDL complex prepared in this way had cytotoxic activity 
(fig. 47) against human glioma cells in the microtitre assay, Section 
2.3.12.) However, the buffer change also reduced the overall 
efficiency of the LDL loading procedure by a factor of 2 (table 16). 
Thus the 0.02M phosphate buffered saline, 0.02M EDTA, pH 8.2 was used 
in all of the following CBE-LDL preparations by Stoffel's method. In 
order to increase the net amount of drug recovered in LDL, the 
exchange step from cholate micelles to HDL was omitted, that is, the 
drug-laden micelles were incubated immediately with LDL and 
d>1.21 Kg/L bottom fraction. Section 2.3.2. This increased the 
overall incorporation of the drug-ester 3-fold (Table 16), with no 
obvious effects on the integrity of LDL. CBE-LDL prepared in this way 
was not obviously different from either native-LDL or CBE-LDL 
prepared by transfer of drug to LDL from cholate micelles via HDL. 
Plasma decays (figs. 48(a) and (b)) for each of the aforementioned LDL 
species made using radioiodinated LDL, Section 2.1.3, were measured in 
rabbits as described in Section 2.3.8. and simultaneously compared with 
the plasma decay of native LDL.
2.4.2. COMPARISON OF CBE CONCENTRATION MEASURED BY SPECIFIC
ACTIVITY AND HPLC,
Until equipment was available for the assay of chlorambucil by HPLC, 
the drug-ester was synthesised with trace amounts of cholesterol
and "apparent" drug concentration was measured by specific  ^h] - activity. 
This approach assumed that the drug-ester link was not being 
hydrolysed during the incorporation procedure - an assumption which 
later proved to be false.
Chlorambucil-ester-laden LDL was prepared as described in Section 2.3.2.
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Figure 47: Comparative cytotoxicities of chlorambucil and
chlorambucil ester-LDL (prepared by the method 
outlined in fig. 15, using phosphate buffered- 
instead of tris buffered- saline. Each point 
is the mean of duplicate incubations.
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PLASMA DSCAYSCF 125 [-m a t .'VE AND 131 !_'|-|d l -CSE-LD1 
ON A  NEW ZEALAND WHITE RABBIT
100*
Cl
Cl
■ 125 l-NATIVE LDL
0_
131 1-HDL-CBE-LDL
0 168 2412 204
b)
Time after injection (hours)-,
PLASMA DECAYS OF 131 I-NATIVE AND 125 |-CHOLATc' -CBE-LDL 
IN A N E W  ZEALAND WHITE RABBIT
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125 I-NATIVE-LDL
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Figure 48: Plasma decays of native-LDL and chlorambucilester(CBE)-
LDL prepared by exchange of drug from a) micelles to LDL 
via HDL ('HDL'-CBE-LDL) or b) micelles to LDL ('cholate 
CBE-LDL)
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iLi oo of the solution wene assayed for CBE by  ^ry —activity
and HPLC and found to contain 0.72 mg/mL and 2.5 ^g/mL by the 
respective methods. Lowry protein assay showed the solutions to have a 
protein concentration of 0.56 mg/mL. Thus only 3 molecules of drug 
had been incorporated per LDL particle, not 950 as calculated by 
specific activity. The CBE experiments already reported (figs. 45-48, 
table 16) then gave overestimates of the drug-ester incorporation into 
lipoproteins and consequently the results of these studies may be 
interpreted only qualitatively.
In all subsequent experiments with CBE, the drug-ester concentration 
was measured by HPLC, Section 2.3.6.
2.4.3. DEGRADATION OF CBE DURING INCUBATION PROCEDURES
Measurement of the CBE concentration in the cholate micelle mixture 
during the course of its incubation with LDL, showed that a large 
proportion of the ester had been degraded, leaving only 20-40% of the 
original amount of ester in the solution after 24 hours.
The d>1.21 Kg/L fraction of human plasma. Section 2.1.2., was used in
the incubation as a crude preparation of cholesteryl-ester transfer
protein, a plasma constituent which mediates the transfer of
cholesteryl esters between LDL and other lipoproteins. Since this
fraction contains numerous other enzymes, including LCAT, it was
thought possible that the drug-ester was being hydrolised enzymically.
199
Sodium iodoacetate (NalOAc), an inhibitor of LCAT was added to the 
LDL/cholate/d>l.21 Kg/L fraction mixture in an attempt to reduce the 
hydrolysis rate. Section 2.1.3. Another approach to reduce enzyme 
degradation of the compound was to inactivate a number of enzymes by
104
heating the d^I«21 Kg/L plasma fractzou to 60 C, w Ii x c It  leaves
198
cholesteryl ester transfer protein unaffected
The degradation of the drug-ester with time under each of the conditions 
used is shown in fig. 49. None of the agents gave any increase in the 
amount of intact drug-ester remaining after 24 hours, on the contrary, 
they increased its degradation. It is interesting to note that there 
was no concurrent increase in the concentration of the free chlorambucil 
in any of the incubations, suggesting that the drug-ester degradation 
was not simply a hydrolysis procedure.
If therapeutic amounts of CBE are to be incorporated into LDL, other 
methods of incorporation must be considered, since the cholate method 
gives a final concentration of only a few micrograms of CBE per mg of 
LDL protein.
2.4.4. TRANSFER OF CBE FROM SYNTHETIC MICROEMULSIONS TO LDL
CBE-microemulsions were prepared as outlined in Section 2.3.4., using 
either DMPC or DPPC as the phospholipid component. Using DMPC 
emulsions, the final amount of drug in LDL was slightly higher, .'. DMPC 
was used in all subsequent preparations of CBE-containing mioroemulsions. 
Recovery of the drug-ester at each stage of the preparation of CBE-LDL 
using these particles is shown in table 17. Even when contained within 
mioroemulsions, and in the absence of plasma proteins, 50% of the 
drug-ester is degraded during overnight incubation, table 17.
Typioal recoveries of drug and LDL are shown, for each stage of the 
microemulsion/LDL preparation, in table 18. Less than 15% of the 
initial drug used is recovered in LDL but this is 100—times more than
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STAGE OF PREPARATION
PERCENTAGE OF CHLORAMBUCIL 
ESTER REMAINING
DMPC MICROEMULSIONS
Incubation Mixture (t= 0 hrs.)
" " (t= 4 hrs.)
" " (t=24 hrs.)
Mioroemulsions only (t=24 hrs.)
Chlorambuci1-Ester-LDL 
(after centrifugation)
100
60
48.6
49
48
DPPC MIOROEMULSIONS
Incubation Mixture (t= 0 hrs.)
" " (t= 4 hrs.)
" " (t=24 hrs.)
Mioroemulsions only (t=24 hrs.)
Chlorambucil-Ester-LDL 
(after centrifugation)
100
59.5
51.9
49
40.8
Table 17 : Comparison of incorporation of chlorambucil
cholesteryl ester into LDL by exchange from 
mioroemulsions containing drug, cholesterol 
oleate and Dimyristoyl Phosphatidyl Choline 
(DMPC) or Dipalmitoyl Phosphatidyl Choline 
(DPPC).
STAGE OF PREPARATION
% CBE 
REMAINING
% LDL PROTEIN 
REMAINING
Incubation mixture (t= 0 hrs.) 100
Incubation mixture (t= 5 hrs.) 78
CBE-LDL (after centrifugation) 44
CBE-LDL (De-salted) 35
CBE-LDL (after 0.22pm filtration) 28
100
100
75
62
55
Table 18 : Recoveries of chlorambucil cholesteryl
ester (CBE) and LDL protein at each 
stage of the preparation of CBE-LDL as 
described in section 2.3.4.
Values shown are the mean of 3 preparations
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the drug recovery from the cholate procedure.
The proportions of drug and LDL protein in several preparations of 
CBE/LDL by this method are variable, as shown in table 19. On average, 
100 drug molecules (92-63) are incorporated per LDL particle.
2.4.5. DEGRADATION OF CBE IN LDL DURING STORAGE AT 4°C
Aliquots of CBE-LDL (135 |ag CBE/mg LDL protein) were stored at 4°C.
Every 24 hours for 3 days, an aliquot was removed and assayed for CBE 
by HPLC, Section 2.3.6. The decay profile for the drug-ester under 
these conditions is shown in figure 50. In the first 24 hours, the 
ester decayed rapidly, leaving only 35% of the original ester in 
solution. Thereafter, a further 5% of the drug is lost over the 
following 48 hours. The absence of free chlorambucil in the solution at 
any time implies that the drug-ester is not being hydrolysed to yield 
free drug.
2.4.6. ADRIAMYCIN-LDL
Several methods of incorporating adriamycin into LDL were employed,
23
Section 2.1.5. As reported by Iwanik et al , incubation of LDL with 
Adriamycin in sodium chloride/phosphate buffer causes immediate 
aggregation of LDL and drug. In an attempt to reduce this precipitation 
we used LDL solution immediately from the zonal preparation,
Section 2.1.1., without concentrating it or removing any of the sodium 
bromide. This did not completely prevent aggregation in any of the 
buffers used but about 10% of the LDL and some drug remained complexed 
and in solution, and was subsequently purified and assayed for drug. 
Section 2.3.6, and protein, Section 2.3.7. Proportions of drug and
CHLORAMBUCIL ESTER LDL
*
PROTEIN DRUG TO PROTEIN
CONCENTRATION 
1(pg/mL) (nmol/mL)
CONCENTRATION 
(mg/mL) (nmol/mL)
RATIO
.(gram/gram) (nmol/nmol)
181 269 5.5 11.0 0.033 24
752 1120 7.8 15.6 0.096 72
530 788 4.6 9.2 0.115 86
221 328 1.7 3.4 0.130 97
1130 1679 5.0 10.0 0.226 168
180 267 7.5 15.0 0.024 18
1580 2348 6.5 13.0 0.243 180
* LDL protein concentration calculated assuming a molecular 
weight of 500,000 Daltons for the apoprotein B content oi 
each LDL particle.
Table 19 : Proportions of chlorambucil cholesteryl ester
and protein in CBE-LDL complexes prepared as 
described in section 2.3.4. On average, 
92-63 drug molecules were incorporated per 
LDL particle.
Degradation O f  Chlorambucil Ester Encapsulated In LDL 
And stored At /CC For Several Days
100
percentage
GO
Ester 
Remai ning 40
20
4 4!3 "72 9(3
Time (hrs) .
Figure 50: Degradation of chlorambucil ester in a
preparation of the drug-LDL complex 
containing 371 pg of drug ester and 3.8 mg 
of LDL protein per mL of solution. The 
complex was stored at 4°C for several days 
and aliquots removed at intervals for 
drug quantitation by HPLC as described in 
Section 2.3.6.(C).
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protein in adriamycin—LDL complexes prepared by the methods described
in Section 2.3.5 are shown in table 2o. After 4 hours incubation in
DMSO and PBS buffers, only a few drug molecules had partitioned into
each LDL particle. This number was increased by prolonging the
incubation time to 24 hours. On the basis of these experiments,
24 hours incubation of drug in DMSO buffer. Section 2.3.5.(c),
produced LDL with the highest adriamycin content. Incubation of
drug and LDL at higher pH, Section 2.3.5.(f), produced no increase in
incorporation. On the contrary, slightly less drug was included,
table 20, and significant amounts of adriamycin degradation products
were apparent, fig. 51, in the pH 10 incubation mixture when analysed
by HPLC, Section 2.3.6. after 24 hours. However, it is interesting to
note that only Adriamycin had been incorporated into LDL. Surfactants
were used to enlarge the LDL particle and so facilitate the entry of
203
adriamycin into the core space. Tucker et al reported that several 
different surfactants, including those used here, caused rapid 
increases in the Stokes radius of the LDL particle. Adriamycin-LDL 
complexes prepared after incubation of LDL with Brij-35, Triton X-100, 
and SDS, Section 2.3.5.(g), were,disappointingly, not much higher in 
drug content than those prepared without surfactants, table 20. As 
with the other methods, the incorporation of the drug was quite erratic. 
SDS caused around 80% of the LDL protein to precipitate, before the 
adriamycin was added. No aggregation was observed in any of the other 
surfactant/LDL mixtures prior to drug addition.
By subjecting LDL to gradually increasing concentrations of adriamycin, 
via dialysis, it was hoped that the drug would be incorporated into the 
LDL particle without such a high degree of aggregation. The actual 
amount of drug which bound to LDL v;as less than 1% of the amount 
available, even in the most concentrated adriamycin solutions, fig. 52.
s
M
a
s
<
M
K
§
2
H
W
O
Pi O
CP H
Eh
O <
H Pi
CD
3
Pi
O
2
2 O
M M
w Eh
Eh <
O Pi
CÜ £h
CP 2
M
P Ü
Q 2
P O
Ü
2
2
O
M M
Ü P
>- <
Pi
< P
M 2
Pi w
Q o
< 2
O
CD
2
O
M
P M
< 2
m M
3 P
Ü
2
M
Q
I
W
O
E
C
O
E
C
I
E
►J
E
W)
M
O
z:
CM CMCO
3  
1—1 3 3 3
1—1 
3 1—I
CO 3 3
CM 1—!
3
3
CO LT) (O
CM 3 CM "sT rH CO 3 CD 3 3 3 3E O CO O f—1 P o o o CM O P O O
CO O o O O o o o O O o O OP
PÛ O o O o O o o o O O o O O
CM 3 3 3 CD CM O 3 3 CM 3 3 O
t—j O O O O 3 3 O 3 3 3 3 rH ppo O O O O O O O O O O O o p
o O CD 'cr 3 O O O CM O O 'cr o
3 3 CM 3 o 3 CD 3 3 3 33 3 P 3 1—i 3
r4 C]-
O  CM o
iH (D CD
3 3 3 3
3 O I—1O
CM CM CM CM CM CvJ
O O 
C/3 cn CO cn 
m cQ 
cu a .  Q  Q
op
3
2
M 2
2 CO
H
Ü 1—1
> COW P CO
P CD 2
<
) P O o o1O C/0 3 3: 2 2 2 21 Ü Q O P
1—1 3 O O 2 o
3 O 3 3 Ù0 Ü
*H
P 3 3 3 O 0) p
3 O 3 3 O O o 3 O 3 O CD 0)
P 'M'O P 3 sr 1—1 3 3 sr 3 3 3 1—1o
O P CD 3 3 o 1—1 O 3 1—13 1—1 O E
'M' "M"
CM CM CM CM CM
8 8
i n  in  X  X  
CO CO
■"3 *-)
H i M  M  M  c/3
DS Pi C:: K Q
m  D3 H  H  C/3
x :
Ü
ca
(U
Cm
O
■P
C
03
-P
§
Ü
m
o
a
CO
03
X:
p
m
c
o
-p
rH
co
Q
o
8
o
o
in
Oh
O
M
C■H
Ë
Z
C/3
C/3
CO
T3
03
P’
CO
D
Ü
rH
cO
o
c/3
cO
p
T3
03
P
CO
a
03
p
&
c/3
03
X
a
E
Q
P
I
C
•H
Ü
E
cO
•H
P
TO
CO
in
P
O CO
CM
?
c
C 'H
0 Ü
•H 2
P E
CO (0
P P
4-> P
C 3
00 <
CO 0)
c 1—I
o. o
o p
p
C p
•H CO
oo CO O
p 3
o p
p Q OO
2 P P
* P
g
Ü Ü 
03
C  C/3 
•H
03 C 
P  P
o
P  X) 
CO 03 
P  
X3 -H 
C  p  
CO Ü
cn
03 
X3
A
lA) (B)
LU
u
Z
LU
U
CO
LU
O::
O
= )
1
-4-
3 0  2 0  1 0  0 3 0  2 0  1 0  0
R E T E N T I O N  T I M E  ( m l )
Figure 51 : HPLC profiles of adriamycin/LDL incubation
mixtures after 24 hours at 25 °C in buffers 
containing 10% dimethyl sulphoxide and
(A) 0.15 M NaCl, pH 7.2 (sample diluted 1: 10)
or
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function of the free adriamycin concentration, fig. 53, began to reach 
a plateau. The aggregation of LDL was not significantly reduced by 
the dialysis procedure, which yielded adriamycin-LDL containing up to 
18 drug molecules per particle.
2.4.7. DAUNOMYCIN-LDL
Daunomycin-LDL was prepared as described in Section 2.3.5.(a). The 
degree of daunomycin incorporation was variable, table 21, as with the 
other drugs studied. On average, 120 daunomycin molecules (range 40-190) 
were sequestered within each particle, giving drug concentrations up to 
0.73 mg/mL.
2.4.8. IN VITRO TESTING OF CYTOTOXICITY OF DRUG-LDL COMPLEXES
Daunomycin-LDL (D-LDL), adriamycin-LDL (A-LDL) and chlorambucil-ester- 
LDL (CBE-LDL) complexes were prepared, as outlined in Sections 2.3.4 and 
2.3.5. The cytotoxicities of these complexes were compared to those 
of the native drugs. In all experiments, controls were set up 
containing no drugs. Identical plates were prepared with native LDL 
or LDL which had undergone the drug incorporation procedure, in the 
absence of drug. These controls induced no significant difference in 
cell survival from that seen in the cells to which neither drug nor LDL 
had been added. Additionally LDL and uncomplexed drug, added 
separately to the medium induced dose response exactly like cells 
treated only with native drug. All of the complexes studied had 
cytotoxic effects, although the extent of enhancement of cell kill 
conferred by the use of LDL as a vehicle was variable.
In G-CCM glioma cells, daunomycin-LDL was less toxic than an equal
Incorporation O f  Adriamycin Into LDL By Dialysis
Molecules 
O f
Particle
24
n
204 0 8 00 1
Adriamycin Concentration  
In Dialysis Solution 
(pg/ml)
Figure 53: Incorporation of adriamycin into LDL by
dialysis into the lipoprotein solution, 
as a function of the free adriamycin 
concentration.
DAUNOMYCIN-LDL
DAUNOMYCIN LDL
*
PROTEIN DRUG TO PROTEIN
CONCENTRATION 
(|ig/mL) (nmol/mL)
CONCENTRATION 
(^g/mL) (nmol/mL)
RATIO
(gram/gram) (nmol/nmol)
95 168 650 1.3 0.146 130
300 531 1600 3.2 0.188 - 166
280 496 6500 13.0 0.043 38
400 709 2500 5.0 0.160 142
379 673 5000 10.0 0.076 67
725 1285 3400 6.8 0.213 189
* LDL protein concentration calculated assuming a molecular 
weight of 500,000 Daltons for the apoprotein B content of 
each LDL particle.
Table 21 : Proportions of daunomycin and protein
in daunomycin-LDL complexes prepared 
as described in section 2.3.4. On 
average 122-58 drug molecules were 
incorporated per LDL particle.
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dose of native drug, fig.54. When tested in the microtitre system,
-6
Section 2.3.12, complex and drug had ID^^'s of 3.5 x 10 M and 
5.6 X  10 respectively. When tested on L-DAN cells by clonogenic 
stem cell assay,Section 2.3.13, free and LDL-bourne drug were almost 
indistinguishable in their cytotoxicity, table 22, despite the presence 
of high receptor-mediated LDL assimilation in L-DAN cells, fig. 55, 
Section 2.3.17. The clonogenic ID^^'s for intact spheroids which were 
disaggregated after treatment. Section 2.3.13, showed that spheroids 
were significantly less sensitive to both daunomycin and daunomycin-LDL 
than their monolayer counterparts, table 22. Spheroid growth delay 
Section 2.3.13, was significantly longer for daunomycin-LDL compared to 
native daunomycin at a drug concentration of 5 yg/mL, table 22. 
Qualitative fluorescence microscopy on the spheroids after drug exposure 
showed that D-LDL, fig.56 had diffused further into the spheroids than 
free daunomycin, fig. 57. In HeLa cells (microtitre assay. Section 
2.3.12) the D-LDL complex was marginally more cytotoxic than the free 
drug, fig. 58.
Adriamycin, when carried in LDL, was active at a lower concentration
-8 -7
than free drug, fig. 59, with ID^^ 1.1 x 10 M compared to 1.6 x 10 M
for native adriamycin, when tested on HeLa cells in the microtitre assay
Section 2.3.12.
Chlorambucil was more effective as a cytotoxic agent when carried in 
LDL, fig.60. The ID^^ of the drug fell from 1 x 10 to 2 x 10 
when transported within LDL.
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Figure 54: Comparative cytotoxicities of daunomycin and
daunomycin-LDL on human glioma cells in the 
microtitre assay. Each point is the mean of 
duplicate incubations in three experiments.
L-DAN (Human Non-Small-Cell Lung Carcinoma)
EXPOSURE TO
Daunomycin Daunomycin-LDL
MONOLAYER
CLONOGENIC SURVIVAL (ID ) 1.5 jig/mL 1.6 jig/mh
SPHEROIDS
CLONOGENIC SURVICAL (ID^„)
50
1.9 jig/mL 1.3 yg/mL
GROWTH DELAY 20 days 23.2 days
Table 22 : Comparative cytotoxicity of daunomycin and
daunomycin-LDL, assessed in monolayer and 
spheroid culture as described in section 
2.3.13.
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Figure 56 : Fluorescence micrograph of an L-DAN spheroid
following exposure to daunomycin-LDL.
Figure 57: Fluorescence micrograph of an L-DAN spheroid
following exposure to native daunomycin.
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Figure 58: Relative cytotoxicities of native and LDL-
encapsulated-daunomycin against HeLa cells 
in the microtitre drug sensitivity assay.
Each point is the mean of duplicate incubations 
in three experiments.
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Figure 59: Relative cytotoxicities of native- and LDL encapsulated-
adriamycin against HeLa cells in the microtitre drug 
sensitivity assay. Each point is the mean of duplicate 
incubations in three experiments.
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2.4.9. IN VIVO TESTING OF DRUG-LDL COMPLEXES IN THE SRC ASSAY
Daunomycin-LDL or daunomycin were given by IV injection, at a dose of
4 mg/Kg, to groups of mice implanted with primary gastric tumour, as
described in Section 2.3.14. The apparent increases in tumour size
for each group are shown, along with those for untreated animals,
in fig. 61,. A significant inhibition in tumour growth (p<0.05,
Wilcoxon) was observed only in the mice treated with D-LDL. However,
histological examination of tumour sections revealed that the
apparent tumour growth was actually a measure of lymphocyte infiltration,
and very few viable tumour cells were present on day 6 in any of the
tumour implants, whether treated or untreated, fig. 62. Thus, the
observed reduction in "tumour" size in mice treated with D-LDL was
actually a result of drug induced immunosuppression. The SRC assay
214
has since been shown to be invalid for primary gastric tumours 
A second group of mice was implanted with rat Walker256 tumour 
(obtained as described in Section 2.1.12) and treated with daunomycin, 
D-LDL, LDL or left untreated. Despite the presence of a large number 
of viable tumour cells and only a small proportion of lymphocytes, no 
difference in tumour growth was observed in any of the drug or LDL 
treated mice when compared to controls.
Mice implanted with Walker256 tumour were treated with chlorambucil, 
CBE-LDL (8 mg of chlorambucil per Kg body weight) or LDL. Results 
obtained are shown in fig. 63. Both chlorambucil and chlorambucil-LDL 
were successful in suppressing growth of tumour. The LDL-treated group 
did not show any significant difference in tumour size when compared to 
the control group. Histology showed viable tumour cells to be 
present in all tumour implants, but variable degrees of lymphocyte 
infiltration, necrosis and fibrosis, fig. 64, were observed in a
Glioma Microtitre Assay
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Figure 60: Comparative cytotoxicities of native chlorambucil
and chlorambucil ester-LDL against human glioma 
cells in the microtitre drug sensitivity assay. 
Each point is the mean of duplicate incubations 
in three experiments.
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did not show any significant difference in tumour size when compared to 
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Figure 62: Haematoxylin and eosin stained section of
mouse kidney and gastric tumour implant on
day 6 of the SRC assay. Note the large
degree of lymphocyte infiltration (A) and 
lack of viable tumour cells (B).
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Figure 64 (l-IV): Haematoxylin and eosin stained
sections of mouse kidney and 
Walker256 tumour implants on 
i day 6 of the SRC assay.
Note the areas of
(A) lymphocyte infiltration
(B) necrosis
(C) fibrosis
(D) viable tumour cells
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random manner in each group, making assessment of the tumour size 
data qualitative rather than quantitative. In this group of animals 
the opportunity was taken to measure white blood cell counts, Section 
2.3.15. Chlorambucil-treated animals had significant immuno­
suppression, fig.65, with the mean value only 25% of control. As 
expected, native LDL-treated mice showed no reduction in white blood 
cell number. The drug carried in LDL appears to have reduced the 
extent of immunosuppression with mean white blood cell count 81% 
of control(not significant, Wilcoxon) in CBE-LDL treated animals, while 
maintaining the same degree of. tumour kill as an equivalent dose of 
native chlorambucil.
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SECTION 3 : DISCUSSION
Ill
3. DISCUSSION AND CONCLUSIONS
3.1. LDL RECEPTOR ACTIVITY IN VIVO
12—22Numerous in vitro experiments have shown that LDL may be a
useful vehicle for the selective delivery of drugs or radioisotopes
to cancer cells. However, until recently, little was known of the
likely degree of specificity which LDL would have as a selective
targeting vehicle in vivo. Growing tumour cells, like other rapidly
dividing cells, require a considerable amount of cholesterol for
membrane synthesis. In many cell types it has been reported that LDL,
the major cholesterol-carrying lipoprotein in human plasma, is the
25
preferred source of the sterol when available. Alternatively cellular
25
cholesterol requirements are met by de novo synthesis from acetate
In this study a double-isotope procedure was used to assess relative
receptor-mediated and receptor-independent catabolism of LDL by
individual organs and tumours in mouse and rat models. This approach
67 93 94has been shown previously ’ ’ to be adequate to detect changes in
LDL catabolism induced by diet or lipid-lowering drugs. In the
animals examined in the present study, as in the human, the liver and
adrenal gland are by far the most active in assimilating LDL via both
receptor and non—receptor routes. Because of its size, the liver is
responsible for the catabolism of a large proportion of plasma LDL and
so plays a dominant role in LDL metabolism in control and tumour-
bearing animals. Nevertheless, tumour cells were active in taking up
LDL. The Mac-13 tumour exhibited substantial receptor-mediated uptake
of the lipoprotein (fig.19) and was second only to liver in activity.
This was also true of the polyoma virus-induced adenoma in mice (fig.21)
193
Colonic tumours generated by administration dimethylhydrazine to 
rats was considerably more active in LDL assimilation via receptors
112
than any other tissue examined, including liver (fig.22) and Walker-256 
rat tumour was also active in receptor-mediated LDL catabolism, 
assimilating by this route almost as much LDL as liver (fig.23). In 
the experiments using hamster pancreatic tumours (fig.26) only total 
LDL uptake (i.e. uptake by both, receptor-independent and receptor- 
mediated routes) was measured. Consequently no definite conclusion 
can be drawn regarding the receptor activity of these tissues. Here 
the tumours' acquisition of LDL was modest in comparison to the 
relatively high levels of LDL assimilation in other hamster tissues.
In the rat model (fig.22), total LDL uptake by colonic tumours was 
surpassed only by liver and spleen. The high activity of the spleen 
probably reflects the removal of denatured tracer material, which is 
mediated by cells of the R.E. system. Although this corresponds to 
less than 5% of the injected dose, the organ appears to be particularly 
avid since the denatured tracer is directed specifically at it.
Thus all of these tumours, although of varying aetiology, exhibited 
substantial LDL catabolic activity and are potentially susceptible to 
LDL-mediated cytotoxic therapy. However, specificity remains a 
problem and it is likely than the liver and adrenal glands would suffer 
during chemotherapy, although it should be noted that the presence of 
tumour in mice appeared, by some undefined mechanism, to reduce 
receptor—mediated hepatic uptake of LDL (tables 5 & 7). Certainly, 
there were no macroscopically apparent métastasés in the animals' 
livers which could have contributed to this effect. Consequently, it 
is necessary to protect these organs from the toxic effect of LDL 
therapy by reducing their receptor expression. This is possible since 
the number of receptors expressed by the cells of each organ can be 
influenced by changing the intracellular pool of cholesterol. Kovanen 
et al^^ have shown that, in mice, adrenal LDL receptor activity is
113
markedly activated by injections of ACTH and, in the dog, it has been
demonstrated that hepatic receptor activity can be suppressed by
dietary supplements of cholesterol^^^ or bile acids^^^ 197^ However,
in the groups of mice examined here there was little impact of
cholesterol feeding on receptor-mediated hepatic LDL uptake (table 13)
despite a substantial increase in plasma cholesterol in response .to
diet (table 6). Interspecies variation in the ability of cholesterol
to inhibit receptors is well recognised. For example, dietary sterol
supplementation is ineffective in changing rat plasma cholesterol
29levels since the bulk of excess sterol is excreted in the bile . In 
215
man on the other hand, the primary response appears to be to export 
cholesterol into the plasma as LDL rather than retain it in the liver 
and modulate receptor activity; and bile acid feeding in the mice used 
in the present investigation was more successful in reducing the 
expression of hepatic LDL receptors than was dietary cholesterol 
supplementation (table 14). This parameter fell by 25% (p<0.05, 
Wilcoxon rank test) in the control mice and by 17% (p40.05) in the 
tumour-bearing animals. Presumably the reduced activity is consequent 
upon suppression of bile acid production from cholesterol, leading to 
an increase in the hepatic sterol pool and downregulation of the 
liver membrane receptors (fig.27). In rats bearing colonic tumours 
however, bile acid feeding did not produce a similar effect (table 15). 
Taurocholate-treated tumour-bearing mice also showed reduced receptor- 
mediated adrenal LDL uptake, a response which was not observed in the 
control group (table 14). This unexpected phenomenon, like the 
reduced hepatic receptor activity seen in tumour-bearing mice, 
presumably reflects a change in lipoprotein metabolism which is 
secondary to the presence of tumour.
LDL uptake by the adrenal gland wa$ successfully suppressed by the
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administration of hydrocortisone (table 14). In the control and tumour- 
inoculated mice, injection of the steroid lowered adrenal LDL receptor 
activity by 48% and 30% respectively (p<0.05, Wilcoxon rank test, in 
both cases). In rats with colonic tumours (table 15) hepatic uptake 
of LDL was reduced by 40% (p<0.05, Wilcoxon rank test) after 
hydrocortisone administration and adrenal receptor activity was lowered 
by 40% and 30% (both p<0.05) in control and tumour animals respectively,
When hydrocortisone was combined with taurocholate feeding, both 
hepatic and adrenal LDL uptakes were lowered in the mice without 
concomitant lowering of the activity of the tumour (table 14).
This regimen also successfully lowered adrenal uptake in the tumour- 
bearing rat model (table 15). It is interesting to note that the 
ovaries of rats receiving hydrocortisone alone or with bile salts had 
significantly suppressed LDL receptor activity. This was not merely a 
secondary response to tumour presence since it also occurred in the 
matched control group (table 15). The mechanism for this effect is 
unclear.
3.2 EVIDENCE FOR LDL UPTAKE IN TUMOURS USING CUMULATIVE MARKERS OF 
LDL CATABOLISM
LDL labelled with radioiodinated cholesteryl linoleoyl ether^^^ or
105
radioiodinated cellobiose-tyramine was used to obtain a cumulative 
index of the extent of catabolism of the lipoprotein by the tumour. 
These tracers have been reported to be internalised by the cell in an 
identical manner to native LDL, but once inside lysosomes they resist 
degradation and are retained there. Less than 35% leaks back into the 
circulation over a period of 24 hours, in contrast to the immediate 
release into the plasma of iodotyqosine from conventionally labelled
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I-apo B-LDL. In MAC-13-inoculated mice, the tumour as a whole was 
second only to liver (fig.24) in assimilating labelled LDL. Hepatic 
uptake of I-CE-LDL by the receptor pathway was again suppressed by the 
presence of tumour (p<0.05, Wilcoxon rank test), as was originally 
observed using I-apo B-LDL.as tracer (fig.19). LDL receptor activity 
in kidneys and adrenals was also suppressed in the tumour-bearing 
animals.
The uptake of LDL via both receptor-dependent and receptor-independent
pathways by rat colonic tumours (fig.25) and hamster pancreatic
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tumours (fig.26) was measured using I-CT-LDL. In both models 
tumours were highly active in this regard, although several normal 
tissues in the hamster model showed a similar response.
In assessing the above results, it must be borne in mind that 
heterologous, human, LDL was used in the animal models because of its 
ease of preparation and known biological properties. Such an 
approach may produce different results than might be obtained if 
homologous LDL were used, but these should be of minor quantitative 
significance.
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3.3 DRUG INCORPORATION INTO LDL
The LDL particle consists of an apolar core of cholesteryl esters
and triglycerides surrounded by a phospholoid monolayer containing
27 34
free cholesterol and apoprotein B ’ . This provides several sites
for the insertion of drug molecules, depending on their lipid 
solubility. The core is by far the best site, since chemically 
sensitive drugs sequestered there would be well protected from serum 
hydrolases and the potentially damaging effects of an aqueous 
environment. Furthermore, the core has the capacity to store a 
large number of drug molecules. However, only very hydrophobic agents 
are suitable for inclusion in this domain. A second site for drug 
intercalation is the phospholipid monolayer. Agents which have both 
polar and lipid soluble components may partition here, between the 
apolar core and the aqueous environment, but in this location, they 
are less well protected from serum hydrolases and water and further, 
may be able to stimulate the immune system to remove the drug-LDL 
complex from the circulation. A third approach would be to attach the
17,
drug covalently to the apoprotein moiety of the LDL particle , 
However, there are a number of immediately obvious drawbacks here 
since
1) Drug attachment to apo B may distort the protein 
and reduce or abolish completely its binding
to LDL receptors.
2) The drug-LDL link must be successfully hydrolysed 
to liberate the active agent within the cell.
3) The potential of each LDL particle for storing
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drug in this manner is considerably less 
than the capacity of the core.
4) Drug carried in this way is exposed to water 
and serum enzymes.
5) Distortion of apo B in linking the drug
molecules may render the complex susceptible
to removal by the immune system.
Several procedures have been detailed as adequate for the incorporation
of trace amounts of apolar substances into the core space of the LDL
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particle. However, only Kreiger's method , which, in effect,
produces "synthetic LDL", has been shown to insert significant amounts
of exogenous substances into the lipoprotein. "Kreiger particles",
although they react like native LDL in vitro are rapidly removed from
circulation by cells of the R.E. system when injected in vivo. This
147
method however is still potentially useful since Masquelier et al 
have modified Kreiger's method to produce an LDL species containing a 
lipophilic anthracycline (AD-32) which is removed from mouse plasma at 
a similar rate to that of native human LDL.
Our attempts to incorporate drugs into LDL focused on using native 
human LDL as acceptor in order to reduce potential R.E. clearance of 
the drug complex in vivo. Drugs were either partitioned into the 
lipoprotein from concentrated drug solutions in various aqueous 
buffers (anthracyclines) or by exchange from HDL or micellar lipid 
suspensions (chlorambucil cholesteryl ester).
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3.4 DAUNOMYCIN AND ADRIAMYCIN
Daunomycin was easily intercalated into LDL following the method
23
described by Iwanik et al . In solutions of high daunomycin con­
centration, an average of 190 drug molecules were able to diffuse into 
each LDL particle (table 21). The resulting complexes retained their 
specific binding ability, 99% of the apo B being precipitated on 
interaction with LDL antibodies. Furthermore, daunomycin-LDL uptake 
into P388 leukemic cells was shown by these authors to be subject to 
competition from native LDL but not HDL. Interaction of the
daunomycin-LDL complex with DNA resulted in the quenching of only 45%
23of the fluorescence of the drug . The size of the DNA molecule
precludes its entry into the core space of the particle and it is likely
that only drug molecules sequestered on or near the surface of the LDL
particle are susceptible to quencing by this probe. A further 13%
23
of the fluorescence was quenched by potassium iodide , since this
agent has access to parts of LDL that DNA is unable to reach. Thus 
23Iwanik et al deduced that around 50% of the daunomycin is loosely 
held on the surface, with the remainder located in the hydrophobic 
core of LDL. This was further confirmed by the "leakage" of 
approximately 40% of the daunomycin from LDL during centrifugation at 
a density of 1.063 Kg/L.
Despite the structural similarities between daunomycin and adriamycin 
(fig.11), the latter is much more reluctant to partition into LDL. 
Adriamycin, when incubated with the lipoprotein under conditions 
similar to those used for preparing daunomycin-LDL, caused its
23
immediate aggregation, a reaction which has been observed by others 
Consequently, alternative approaches were considered in the 
preparation of adriamycin-LDL, since this complex has a much larger
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potential spectrum of clinical use than daunomycin-LDL. LDL is
known to be less prone to aggregation when stored at low concentration
in solutions of high ionic strength. For this reason, many of our
experiments used the pooled LDL fractions obtained directly from the.
rate-zonal centrifugation^^^. Nevertheless, aggregation still
remained a problem, possibly due to the formation of an insoluble
complex between the drug and cholesterol on the surface of LDL.
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Brown et al used a sodium chloride buffer containing 10% DMSO (v/v)
in a procedure for incorporating labelled cholesteryl esters .into' LDL.
This approach in our hands generated a complex in which a small amount
of adriamycin became associated with the lipoprotein. Comparison of
the drug incorporation at pH7.2 and pH 10 showed neutral conditions to
be better than basic by a factor of 2 (table 20). At pH.10 there was
a larger degree of drug degradation (fig.51) although only native
adriamycin was incorporated into LDL to any detectable level, i.e.
none of the drug's metabolites were as. lipophilic as or more lipophilic
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than the native drug. Tucker et al investigated the use of 
surfactants for enlarging the structure of the LDL particle. Rapid 
increases in the Stokes radius of the LDL particles were observed after 
exposure to a variety of surfactants but the incorporation of 
adriamycin into these surfactant-enlarged LDL particles was not 
significantly higher than that obtained in the absence of surfactants 
(table 20). It would appear therefore that steric factors are not the 
major cause of the low adriamycin concentration observed in adriamycin- 
LDL preparations. It is more likely that the hydrophobic environment 
provided by the LDL core is not conducive to sequestration of the drug. 
Since the only difference between adriamycin and daunomycin is a 
hydroxy substituent on C14 in the former, it is obvious that this 
highly hydrophilic group has a dominating effect on the lipid solubility 
of the drug. Better incorporation might be achieved if this hydroxy
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group were selectively esterified by, for example, a fatty acid
21residue. Vitols et al have esterified adriamycin with linoleate 
at this position and have coupled N-retinoyl leucine to the amino 
group of the sugar. 100-200 molecules of this derivative became 
incorporated into each LDL particle although the authors do not 
comment on its aggregant effect on LDL in solution.
3.5. CHLORAMBUCIL
The chemical structure of chlorambucil (fig.11) was suitable for 
estérification with cholesterol. This was achieved by a single 
reaction, using dicyclohexylcarbodiimide as a coupling agent. The 
object of this derivatisàtion was to produce a molecule which would 
be more amenable than the original chlorambucil molecule to 
incorporation into LDL. The benefits of synthesising a cholesteryl 
ester were three-fold:-
1) The polarity of the carboxylic acid group 
was markedly reduced, making the drug-ester 
more hydrophobic than the native drug
2) Cholesteryl esters are the native occupants 
of the core of LDL and the subsequent 
incorporation of chlorambucil cholesteryl 
ester there should produce minimal 
disruptions of the structure of the 
lipoprotein
3) There exists a cholesteryl ester transfer 
protein in human plasma which mediates the
121
exchange of cholesteryl esters between LDL 
and HDL and which may be utilised for 
incorporation of the drug-cholesteryl ester 
into LDL.
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Stoffel et al have described a method for loading labelled
cholesteryl esters and fatty acids into HDL by exchange from cholic
acid/lipid micelles. Taking this process a stage further, iodinated
cholesterol linoleoyl ether was incorporated into LDL by exchange from
HDL, utilising the cholesteryl ester transfer protein from human 
191
plasma . Initially this was the method used for chlorambucil ester
incorporation, but the resulting LDL complex had virtually no cytotoxic
activity (fig.46). This lack of cytotoxicity had two obvious possible
causes: either the cells did not have adequate receptor expression;
or the drug was being inactivated during the incorporation procedure.
The former explanation was ruled out since the glioma cell line used,
20
G-CCM, had already been reported to have high receptor expression 
under similar conditions. On examination of the buffers used in the 
loading process tris^hydroxymethyj) methylamine (tris) was identified 
as a probable culprit for the drug inactivation. This nucleophile 
was likely to be attacking the carbon attached to chlorine on the 
chloroethyl side chains of chlorambucil, releasing chloride and , 
rendering the drug inactive. Drug activity was conserved by 
replacing tris buffer with phosphate buffer, although the incorporation 
of chlorambucil ester remained low (table 16). Later, drug ester was 
exchanged from the cholic acid/lipid micelles directly to LDL, with 
an increase in the overall drug recovery (table 16) and no obvious
effects on the integrity of the lipoprotein. By following the
cholesteryl chlorambucil ester incorporation by HPLC at each stage of
the cholate preparation, it was clear that a substantial amount of the
122
drug had been degraded over the course of the experiment. Studies
on the degradation reaction surprisingly showed no free chlorambucil in
the solution. Consequently the process appeared not to involve simply
a hydrolysis of the ester bond between chlorambucil and cholesterol.
At first the degradation was attributed to enzymes present in the
crude preparation of cholesteryl ester transfer protein, but the extent
of disappearance of the drug ester was higher in solutions containing
no enzymes (fig.49) This is in accordance with the observation by 
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Alberts et al that free chlorambucil is degraded faster in water 
than in human plasma in vitro.
As an alternative to the modified Stoffel procedure (Section 2.3.2), 
which yielded LDL of low drug content, Craig's procedure (Section 
2.3.4) for making drug/lipid microemulsions was examined. This 
method was originally devised for making LDL of defined cholesteryl 
ester composition and involves preliminary preparation of drug-lipid 
microemulsions. The process is much shorter than the Stoffel method, 
thus reducing the degree of drug degradation. Up to 30% of the drug 
used was recovered in LDL after exchange from' these microemulsions and 
the drug-LDL complex was easily separated from them by micro­
filtration and centrifugation. It is interesting to note that, on 
storage at 4 ° C ,  a portion of the drug within the LDL complex was 
degraded rapidly over the first 24 hours and thereafter degradation 
was much less significant (fig.50). This biexponential drug decay points 
to the possibility that chlorambucil cholesteryl ester molecules are 
located both on the surface (the rapidly degraded component) and in the 
core of the LDL particle. Assuming that this deduction is correct, 
core-located drug molecules obtain protection from the aqueous environ­
ment when sequestered in LDL under the conditions used. Native 
chlorambucil decays with monoexponential kinetics^^^, leaving only 10%
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of the original drug after 6 hours incubation at pH7 and 25^C, 
compared with recovery of 50% of the drug in LDL after 24 hours of 
incubation under similar conditions, a further indication of the 
protective environment provided by LDL.
3.6 IN VITRO TESTING OF DRUG-LDL COMPLEXES
The sensitivity of tumours to various antineoplastic agents in vitro
has long been studied as a possible indicator of their in vivo
response to proposed chemotherapeutic regimens. The relative in vitro
colony forming ability of treated and untreated cell samples is
207commonly used as a method of assessing drug sensitivity . However, 
this method is not always readily applicable to primary cultures of 
human tumours as a result of their low cloning efficiency and slow 
growth rate. Furthermore, assays based on cell proliferation ability 
alone require extensive cell counting and are impractical for large 
numbers of samples. As an alternative to clone counting, cellular 
metabolic activity may be measured after exposure to drugs. Protein 
synthesis is one biosynthetic event which has been identified as a 
fundamental metabolic process, without which the cell cannot survive. 
Since leucine is an essential amino acid, the cell must acquire it 
from the surrounding medium and protein synthesis is most unlikely 
to occur without incorporation of this molecule. Thus |^ h^]-leucine 
may be added to the culture medium and its extent of incorporation will 
be indicative of the metabolic activity of the cells. Consequently, 
the absence of intracellular |^ h^]-leucine several hours after drug 
removal will almost certainly correlate with cell death. A 
microtitre drug sensitivity assay based on such an approach has been 
described for HeLa^^^ and human glioma^^^ cell lines. This procedure 
has several advantages over the afprementioned clonogenic assays.
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particularly with regard to the large numbers of replicates which can 
easily be handled. The relatively long drug exposure time ensures that 
the majority of the cells in culture are able to pass through the 
entire cell cycle at least once during this period. Consequently, 
even phase-specific drugs may be adequately assessed by the procedure.
Intermediate between monolayer culture systems and in vivo tumour models
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is the spheroid model of cell culture. In this system, cells are 
grown in multi-layer 3-dimensional arrays which are able to mimic better 
the arrangement of cells in the intact tumour. The ability of drugs 
to penetrate the microarchitecture of tumour cell layers is a variable 
which the monolayer system completely ignores. This distribution 
factor can be tested, to some degree at least, in the spheroid culture 
system. Drug penetration is, of course, of major importance in the 
treatment of tumours, since the deeper the drug is able to move into the 
tumour, the larger the fraction of tumour cells which’ will be killed.
Since relatively high concentrations of daunomycin were able to be 
incorporated into LDL, this complex was tested on a variety of cell
culture systems. In monolayer experiments, using human glioma cells
(fig.54) and HeLa cells (fig.58) in the microtitre assay and L-DAN cells 
(table 22) in the clonogenic assay, the targeting of daunomycin within 
LDL did little or nothing to increase the cytotoxicity of the drug.
There are two obvious reasons for this lack of enhancement of daunomycin 
cytotoxicity ;-
1) Drug accumulation within the cell is not increased
when daunomycin is carried within LDL either because 
the daunomycin influx/efflux mechanism is altered
by the change in the initial metabolic treatment of
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the drug following internalisation via the LDL 
pathway or because the LDL pathway in these cells 
becomes saturated at relatively low daunomycin-LDL 
concentrations; alternatively
2) Daunomycin may be denatured during its 
internalisation with LDL, before it can 
successfully carry out its cytotoxic action.
23
Iwanik et al in their experiments.with daunomycin-LDL on human 
leukemic cells found that drug accumulation within the cells was higher 
when the drug was administered within LDL, but, unlike the native drug, 
which was located, as expected, mostly in the nuclear fractions of the 
cells, daunomycin delivered via LDL was more abundant in the microsomal- 
mitochondrial- lysosomal membrane fractions. This observation lends 
credence to the possibility that the drug had undergone a metabolic 
transformation before its cytotoxic action could be achieved. Of 
course, drug and LDL uptake and membrane fractionation experiments 
would have to be carried out on the cell lines used in our work to 
evaluate the validity of the above explanations. The results of the 
spheroid experiments were more favourable, daunomycin-LDL being more 
effective than native drug on the spheroids both when measured by 
spheroid growth delay and in clonogenic assay after disaggregation. 
Fluorescence microscopy on spheroid cross-sections after drug 
exposure (fig.56,57) showed that daunomycin had penetrated further into 
the tumour structure when carried within LDL. This■improvement-in. drug 
distribution obviously had a beneficial effect on the growth delay of 
the spheroids treated with daunomycin-LDL.
Adriamycin was more successful as a cytotoxic agent when administered
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within LDL to HeLa cells in the microtitre assay (l'ig.59). The action
of this drug differs from daunomycin in that it has well-documented
130cytotoxic effects in the cytoplasm and at the plasma membrane, as
172
well as at the nucleus . Consequently the change in drug
23distribution seen when daunomycin was carried in LDL , if it occurs in
a similar manner with adriamycin-LDL, may not decrease the cytotoxicity
of adriamycin so significantly, or may even increase it. Lysosomal
degradation of adriamycin is not a problem with free or LDL-borne
drug since it has already been shown that this anthracycline is
216resistant to lysosomal enzymes . There is also the possibility that 
adriamycin uptake into HeLa cells is low in comparison to drug uptake 
via LDL.
Chlorambucil cholesteryl ester-LDL was by far the most successful of
the complexes tested in the glioma microtitre assay, with the ID^^ of
the drug lowered by a factor of 2CC when it was targeted in LDL (fig.6C)
As already mentioned, encapsulation of the chlorambucil ester within
LDL appears to reduce the hydrolysis rate of the drug and this may
result in the availability of a comparatively higher concentration of
active drug inside the cell over the period of drug exposure. Influx
217
of nitrogen mustards has been shown to be an active transport
process in human leukemic and normal lymphoid tissue. Chlorambucil-
218
resistant cells of Yoshida ascites sarcoma have been reported to
accumulate 5C% less drug than their sensitive counterparts, under
identical conditions. Therefore the cell's ability to internalise
chlorambucil may have a profound effect on cellular susceptibility to
218
this agent, although in the case of the Yoshida ascites sarcoma , 
other differences were also observed between the sensitive and resistant 
sublines. Targeting of chlorambucil within LDL in this way may then 
conceivably increase the drug's cytotoxic effects simply by increasing
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drug influx, so exposing tumour to high drug concentrations for a
219longer period. It has also been postulated that, once inside the 
cell, chlorambucil immediately associates with lipid-protein complexes 
whence it is released at a slow rate prior to carrying out its 
alkylating action. Thus, administration of the drug within LDL may 
effectively insert the drug into the cell at a stage further along its 
normal metabolic pathway. Conversely, the distribution of daunomycin 
within subcellular compartments is markedly different when it is 
administered within LDL, and this difference may well account for the 
observed decrease in cytotoxicity of daunomycin-LDL compared to the 
native drug.
3.7 IN VIVO TESTING OF DRUG-LDL COMPLEXES - THE SUBRENAL CAPSULAR ASSAY
Cell experiments are of value in predicting the likely sensitivities 
of tumour cells to antineoplastic drugs, but they do not take into 
account the effects of other organs on the distribution, metabolism and 
excretion of the drug. The object of using drugs within a targeting 
vehicle is to favourably alter the pharmacokinetic disposition of the 
drug so that tumour cells are harmed considerably more than normal 
tissues. This property can, obviously, only be tested significantly 
using an in vivo tumour system. Also, drugs requiring in vivo 
activation may only be adequately assessed using an animal model unless 
the active agent can be isolated. There is still considerable 
controversy over the best type of animal model to use for experimentation 
with cytotoxic drug regimens and over the relevance of the results 
obtained with regard to extrapolation to the human situation. In many 
of the models currently in use, drugs are administered very early in the 
growth of the tumour, often less than 24 hours after implantation, 
whereas in the clinical situation the neoplasm, and often métastasés.
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are usually long established before treatment commences. Although 
transplantable animal tumours are, in general, much faster growing 
than human tumours, the administration of drugs to the animals occurs 
undoubtedly at a relatively early stage in the progression of the 
neoplasm. Also, doses up to the (the lethal dose which kills 10%
of the animals which receive it) are often used against animal tumours 
while similar doses cannot be used in humans.
In order to test drug-LDL complexes in vivo the mouse model first
212
described by Bogden et al was employed. This model, the Subrenal
Capsular (SRC) assay, involves implantation of tumour fragments under
the renal capsule in normal immunocompetent mice. Bogden's model has
several advantages over other tumour systems. The assay is rapid,
220giving a result in only six days, and other workers have used the
same procedure with a four-day timescale. Normal immunocompetent 
218
mice are used , so reducing the need for sterile conditions.
Fragments of solid tumours are implanted thus maintaining the spatial
relationship between tumour cells of the same, and different
subpopulations, a relationship which may have a profound effect on drug
penetration into the tumour and ultimately on overall tumour response 
221to chemotherapy . The drug administration protocol resembles that 
used in the treatment of humans, unlike the single drug dosage scheme 
employed in many animal models.
Results obtained here using daunomycin-LDL against a human primary 
gastric adenocarcinoma (fig. 61) appeared at first to be very promising 
with tumour showing an apparently lesser size increase after treatment 
with the complex compared to treatment with native daunomycin.
However, histological examination of tumour sections revealed a major 
problem with the SRC assay: Bogden'^s original statement that the host
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immune system did not invade the tumour implants to any great extent
212
until after six days was incorrect. The large, but variable degree 
of lymphocyte infiltration observed in all tumour groups made the 
interpretation of results, by measurement of tumour dimensions, very 
difficult. This was further complicated by the low numbers of viable 
tumour cells present at day 6 (fig.62), even in the control animals, and 
it was concluded that the apparent differences in tumour size were in 
fact differences in lymphocyte infiltration. It appeared therefore 
that daunomycin-LDL had a greater effect in suppressing the mouse 
immune response (and limiting immunocyte infiltration) than that 
observed after treatment with native daunomycin.
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At only one day after tumour implantation, Cunningham et al noted a
considerable lymphocytic infiltrate in tumour graft sections. Others 
222 223too ’ have observed immunocyte contributions to tumour size,
although many have classed this contribution as insignificant, stating
223
that it accounted for less than 20% of the total tumour size
However, even at this relatively low level, the degree of lymphocyte
infiltration may bias the results, as in the case of daunomycin-LDL
above, since many of the common cytotoxic agents have marked
220
immunosuppressive activity. Levy et al have composed a scoring 
system whereby tumour size, lymphocyte infiltration, necrosis and 
fibrosis are among the factors taken into consideration. This is 
obviously a better system of assessment but it has the disadvantage of 
requiring more detailed and more laborious analysis of tumour sections 
before conclusions can be drawn. After consideration of the low 
number of viable tumour cells in the control animals and the significant 
degree of lymphocyte infiltration in the grafts used for testing 
daunomycin-LDL, and numerous other grafts of this type, the SRC assay
was concluded^^^ to be of no value.in assessing the chemosensitivity of
130
human primary gastric tumours.
When animal tumours were used in the SRC assay a less extensive
214
lymphocyte response was observed . The rat Walker-256 tumour,
originally a mammary adenocarcinoma, has been used in rat models for
many years. When daunomycin and daunomycin-LDL were tested against
this tumour, neither agent was able to limit its growth; but after
treatment with chlorambucil ester-LDL or chlorambucil, Walker-256
tumour sizes were smaller than those observed in the control or native-
LDL treated groups (fig.63). Microscopic evaluation of tumour sections
showed large aggregates of viable tumour cells in each graft, but also
present in random fashion throughout both control and test groups were
variable proportions of necrotic, fibrotic and lymphocytic tissue,
although lymphocytic infiltration was at a much lower level than that
observed with the primary gastric tumours. The pattern of tumour
necrosis, when present, was always the same. Those tumour cells in
the layers furthest from the kidney surface were the first to die
(fig.64). This implies that the tumour's demand for nutrients were in
excess of the capabilities of the transport system within the graft,
despite the concentration gradient between kidney and graft and the
presence of simple blood vessels within the tumour. Perhaps this
indicates another limitation of the SRC assay, although other 
212 220groups ’ have reported high percentage increases in tumour size 
with no mention of necrosis.
So, interpretation of the results obtained from the SRC assay is not 
straightforward since factors other than tumour dimensions must be 
taken into account.
The object of using a vehicle for chemotherapeutic agents is not only
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to deliver more drug to its site of action, thereby inducing more 
tumour cell kill, but also to decrease its toxic effects on normal 
tissues. A common dose-limiting side effect of cytotoxic therapy is 
immunosuppression and since the degree of lymphocyte infiltration into 
tumour in experiments with gastric tumours was affected by daunomycin- 
LDL , white cell number per mL of blood was measured following drug 
exposure in later studies. On comparison of the mean white blood cell 
counts in each treated group with the control group on day 6 of the 
assay (fig.65), only native chlorambucil was found to have a significant 
lowering effect. Thus, since chlorambucil and chlorambucil ester-LDL 
treated groups exhibited similar rates of tumour growth (fig.63), this 
drug, when carried in LDL, may be said to exert the same apparent 
tumour inhibition as an equivalent dose of the native drug, with less 
severe immunosuppression.
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3.8 CONCLUSIONS
The consistent lack of success in designing specific drugs which will
effectively destroy tumours without harming other tissues has prompted
the development of new methods of delivery for the existing cytotoxic
1—7agents. Several drug-vehicle combinations have been used with
varying efficacy. Liposomes^ fulfilled a number of the requirements
of the ideal vehicle, but tumour specificity and extensive clearance
8—11of these particles by the R.E. system in vivo remain serious
12problems. Following the observations of Ho et al and later Gal and 
13
co-workers , a "natural liposome", low density lipoprotein, was 
proposed as a vehicle for cytotoxic drugs or imaging isotopes.
12-22Numerous reports on LDL assimilation by cultured human and animal
tumour cells have been published, and the concensus of opinion is that 
neoplastic cells express higher LDL receptor activity than their 
equivalent non-neoplastic counterparts, although there have been
224—226
instances of cultured cancer cells with defects in LDL metabolism ^
Receptor-mediated uptake of LDL by solid tumours has been measured in 
several animal models (Section 2.2) and was found to be second only to 
liver and adrenal glands on a gram for gram basis. Thus LDL is not a 
totally specific carrier in vivo, but it may be sufficiently so to 
favourably increase the benefit:risk ratio of treatment. Specificity 
may be enhanced by reducing receptor-mediated uptake of LDL by liver 
and adrenal glands by administration of the appropriate agents (Section 
2.2).
The efficacy of chemotherapy depends critically on effective penetration 
of the drug into tumour microarchitecture, although the investigation 
of this property in vivo has been ^largely neglected. In order to
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enhance drug penetration, a number of lipophilic cytotoxic agents have
229been synthesised, and these are currently being evaluated . As an
alternative, existing drugs may be introduced further into the tumour
within a lipophilic carrier. Daunomycin, encapsulated in LDL, showed
more extensive penetration into tumour spheroids than did the native
228drug (figs. 56 & 57) or a number of lipophilic anthracyclines and 
consequently induced a considerably longer growth delay in this model 
system. It would therefore be of interest to obtain a measure of 
comparative distributions of free and LDL-encapsulated drug in animal 
tumour models and correlate drug penetration with tumour regression.
A potentially useful property of this delivery system was illustrated^^^
using daunomycin-LDL on anthracycline-resistant leukemic cells. Drug
carried by the lipoprotein was able to penetrate the resistant cells
much better than the native drug, suggesting that resistance was
mediated by a change in the membrane transport of the daunomycin.
Since acquired resistance is an all too common phenomenon following
initial chemotherapy, the use of LDL as a vehicle for some cytotoxic
agents may help to circumvent this problem. Further resistance is
unlikely to be a result of blocking this route of entry since the
tumour must rely heavily on LDL for the cholesterol it requires to
maintain its rapid rate of membrane synthesis^^, and LDL has been cited
as a necessary cofactor for the initiation of DNA excision repair in
227cultured human lymphocytes . Thus the cells of tumours receiving, 
in LDL, a chemotherapeutic agent which attacks DNA, are likely to 
further increase their LDL receptor expression and this positive 
feedback may enhance the cytotoxic effects of the drug-LDL complex.
To-date, the extent of drug incorporation into LDL is probably too low 
for therapeutic use in humans. Perhaps additional improvements to core
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replacement techniques, like Kreiger's method’*’^ '^ , may permit the
synthesis of LDL with a high drug content, which behaves like native
LDL in vivo. Alternatively the optimisation of methods of fusing drug-
rich microemulsions with LDL^^^, as used in producing chlorambucil-
ester—LDL (Section 2.3.4) might produce drug-laden LDL particles which
retain their native structure. However, it may be that the recently
228introduced "intensely potent anthracyclines" will enhance the
efficacy of existing procedures for making drug-LDL complexes for
228clinical use. These new drugs are active at 1/lOth to 1/lOOth of 
the doses commonly required for existing anthracyclines, and sufficient 
levels of these agents may therefore be incorporated into LDL simply by 
the diffusion techniques used previously (Section 2.3.5).
Another aspect of drug-LDL complexes which requires further study is
the way in which the cytotoxic agents are distributed within the
lipoprotein particle. For example, it appears that approximately 30%
of the chlorambucil cholesteryl ester (Section 2.4.5) and 50% of the 
23
daunomycin are located in the apolar core of the lipoprotein, while 
the remainder is held on the surface. The degree of protection 
afforded to core-located drug has not yet been documented, nor has the 
rate of leakage of drug molecules into plasma, but these properties are 
likely to be of importance in determining the efficacy of delivery of 
some cytotoxic agents.
Existing preparations of drug-LDL complexes, of course, require further 
testing in animal models, although unlike new cytotoxic agents, many of 
the toxic side effects of these drugs are already well known. The 
distribution of drug should, however, be dictated by the vehicle, and 
the major sites of toxicity may consequently be quite different from 
those of the free drug. Studies with radioiodinated LDL in animal
135
tumour models (Section 2.2) have shown that the adrenal glands and the 
liver are likely to be sites of dose-limiting side effects of drug-LDL 
therapy. Comparative dose response and tissue distribution data for 
free and LDL-encapsulated drug should be collected prior to testing any 
drug-LDL preparation in humans. Among the toxic effects which may be 
reduced by administering drugs within LDL is immunosuppression. 
Preliminary work with chlorambucil ester-LDL indicates that the complex 
may be significantly less injurious in this regard than the free drug.
In summary, LDL is a particle which exhibits a number of characteristics 
which make feasible its use as a drug vehicle in vivo. Tumours express 
relatively high LDL receptor activity and it is likely that serious 
damage to other organs can be avoided. Furthermore, LDL enhances drug 
penetration into the tumour and may be of use in overcoming drug 
resistance. It is not unrealistic to expect that, with the development 
of better incorporation methods for existing drugs and the synthesis of 
more potent or more lipophilic drugs, LDL will be successful as a 
targeting vehicle for the treatment of cancer in humans in the not too 
distant future.
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